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The prostate is a small ovoid gland surrounding the proximal male urethra. Its 
function is the production of a part of the seminal fluid. By its natural history, some 
prostates will enlarge and by doing this, urinary outflow obstruction can occur. The 
process of benign enlarging is caused by hyperplasia. This gives the most common 
name for this pathological condition: Benign Prostatic Hyperplasia (BPH). Obstruction 
of urinary outflow might cause symptoms known as Lower Urinary Tract Symptoms 
(LUTS), although many other factors also can be involved. Treatment is possible in 
several ways depending on factors like severity of these symptoms, bothering 
caused by these symptoms and preference of patient and/ or physician.  
This thesis is focused on three different kinds of transurethral surgery. To explain the 
aims of this thesis, the context of benign prostatic hyperplasia will be described. The 
next paragraphs deal briefly with different anatomical and (patho)physiological 
aspects of the prostate, symptoms caused by BPH, diagnostic tests and different 
treatments.  
 
1.1 ANATOMY AND PHYSIOLOGY  
 
The prostate is a glandular, ovoid shaped organ based at the bottom of the bladder. 
It is present in all male mammals, although there is a considerable diversity in 
anatomy, biochemistry and pathology. In man, the prostate normally weighs about 20 
g, has a length of 3 cm, is 4 cm wide and 2 cm deep. It is commonly referred to as 
having lateral, anterior and posterior surfaces. There is a narrowed apex inferiorly 
which is continuous with 
the striated urethral 
sphincter. Superiorly there 
is a broad basis bordering 
the base of the bladder. 
Some prostatic parts are 
adjacent to fascias of 
surrounding structures that 
form a sort of capsule. 
However, there is no true 
anatomic capsule1.  
The prostate is composed 
of about 70% glandular tissue and 30% fibromuscular stroma. It can be divided into 
different zones: the central zone, the peripheral zone, the anterior fibromuscular 
stroma and the transition zone. The central zone is circumferentially to the 
ejaculatory ducts of the seminal vesicles at the posterior base of the prostate. It 
constitutes 25% of the prostatic glandular tissue. Hyperplasia or adenocarcinoma  
are rare in this zone (only 1 to 5% of all prostate cancers arise in this zone). The 
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peripheral zone is the largest part with 70% of the glandular tissue.  It is this part that 
accommodates 70% of the adenocarcinomas and is most affected by prostatic 
inflammation. Its posterior surface can be palpated by digital rectal examination. The 
anterior fibromuscular stroma  can make up to 30% of the prostatic mass. Normally 
this part is nonglandular, but it can become glandular in adenomatous enlarged 
prostates. Finally, there is the transition zone that normally comprises only 5 to 10% 
of the glandular tissue. This zone is circumferentially to the urethra, which is named 
membranous or prostatic 
urethra in this region. The 
transition zone is the common 
region to become 
hyperplastic, causing benign 
prostatic hyperplasia (BPH). 
About 20% of the 
adenocarcinomas are thought 
to arise in this area. It is 
enclosed by a small 
fibromuscular band, that 
forms the surgical border 
when open prostatectomy is 
performed.  
The prostate is made up of several components: epithelial, stromal, and non-cellular 
components. The tubuloalveolar glands of the prostate form acini, which are lined 
with epithelium. Some of these cells, luminal cells, produce specific products like 
prostate specific antigen (PSA): a secretory proteinase found in high concentration in 
semen. Only small plasma levels are found in healthy men, unless the barrier 
between these cells and blood vessels is damaged by inflammation or prostate 
cancer.  Each acinus is surrounded by stroma containing fibroblasts and smooth 
muscle cells2. These stromal cells are amid a background of extracellular matrix 
made up of a divers group of glycoproteins. It forms a necessary framework in which 
all cells interact. 
The urethral length, inside the prostatic transition zone, spans on average 2 to 2.5 
cm (range: 1.2 to 5 cm)3. The proximal urethra is continuous with the smooth muscle 
of the bladder, which creates the preprostatic sphincter. This type of muscle 
pharmacologically differs from the rest of the bladder. It is stimulated by alpha-
adrenergic fibers, which also stimulate the prostatic smooth muscles. This explains 
the pharmacodynamics of the very popular α-adrenoceptor antagonists, which are 
used in many men with bladder outlet obstruction. Continence can sometimes be 
maintained by the preprostatic sphincter in men with a destroyed striated urethral 
sphincter4.  
Transition zone
Peripheral zone
Central zone 
Anterior fibromuscular stroma
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The urethra angulates halfway the prostate approximately 35 degrees anteriorly 
(range: 0 to 90 degrees). In the posterior midline, a crest projects into the urethra, 
which is named collicullus seminalis 
or verumontanum. It is an important 
landmark in transurethral surgery, 
that should be handled with care. At 
its apex, a small orifice is found, 
named the utriculus. It is a Müllerian 
remnant, also known as the ‘male 
vagina’. In males with ambiguous 
genitalia, this structure can be well 
developed into a prostatic ‘vagina’. 
Laterally of the utriculus are the two 
orifices of the ejaculatory ducts. 
These are connected with the 
seminal glands and the vasa 
deferentia. This is the place where 
semen, mixed with seminal fluid, 
enters the urethra and mixes with 
prostatic fluid. Laterally of the 
verumontanum grooves are formed, 
which are named prostatic sinuses. 
All glandular elements of the prostate drain into these sinuses by several small 
orifices. This mixture of semen with different fluids forms the ejaculate, which is on 
average 3 ml. It is composed of high concentrations of many substances, of which 
the physiological function is at present only minimally known. They are probably not 
essential for fertilization, but they may optimize its conditions. 
 
1.2 PATHOFYSIOLOGY, EPIDEMIOLOGY AND NATURAL HISTORY OF 
BPH 
 
For unknown reasons, abnormal growth of the prostate is almost unique to human 
and dogs. It is not seen in other mammals. Also intriguing is the fact that this 
abnormal growth seems to be limited to the prostate. Embryologically related sex 
accessory tissues, like the seminal vesicles and bulbourethral glands, demonstrate 
only very rarely tumours. Many factors are involved in prostatic growth. The two long 
known etiologic factors for the development of BPH are aging and functional testes5. 
However, this concept is displaced by modern research which proposed a more 
complex concept of prostatic growth. Although this concept is unfinished, it involves 
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many factors divided into intrinsic and extrinsic factors6. Intrinsic factors are derived 
directly from within the prostate: epithelial components, stromal components and the 
extracellular matrix interact with one another and provide a self-perpetuating growth 
mechanism using various growth factors. Extrinsic factors influence prostatic growth 
from external sources with the testes as most important organ. The testes form an 
endocrine organ that influences growth by several substances of which androgen is 
by far the most powerful mitogen. Other external factors are also important of which 
environmental and genetic factors are subject of scientific discussion. 
If the balance between cell division and apoptosis leads to a numeric increase in 
cells, this is named hyperplasia. This can happen in the prostate leading to benign 
prostatic hyperplasia (BPH). The term hypertrophy, meaning increase in cellular 
volume, is pathologically incorrect. In the prostate, hyperplasia is almost exclusive for 
the periurethral transition zone7. Most seen is a form of nodular hyperplasia, in which 
both stromal and epithelial cells increase numerically. During the first 20 years of 
BPH development, there is an increase in the number of nodules8, whereas in a later 
stage some of these nodules proliferate to become large nodes. 
Autopsy studies revealed that BPH was not found in men younger than 305. 
Prevalence of BPH increased after this age, peaking at 88% in men in their eighties5. 
This (microscopic) hyperplasia can lead to macroscopic BPH, also named benign 
prostatic enlargement (BPE). In about 50% of the men with microscopic BPH, this will 
lead to a macroscopically enlarged gland (BPE)9,10,11. 
Prostate size can be determined in several ways. In clinical practice, digital rectal 
examination (DRE) and transrectal ultrasound (TRUS) are commonly used. The 
volume of the normal prostate is about 20 ml by the third decade5. Cross-sectional 
studies have demonstrated a slow but ongoing increase in prostatic volume with age 
from approximately 25 ml for men in their fourth decade to about 35 to 45 ml for men 
in their eighth decade12,13,14. 
Benign prostatic enlargement (BPE) can lead to benign prostatic obstruction (BPO). 
This infravesical obstruction can compromise urinary flow and will induce changes in 
the bladder wall. Obstruction-induced changes lead to the development of detrusor 
smooth muscle hypertrophy, which is endoscopically seen as trabeculation. 
 
1.3 LOWER URINARY TRACT SYMPTOMS (LUTS) 
 
The relationship between the histologic (BPH), anatomical (BPE) and mechanical 
(BPO) entities on the one hand and urinary symptoms on the other hand is complex. 
The etiology of urinary symptoms has long been connected strongly to the prostate. 
In this way the term ‘prostatism’ was used for many male symptoms. It became clear 
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however, that symptoms could be found in men with one, two, three or none of the 
aforementioned entities. Even in old males it is possible to find symptoms without 
prostatic pathology. Their symptoms can be caused by other age related pathology, 
like detrusor instability or low bladder volumes due to hypersensitivity or bladder 
carcinoma15,16. Other lower urinary tract pathology may also cause similar problems, 
like cystolithiasis, infection or prostate cancer17,18. The finding that similar urinary 
problems can also occur in women, provides further evidence that these symptoms 
can arise independent of prostatic presence19,20,21.Therefore, the term lower urinary 
tract symptoms (LUTS) has been introduced22. It covers all voiding and storage 
symptoms, without stating anything about etiology or gender.  
 
Table 1 showing a subdivision of lower urinary tract symptoms (LUTS). 
 
Voiding symptoms Storage symptoms 
Weak urinary stream Frequency 
Abdominal straining Nocturia 
Hesitancy Urgency 
Intermittency Incontinence 
Incomplete bladder emptying Bladder pain 
Terminal en postmicturitional dribbling  
Dysuria  
 
 
Although voiding symptoms are very prevalent in men with LUTS associated with 
BPH, storage symptoms like urgency and nocturia appear to be the most 
bothersome23. 
LUTS can be quantified by using questionnaires developed by the American 
Urological Association (AUA). The measurement committee of the AUA developed 
the International Prostate Symptom Score (I-PSS) to quantify the prevalence of 
symptoms24. The I-PSS consists of seven questions, concerning incomplete 
emptying, frequency, intermittency, urgency, weak urinary stream, hesitancy and 
nocturia. Questions can be answered on a scale of 0 (not at all) to 5 (almost always). 
The sum of the scores forms the index, varying from 0 to 35, and is also known as 
the symptom score index. Of even more importance for treatment is the 
bothersomeness of these symptoms and their effect on the quality of life25,26. 
Therefore the AUA measurement committee also developed and validated a 
Symptom Problem Index (SPI) with 7 bothersomeness questions of which each 
corresponds to a symptom question of the I-PSS27. Each question can be answered 
on a scale of 0 (not at all) to 4 (very much), leading to an index varying from 0 to 28. 
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The same committee also developed a Quality of Life question:” If you were to spent 
the rest of your life with your urinary condition just the way it is now, how would you 
feel about that?”. It can be scored from 0 (delighted) to 6 (terrible)24. Another AUA 
validated questionnaire, that quantifies how much urinary problems affect various 
domains of health, is the BPH Impact Index (BII)27. Most used is the I-PSS (ranging 
from 0 – 35), which is often utilized to classify patients according symptom severity: 0 
to 7 points is classified as mildly symptomatic, 8 to 19 points as moderately 
symptomatic and those scoring 20 to 35 points as severely symptomatic. Worldwide 
epidemiologic studies demonstrated significant differences in symptom prevalence 
between nations, but an increase in symptoms with advancing age is always evident 
28,29,30,31. 
 
1.4 DIAGNOSTICS IN MEN PRESENTING WITH LUTS 
 
The etiology of LUTS can vary and is certainly not always related to prostatic 
pathology. LUTS can be caused, or more generally, can be associated with (a 
combination of) BPE, BPH or BPO. BPE can be measured by DRE or TRUS. BPO 
can be measured by urodynamics. BPH can only be diagnosed microscopically and 
is not of interest in a clinical setting. As stated before, other lower urinary tract 
pathology may also cause LUTS.  
The International Scientific Committee of the 5th International Consultation on BPH 
has made several recommendations in the diagnostic work-up of men presenting 
with LUTS32. Work-up is divided into an initial evaluation and a urologic (specialized) 
evaluation. Tests are divided into recommended and optional tests. 
 
 
1.4.1 Initially recommended tests 
 
History: an adequate medical history about (dis)functioning of the urinary tract in the 
context of the patient’s general health is mandatory. 
 
Quantification of symptoms: of major importance is the quantification of symptoms, 
their associated bothersomeness, their effect on quality of life and their impact on 
various domains of health. The AUA validated several questionnaires, which have 
been translated in many countries. These are described in the previous paragraph 
concerning LUTS. 
 
Physical examination and digital rectal examination (DRE): DRE must inform the 
physician about size, consistency, tenderness, shape and irregularities suggestive for 
prostate cancer. Next to a DRE, a focused neurological examination together with 
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examination of the external genital organs and the lower abdomen, should be 
performed.  
 
Serum prostate specific antigen (PSA): measurement of PSA in combination with 
DRE increases the cancer detection rate. Although there is no causal relation 
between BPH and prostate cancer, age is an important risk factor in both diseases. 
Detection of cancer next to BPH can change therapeutic options. 
 
Urinalysis: a simple test to determine if the patient has haematuria, proteinuria, 
pyuria or bacterial infection. It can provide information about different pathology 
which can cause LUTS, like urinary tract infection or bladder cancer.  
 
Voiding diary: the use of a voiding diary or frequency-volume chart will inform the 
physician adequately about the number and volume of voids during daytime and 
nighttime. The use of one 24-hour frequency-volume chart is sufficient to gain insight 
into the voiding pattern of men with BPH33. 
 
1.4.2 Specialized, optional tests 
 
Urinary flow rate estimation: urinary flow rate can be measured electronically 
throughout the course of micturition. It is a non-invasive urodynamic parameter. The 
maximum flow rate (Qmax) shows a strong correlation with BPO. Qmax is volume 
dependant34 and voided volumes over 150 ml are necessary to estimate Qmax 
accurately35. A low Qmax does not differentiate between bladder outlet obstruction 
(BOO) or a weak detrusor muscle. A Qmax < 10 ml/s has only a positive predictive 
value of 70% for BOO36. 
 
Residual urine estimation: residual volume is the volume of urine that remains in the 
bladder directly after finishing micturition. In men without LUTS these volumes are 
less than 5 ml in 87% and less than 12 ml in 100%37. However, recently it was shown 
that 30% of elderly male volunteers without LUTS have residual volumes higher than 
50 ml38. Residual volume  can be measured exactly by postvoid catheterization or 
accurately determined by transabdominal ultrasound. Intra-individual variation is 
large39,40. 
 
Pressure-flow studies: these are a part of the urodynamic assessment. Urinary flow 
is recorded simultaneously with measurement of the bladder pressure. The latter is 
recorded invasively by a small catheter introduced transurethrally into the bladder. It 
is the only way to differentiate between a low maximum urinary flow (Qmax) 
secondary to bladder outlet obstruction (BOO) and patients with a low Qmax due to 
other pathology, like an impaired detrusor function or neurogenic bladder. This test is 
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recommended if the initial evaluation, flow rate and postvoid residual urinary volume 
are not sufficient enough to make a diagnosis of BOO. Especially if surgery is one of 
the treatment options, pressure-flow studies can be valuable. The data that are 
generated by a pressure-flow study make it possible to categorize patients according 
to their urethral resistance, which results from the combination of flow and detrusor 
pressure. The introduction of a nomogram was in 197941, which categorized patients 
as obstructed, equivocal or unobstructed. There is still controversy about the 
demarcation of these different categories. Different methods have been developed to 
analyze and quantify pressure-flow plots42. In this thesis, the Schäfer’s obstruction 
grade is mostly used. This classification system is derived from the linear passive 
urethral resistance relation (linPURR)43. The linPURR has to be plotted in a specific 
pressure-flow diagram, which is divided in seven areas corresponding to different 
outflow resistances. Patients with Schäfer grades 0 and 1 are called unobstructed, 
those with Schäfer grade 2 are similar to the previous mentioned equivocal men and 
those patients with Schäfer grades of 3 to 6 are called obstructed44. 
 
Filling cystometry:  this test is not recommended in routine cases, but will be shortly 
mentioned here, because it is often used in the studies described in this thesis. It is 
part of a urodynamic evaluation in which the bladder is filled with saline through a 
transurethral or suprapubic catheter at a constant rate. Simultaneously bladder 
pressure is measured. Filling cystometry provides information about the maximum 
cystometric capacity, uncontrolled detrusor contractions and bladder compliance. 
 
Transrectal ultrasonography (TRUS): TRUS provides the most accurate information 
about prostatic size45. DRE provides easily volume information, although the 
reliability across observers is poor46 and is less precise than TRUS47. In BPH it is 
necessary to have adequate information about volume and shape because this can 
alter surgical options. Furthermore, if PSA and/ or DRE are suggestive for prostate 
cancer, TRUS can give additive information and can be used to guide a biopsy 
needle17. 
 
Imaging of the upper urinary tract: Imaging of kidneys, collecting system and ureters 
by intravenous urography (IVU) or ultrasound is not recommended. IVU’s were 
performed almost routinely in the past, but only in a small proportion this lead to a 
change in management. Symptoms like haematuria or urolithiasis increase the 
likelihood of clinical relevant findings48. 
 
Endoscopy of the lower urinary tract: in earlier days, urethrocystoscopy was routinely 
performed in patients presenting with LUTS. However, the relation between the 
optical appearance of the prostatic region and treatment outcome is almost not 
studied and the general opinion is that this relationship is very poor. Visualization can 
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be necessary to rule out other pathology. It should only be performed if symptoms 
like gross haematuria are presented or to select or rule out specific invasive 
treatments. 
 
1.5 TREATMENT OF MEN WITH LUTS 
 
Many options are available for today’s men presenting with LUTS associated with 
benign prostatic pathology. Depending on bothersomeness of their symptoms and 
clinical parameters like prostatic volume and obstruction an optimal choice can be 
made in a shared process between physician and patient. Treatment options can be 
divided into: watchful waiting, medication, open surgery and transurethral (or 
minimally invasive) surgery and prostatic stenting. The different options will briefly be 
explained with emphasis on the minimally invasive treatment options. 
 
1.5.1 Watchful waiting 
 
A substantial amount of patients will present with LUTS, but will refuse or postpone 
medical or surgical therapy. Reasons can be that the symptoms are not bothersome 
enough, or that the potential complications or side-effects do not outweigh the 
inconvenience of their LUTS. Sometimes reassurance that there is no malignancy 
can be enough. In a Dutch study, 41% of patients referred to a urologist with LUTS, 
elected watchful waiting49. In a randomized study comparing watchful waiting to 
resection of the prostate in patients with moderate LUTS, a 3 year follow-up 
demonstrated treatment failure in 17% and 8.2% respectively50. 
 
1.5.2 Medication 
 
Medical therapy can be divided into α1-adrenoceptor antagonists (α-blockers), 
androgen suppression like 5α-reductase inhibitors and phytotherapeutics. Their 
introduction has significantly altered treatment strategies for men with LUTS and 
BPH. Prostatectomy was the only widely accepted treatment for these men before 
1980. Medication does not achieve the subjective and objective improvements seen 
in prostatectomy, but there is still a clinical relevant change. Their advantage is that 
they have fewer and less severe side-effects and most of these effects are 
reversible51. 
 
α-blockers 
 
The prostate and bladder neck contain smooth muscle cells with α-adrenoceptors 
which mediate tension52. This can cause a dynamic bladder outlet obstruction which 
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explains its role in clinical BPH. Several α-adrenoceptor blockers have been 
developed, which can be classified according to their uroselectivity and serum 
elimination half-time. Multicenter, randomized, double-blind, placebo-controlled 
studies have demonstrated safety, efficacy and durability of long-acting α-blockers 
like alfuzosin and tamsulosin. Symptom reduction is in the range of 1-4 I-PSS points 
and maximum flow increase is about 1-4 ml/s53,54,55, which is significantly better than 
with placebo in most studies. Only a few urodynamic studies have been conducted, 
demonstrating some small, but significant, changes in urodynamic parameters56.  
 
androgen suppression  
 
The embryonic development, and in later life, the development of BPH, are androgen 
dependant processes. The most abundant circulating androgen is testosterone, 
secreted primarily by the testes. This is partially converted to dihydrotestosterone 
(DHT), by the enzyme 5-α reductase. DHT is about twice as potent as testosterone in 
the prostate and it also has a greater affinity for its prostate receptor57,58. Surgical 
castration leads to a volume decrease of about 30%59,60. Most used is the selective 
type 2, 5-α reductase inhibitor finasteride. It reduces prostatic volume with 19-
23%61,62,63,64,63,64. However, prostatic volume is only of minor importance in the 
pathophysiology of clinical BPH. The longest-duration study with finasteride is the 
Proscar Long-term Efficacy Study (PLESS)65. Baseline prostatic volume was about 
55 ml. After 4 years, symptom score index decreased with 2.0 points, maximum flow 
rate increased with 1.7 ml/s and prostate volume reduced with 32%. Treatment with 
finasteride for up to 2 years halves the frequency of acute urinary retention and 
reduces the need for prostatic surgery by 55% compared to placebo in patients with 
moderate LUTS66. It is well tolerated and has a good safety profile67. Efficacy has 
only been proven in prostates sized over 40 ml68. Finasteride reduces the group 
mean serum PSA by about 50%69, although the individual effect is highly variable. 
 
phytotherapeutics 
 
Phytotherapeutics, or plant extracts, are complex mixtures of different ingredients. 
Their use varies per country, with market shares of up to 50% in Germany and 
France70. Large patient numbers have sometimes already used some of these 
therapeutics before they see a physician for LUTS71. Their mechanisms of action are 
often unknown. Some suggested modes of action are: anti-androgenic, anti-
estrogenic, inhibition of 5-α reductase or anti-inflammatory72. Clinical studies have 
been conducted with extracts from, for example, Serenoa Repens (Saw palmetta) 
and Pygeum africanum (African plum tree). Several meta-analyses have been 
published about Saw palmetto that support some positive effects on LUTS. One of 
these, published by Wilt et al.73 calculated mean weighted differences compared to 
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placebo: these were a 1.41 point improvement in symptom score, an increase in 
maximum urinary flow of 1.93 ml/s and a reduction in nocturia of 0.76 per night. 
 
1.5.3 Open prostatectomy 
 
This procedure was one of the first surgical interventions in urology. It can be 
performed suprapubically, as was first done in 1894 and popularized by Freyer74,75, 
or retropubically, as was popularized by Millin76. A complete resection of the 
hyperplastic adenoma can be achieved, with a maximum relieve in obstruction. The 
procedure was unchallenged, until TURP became popular in the sixties of the last 
century. There are almost no randomized trials comparing open prostatectomy to 
TURP77. Most important differences are an abdominal incision and longer 
hospitalization. An open procedure is advantageous over TURP in prostates sized 
over 80-100 ml and in patients with coexisting pathology that needs surgery. 
 
1.5.4 Transurethral (or minimally invasive) prostatectomy 
 
In the first half of the last century, open prostatectomy was by far the most performed 
surgical procedure for clinical BPH. It was not until the 1960s that new developments 
improved the quality of endoscopic surgery. In this way transurethral resection of the 
prostate (TURP) became the most popular surgical modality. Unfortunately, its 
success caused a historical, scientific gap, that will never be filled. One did not wait 
for a decent evaluation of the outcome of this kind of surgery. Besides one small 
randomized study, there has been no comparison between open prostatectomy and 
TURP77. Nowadays, it is considered unethical to perform a randomized trial 
comparing these two techniques78. TURP became the gold standard, and it is still 
considered to be so at this moment. However, TURP is associated with a significant  
mortality and morbidity, especially bleeding and perforation. This can make re-
operation or transfusion necessary. In reaction to these findings, modern 
technologies were used to develop new modalities that were less invasive. They 
wanted to match the results of TURP, but with less side-effects, short hospitalization 
and, preferably, lower costs.  
This led to the development of a variety of new minimally invasive treatment 
modalities, mostly using heat to remove excess of prostatic tissue. Methods of 
applying heat varied from radio frequency waves, and electric currents, to laser 
beams. 
The heat applied to the prostate, causes tissue effects depending on temperature 
and duration of the heating process. The different effects will shortly be discussed, 
categorized by increasing temperatures: 
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40°C - 45°C: increasing temperature slightly over body temperature is called 
‘hyperthermia’. This process is used in malignant processes, where it causes 
permanent damage, because malignant cells are more sensitive to heat than normal 
cells. 
45°C - 60°C: when heat is applied for more than ten seconds, this temperature 
causes irreversible protein denaturation.  
60°C - 100°C: irreversible damage by protein denaturation is caused within tenths of 
a second. 
100°C: at this temperature water starts to boil and all excessive heat is used for 
vaporization. Inside the cellular membrane, pressure will increase as vaporization 
starts until the membrane burst. This phenomenon causes an audible effect, named 
‘popcorn’ effect79. 
Higher than 100°C: when tissue water has vaporized, all extra heat will increase 
temperature rapidly. The remaining dehydrated structures will caramelize and 
carbonize, creating a dark brown and black appearance, respectively.  
 
The modalities that are still used in a clinical or scientific setting will be described 
below, with extra attention to the three modalities that are studied in this thesis: 
TURP, contact laser and electrovaporization. 
 
Transurethral Resection of the Prostate: TURP 
 
Transurethral resection of the prostate (TURP) was introduced in the United States in 
the 1920s and 1930s. Small lenses were placed in a rigid tube, to gain urethral 
access. In 1932, a system was built that made it possible to resect tissue electrically 
under direct visualization. The development of fiberoptic lighting in the 1970s in 
combination with wide-angle optic systems, caused a major improvement in 
endoscopical visualisation80,81,82. TURP overtook the leading position of the open 
prostatectomy and became the gold standard for surgical management of BPH.   
TURP is performed by a transurethrally introduced resectoscope, with a semicircular 
wire, the resection loop, at the end. This loops forms the active electrode and 
electricity flows from this electrode into the surrounding tissue and back to the 
passive, return electrode. The latter is  a large surface patch, placed on the patient’s 
thigh or back. An insulation fluid, like isotonic glycine, surrounds the resection loop to 
prevent tissues that are not in direct contact with the electrode. Demineralized water 
would work perfectly, but water causes hemolysis83. The current density around the 
small surface of the active electrode is very high causing a direct cutting effect with 
only minimal tissue changes in the surrounding. Even cells at a few millimeters are 
not coagulated84,85. In this way prostatic chips can be removed, but large vessels 
may cause bleeding. A round, coagulation electrode with a larger surface area is 
than needed. Current density is lower and this causes a more gradual increase in 
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temperature that diffuses to a larger volume86. Most used is the technique described 
by Nesbit half a century ago80, in which the resection is performed in a routine, step-
by-step manner. Prostatic chips can be sent for histological examination. In men with 
at least one prior prostate biopsy, prostate cancer was found in 16.1%, although 
routine exclusion by PSA, DRE and TRUS had been performed before the time of 
surgery87. 
TURP is associated with a mortality form 0% to 0.8% within 1 month Postoperatively 
and 2.8% within one year88,89,90,91. Intra-operative morbidity varies from 6.9% to 
14%90,91, especially bleeding and perforation. Morbidity within 30 days 
Postoperatively varies from 9.5% to 18%90,91 and consists mainly of bleeding with or 
without clot retention. This can make re-operation or transfusion necessary. Late 
morbidity mainly consists of urethral strictures and bladder neck contractures and is 
reported in up to 11.2% within 12 months88. Transurethral resection syndrome occurs 
in about 2%89. It is caused by dilution effects of absorbed irrigation fluid. It is 
characterized by mental confusion, nausea, vomiting, hypertension, bradycardia and 
visual disturbance. 
 
Electrovaporization  
 
The electrosurgical properties depend highly on the shape and surface area of the 
active electrode. The small wire in the TURP electrode leads to tissue dissection and 
the roller ball leads to coagulation. A further development of a large surface area lead 
to the construction of electrovaporizators. They are often constructed as a grooved 
roller bar, like the Vaportrode (Circon-ACMI, Stamford, Conn, USA). The active 
element consists of a grooved cylinder that is 3 mm wide and 3 mm in diameter, that 
can move around a small horizontal axis. Prostatic tissue coagulates and vaporizes 
in contact with the grooves. Similar to TURP, glycine is used as an irrigation fluid. 
There are no prostatic chips that can be sent for pathological examination, as all 
tissue is vaporized. An important difference between TURP and electrovaporization 
in the use of the electrosurgical generator. In TURP, there is always a fresh native 
layer of prostatic tissue left behind after resection that causes only small changes in 
impedance. Electrovaporization however, causes a few millimeters thick coagulated 
layer, which increases electrical impedance. To optimize performance, it is necessary 
to use an impedance independent generator that delivers sufficient power92. 
Recently, newly shaped electrovaporizators have been introduced that combine the 
shape of the standard TURP loop together with a grooved roller bar into a ‘vaporizing 
loop’, which resects and vaporizes at the same time. 
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Transurethral Needle Ablation: TUNA 
 
TUNA uses low-level radio frequency (RF) energy to generate heat. This technique 
had previously been used in cardiology to destroy the additional nervous pathway in 
the Wolff-Parkinson-White syndrome93 and to destroy malignancies94. The TUNA 
generator (Vidamed, Menlo Park, California, USA) produces a monopolar RF signal 
of 490 kHz. This signal is transduced along a special transurethral instrument and 
two special antennas at the end of the tip, into the prostatic tissue. A patch is 
adhered to the patient’s skin that serves as a return electrode. It generates a tissue 
heating varying from 80-100°C, enough to create 1-cm necrotic lesions95. TUNA can 
be used with topical anaesthesia. Clinical results are close to TURP, although long-
term results are limited96. The most common complication is post-operative urinary 
retention in up to 40% of patients97. 
 
Transurethral Microwave Therapy: TUMT 
 
Similar to TUNA, radio frequency energy is used to heat tissue, but in TUMT the 
frequency is much higher. Depending on the type of generator used, RF’s vary from 
902, to 1296 or 1928 MHz. These RF’s penetrate tissue deeper than those generated 
by TUNA. TUMT can therefore heat a larger area, but with a lower temperature98. 
This modality was introduced as a transrectal instrument, generating temperatures of 
42 - 44°C with limited clinical results99,100. A transurethral device was developed, 
which could increase prostatic temperatures to 70°C. Since its introduction there has 
been an evolution in this technique in which the applied energy increased from low-
energy TUMT to high-energy TUMT. There are different theories explaining the 
clinical results. Histological studies demonstrated cellular apoptosis and 
necrosis101,102. Another controlled, histological study demonstrated statistical 
significant difference in prostatic α-adrenocepter density103. This would suggest a 
working mechanism, based on the assumption that there is a dynamic component in 
prostatic obstruction. The α-adrenoceptor antagonists intervene in a different way at 
this component. Clinical studies demonstrate good (long-term) symptomatic results 
with a lower morbidity than TURP104,105,106,107.  
 
Laser therapy 
 
The term laser is an acronym describing its mechanism108. It stands for light 
amplification by stimulated emission of radiation. A laser has several specifications 
that make it very interesting for specialized purposes: it produces monochromatic 
light, in a coherent, narrow collimated beam and a high energy density can be 
obtained. In this way it can be transported through small optical fibers (100 – 1000 
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µm) and used for specific tissues. There are different types of laser, depending on 
the medium used to emit light. Four types are used to treat the prostate: 
 
Neodymium: Yttrium-Aluminium-Garnet (Nd:YAG) Laser: This laser consists of a 
YAG rod with the addition of neodymium atoms. It emits near infrared light at a 
wavelength of 1064 nm in a continuous wave. This light is poorly absorbed by water 
and body pigments, which causes it to penetrate relatively deeply. It has good 
coagulative characteristics. 
Potassium Titanyl Phosphate (KTP) Laser: This type of laser uses a KTP crystal to 
double the frequency of a Nd:YAG laser, creating a wavelength of 532 nm. Tissue 
penetration is only half, but energy density is doubled, which increases its 
vaporization and desiccation characteristics. 
Holmium: Yttrium-Aluminium-Garnet (Ho:YAG) Laser: A YAG rod mixed with 
holmium atoms creates a wavelength of 2100 nm, that is emitted in a series of rapid 
pulses over a few milliseconds. It produces a cutting effect by vaporization of tissue 
water and has low haemostatic properties. 
Diode Laser: this a small laser emitting light of 800 – 1000 nm. It does not require 
large cooling devices, necessary for the aforementioned laser types. 
 
The energy of these different lasers is mostly delivered transurethrally by an optical 
fiber. There are however, important differences in the last part of the route where 
laser energy is transferred to the prostatic tissue. There are three different delivering 
procedures: 
 
End firing fibers: laser light is emitted at the end of the fiber and is either directly 
beamed at the prostate (bare tip) or the light heats a tip which is distally connected to 
the fiber, e.g. the sapphire tipped contact laser. 
Side firing fibers: also named visual laser ablation of the prostate (VLAP). These 
fibers incorporate distally a prismatic internal reflector or they have an external glass 
or metal reflector. Laser light is mostly deflected at an angle of 90 degrees. 
Interstitial fibers: these fibers are introduced directly into the prostatic tissue at 
different sides. 
 
Most research has been conducted with Nd:YAG lasers with contact probes (contact 
laser prostatectomy: CLP), or side fire devices (visual laser ablation of the prostate: 
VLAP) or interstitial laser devices (interstitial laser prostatectomy: ILP). Unlike TURP, 
but similar to most other new treatment modalities, there is no tissue available for 
histology. Prostatic biopsy should be performed if there is any suspicion of prostate 
cancer.  
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Visual Laser Ablation of the Prostate: VLAP 
 
This side firing laser device uses Nd:YAG generated laser light. It was one of the first 
laser techniques used in the treatment of BPH and is probably the most studied type 
in laser prostatectomy. One of the earliest systems used, was transurethral 
ultrasound-guided laser-induced prostatectomy (TULIP), which used an ultrasonic 
transducer. The entire prostate could be treated in this way. Although some success, 
this complex device did not stand the test of time109. In all other systems, surgery is 
performed under direct visualization of the laser tip and prostatic tissue. The most 
used method in VLAP is that of coagulation necrosis. Laser light is deflected towards 
the prostatic tissue for 30 – 60 seconds at different clock positions in the prostate. 
The depth of tissue destruction varies depending on tissue properties and laser 
settings and is typically 10 – 12 mm110. Temperatures of 70 – 90°C are reached. This 
results in a slow tissue sloughing taking several weeks, making catheterization 
necessary. Initial results were reported by Costello in 1992111. Later, studies 
randomized VLAP to TURP and demonstrated that VLAP resulted in subjective and 
objective improvements close to TURP112,113. Blood loss is minimal112,114 and it can 
be performed on patients using anticoagulant or with bleeding disorders115,116. 
 
Interstitial Laser Prostatectomy: ILP 
 
Interstitial laser prostatectomy was developed to address the problem of slow tissue 
sloughing that happens in VLAP. A small fiber is transurethrally (sometimes 
perineally) introduced into the prostate. A Nd:YAG or, more recently, a diode laser 
generates laser light to induce prostatic coagulative necrosis. In this way the integrity 
of the prostatic urethra can be preserved. There is no tissue sloughing, because all 
necrosis is removed by the process of tissue repair. The first publication was in 1993 
by McNicholas117. Nd:YAG ILP has demonstrated to result in significant 
improvements, both symptomatically and urodynamically118. ILP has been used in 
patients while continuing warfarin anticoagulant therapy with fair results119. 
 
Contact Laser Prostatectomy: CLP 
 
This modality uses laser light in a very different way than VLAP or ILP. In the two 
latter methods, laser light induces a thermal coagulative necrosis. In this way there is 
no direct removing of tissue like in TURP. CLP is often, but not necessarily, used in 
combination with a Nd:YAG laser. Laser light heats a synthetic sapphire tip attached 
to the distal end of the optical fiber120. This tip is provided with a black infrared-
absorbent coating. Laser energy is than converted to thermal energy which increases 
temperature to several hundred degrees Celsius. In direct contact with prostatic 
tissue this causes a thermal induced vaporization which directly creates a cavity like 
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in TURP. The effect is limited to a maximum penetration of about 1 mm, as apposed 
to the side-fire technique, in which the laser energy may penetrate as far as 1 cm into 
tissue. As opposed to the native layer of prostatic tissue that is left behind by TURP, 
there is a coagulated surface after CLP that minimizes bleeding. Some studies 
described the use of CLP in patients using anticoagulants with fair results121,122. 
Saline is used as irrigant, protecting for the TUR syndrome. Most tissue is removed 
(vaporized) immediately, so there is minimal tissue sloughing postoperatively.  
 
1.5.5 Stents 
 
A completely different approach is the use of a small intraprostatic stent. Stents were 
first introduced by Dotter in 1969123 to stent peripheral blood vessels. In 1980, the 
first description of the use of stents in the obstructing prostate is presented124. Stents 
can be divided into permanent and temporary stents. Permanent stents were first 
introduced as a definite solution for obstructive prostates, often in studies with 
patients unfit for surgery. Complications were high and there are almost no 
publications in recent literature about the use of permanent stents as treatment for 
BPH125,126,127. Temporary stents receive more recent attention128. They are either 
made of nonabsorbable or biodegradable materials, of which the former need to be 
replaced every 6 to 36 months, depending on type and tissue properties. 
Biodegradable and some modern nonabsorbable stents with shape memory 
properties, are nowadays often used in combination with other minimally invasive 
treatment modalities that cause secondary or temporary obstruction, like side-fire 
laser prostatectomy and transurethral microwave therapy129,130. In this way, patients 
are not bothered by the use of a transurethral catheter. 
 
1.6 AIMS OF THIS THESIS 
 
Urodynamics is the only way to quantify bladder outlet obstruction, detrusor 
contractility and lower urinary tract parameters like detrusor instabilities, bladder 
compliance and cystometric capacity. It is recommended by the International 
Scientific Committee of the 5th International Consultation on BPH, if the initial 
evaluation, flow rate and postvoid residual urinary volume are not sufficient enough 
to make a diagnosis of BOO. Especially if surgery is one of the treatment options, 
pressure-flow studies can be valuable. Scientifically, it provides objective information 
about (dis)functioning of the lower urinary tract as opposed to quantified subjective 
information by AUA validated questionnaires. Urodynamics make it possible to 
categorize patients according to their outflow resistance. In this way patients can be 
classified as obstructed, equivocal or unobstructed. However, the demarcation of the 
borders between these categories is somehow arbitrarily.  
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It is generally accepted that men with high urethral resistance preoperatively benefit 
most from bladder outlet obstruction relief. Therefore physicians are rather reserved 
about resection of the prostate in equivocal and unobstructed men. A problem arises 
when a man with considerable LUTS and benign prostatic enlargement (BPE), but 
without infravesical obstruction or other pathology does not want medication at all, 
does not benefit from medication or does not tolerate this treatment. 
 
This problem created the first aim of this thesis: 
 
To evaluate the results of TURP in men with LUTS and BPH who are 
urodynamically not obstructed or equivocal and to compare these results with 
those in men who are urodynamically obstructed. 
 
 
Many new minimally invasive surgical modalities have been introduced in the last 
decade to challenge the gold standard TURP. Contact laser prostatectomy and 
electrovaporization are two of these modalities. Modern scientific standards require a 
methodologically solid comparison of new techniques with the gold standard TURP.  
 
This led to the second aim of this thesis: 
 
To evaluate the results of TURP, contact laser prostatectomy and 
electrovaporization of the prostate. 
 
 
During the initial use of laser prostatectomy it became obvious that the amount of 
blood loss is minimal. This characteristic makes it interesting to apply laser 
prostatectomy in a population of men with LUTS associated with BPH who are 
contraindicated for TURP, because they use anticoagulants or suffer from bleeding 
disorders.  
 
This led to the third aim: 
 
To evaluate the results of laser prostatectomy in men with LUTS associated 
with BPH who use anticoagulants or suffer from bleeding disorders. 
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1.7 OUTLINES OF THIS THESIS 
 
Chapters 2 and 3 deal with the first aim of this thesis. 
 
In chapter 2 men presenting with LUTS associated with BPH are preoperatively and 
6 months postoperatively urodynamically analyzed using uroflowmetry, filling 
cystometry and pressure-flow analysis. At the same time intervals they complete I-
PSS, SPI, QoL question and BII. Patients are treated with the gold standard, TURP. 
In this way, the relation between objective urodynamic parameters on the one hand 
and quantified symptomatic and subjective changes on the other hand are 
determined. These correlations are used to predict outcomes of TURP according to 
preoperative urodynamic values. 
 
In chapter 3 a selected group of men with considerable LUTS and BPE opted for 
surgery, although urodynamics showed an equivocal or unobstructed urinary outflow. 
These men are treated with TURP. A second group of men who are urodynamically 
obstructed also undergoes TURP. Urodynamics are performed preoperatively and 6 
months postoperatively. Symptoms, bother, quality of life and impact on general 
health are quantified using the appropriate AUA questionnaires. The quantified 
improvement six months after transurethral prostatectomy in the unobstructed and 
equivocal men are compared to the outcomes of transurethral prostatectomy in the 
obstructed men. 
 
 
Chapters 4 to 7 deal with the second aim of this thesis.  
 
A prospective randomized controlled study was carried out between 1996 and 2001 
at our clinic to compare the three different treatment modalities. The results of this 
trial are presented in chapters 4 to 7. Included were men over 45 years of age with 
LUTS associated with BPH. All patients underwent history taking, digital rectal 
examination, transrectal ultrasonography, urodynamic evaluation, free flowmetry, 
post-void residual volume estimation, urinalysis and blood analysis.  
Patients had to be urodynamically equivocal or obstructed (Schäfer obstruction grade 
≥2). Their prostate volume had to be between 20 and 65 ml. Patients with any of the 
exclusion criteria of the International Consensus Committee on BPH were excluded 
from analysis. Group sizes were calculated with a power of 90% and statistical 
significance was set at 5%. 
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In chapter 4 TURP, contact laser prostatectomy (CLP) and electrovaporization, are 
compared urodynamically. Pressure-flow studies, filling cystometry and uroflowmetry 
are performed preoperatively and 6 months postoperatively. 
 
In chapter 5 the three modalities are compared using the AUA validated 
questionnaires. Subjective changes are quantified using the International Prostate 
Symptom Scores (I-PSS), Symptom Problem Index (SPI), Quality of Life (QoL) 
question and BPH Impact Index (BII). Preoperatively and the first six weeks 
postoperatively these indexes are measured weekly and later at 3, 6 and 12 months. 
Next to objective complications, some specific morbidity and symptomatic aspects 
are studied using a self-developed questionnaire that is completed by all patients. 
The questionnaire is completed once preoperatively. Postoperatively it is filled out at 
a weekly interval during the first six weeks and later at 3, 6 and 12 months. 
Questions concern pain in the lower abdomino-genital region, pain during voiding, 
haematuria, incontinence, urge and hesitation. Together with the morbidity 
questionnaire, patients are asked to report the average number of voids during the 
daytime and nighttime for the last week. 
 
In chapter 6 the long-term results are studied. In fall 2002, all patients who were 
operated on for more than 18 months ago are re-invited to visit the outpatient 
department. Patients who were previously excluded, are not invited. In this way, 
follow-up times vary individually from 1.5 to 7 years. The same questionnaires are 
used as during the 12 months follow-up: I-PSS, SPI, QoL question, BII, the morbidity 
questionnaires and frequency during daytime and nighttime. Uroflowmetry is 
performed at the outpatient department. 
 
In chapter 7 some economic aspects of the different surgical approaches are 
regarded. Resources are limited and there is an increase in patients presenting with 
LUTS together with an increase in treatment modalities. Therefore, choices between 
(surgical) treatment modalities should also be based on economic aspects. The 
International Consultation on BPH recommends to perform a economic analysis for 
all new developed technologies. Until now these have not been performed for 
electrovaporization and CLP. 
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Chapter 8 deals with the third aim of this thesis. 
 
In chapter 8 a study is presented that describes the use of CLP and a combination of 
CLP with VLAP in so called high-risk patients. These are defined as patients using 
anticoagulants (acenocoumarol or fenprocoumon), using platelet aggregation 
inhibitors or suffering from various bleeding disorders. The patients which are treated 
with CLP in our randomized controlled trial are used as a reference group (normal 
risk patients). All patients are analyzed preoperatively and 6 months postoperatively 
using the aforementioned AUA validated questionnaires and urodynamics, including 
uroflowmetry, filling cystometry and pressure-flow analysis. 
 
In chapter 9, finally, this thesis is generally discussed, final conclusions are made 
and futute perspectives are described.  
 
Chapter 10 comprises a summary in Dutch.
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Abstract 
 
 
Purpose: To establish the predictive value of urodynamics on the outcome of 
transurethral prostate resection for benign prostatic enlargement we correlated 
urodynamic changes with symptomatic improvement, decreased bother, and 
increased general well-being and quality of life after transurethral prostate resection.  
 
 
Materials and Methods: Men with lower urinary tract symptoms were selected if they 
met study criteria and underwent tests recommended by the International Scientific 
Committee on Benign Prostatic Hyperplasia, and if post-void residual volume and 
prostate size were estimated. Patients answered quality of life, symptom index, 
symptom problem index and benign prostatic hyperplasia impact index questions. 
Patients also underwent urodynamic evaluation. Men were included in analysis when 
transurethral prostate resection was selected as treatment modality. Of the 132 
patients included 93 were reevaluated 6 months after transurethral prostate 
resection. 
 
 
Results: Improvements after transurethral prostate resection were significantly 
associated with decreased bladder outlet obstruction (p<0.01). However, 32 cases 
that were unobstructed or equivocal preoperatively also benefited moderately from 
resection. Effective capacity, that is cystometric capacity minus post-void residual 
urine volume, increased by an average of 45% postoperatively. The increase in 
effective capacity contributed to a significant decrease in symptoms and bother, and 
improved well-being. Of the men with a urodynamically proved stable bladder 90% 
maintained a stable bladder after prostatectomy, while in 50% with a urodynamically 
proved unstable bladder it became stable postoperatively. 
 
 
Conclusions: Performing urodynamics preoperatively helps to predict the degree of 
symptom relief, decreased bother and increased well-being after transurethral 
prostate resection.
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Introduction 
 
Surgical treatment for prostatic enlargement associated with benign prostatic 
hyperplasia (BPH) is one of the most common operations performed in the modern 
western world. Using life table methods the lifetime probability of surgical treatment is 
estimated to be 29%.1 Patients have a spectrum of symptoms that are currently 
referred to as lower urinary tract symptoms.2 The International Scientific Committee 
(ISC) of the International Consultation on BPH recommends the quantitative 
documentation of symptom prevalence3 using the International Prostate Symptom 
Scores (I-PSS) questionnaire and quality of life question developed by the 
Measurement Committee of the American Urological Association (AUA).4 
In the past decision making in regard to treatment was mainly based on symptoms 
and the degree of bladder outlet obstruction. However, it was reported that the 
degree of outlet obstruction and prostate size were not associated with symptoms 
and quality of life.5 Moreover, the degree of bother reported by the patient is not the 
same as the presence and frequency of symptoms.6 Symptom bother and negative 
impact on quality of life are the main reasons that patients seek treatment for lower 
urinary tract symptoms.7 Therefore, the AUA Measurement Committee developed 
and validated appropriate scores for quantifying lower urinary tract symptom bother. 
The committee introduced a symptom problem index with 7 bothers questions, of 
which each corresponds to a symptom question on I-PSS.8 The committee also 
developed the BPH impact index, consisting of 4 questions on patient well-being and 
the social implications of lower urinary tract symptoms.8 
The ISC recommends pressure flow studies for evaluating patients before invasive 
therapies or when a precise diagnosis of bladder outlet obstruction is important.3 The 
outcome of therapy appears to be related to pretreatment urodynamic findings since 
patients with obstruction fare better than those without obstruction.9 The urodynamics 
subcommittee of the ISC recommends filling cystometry and pressure flow studies.9 
The committee claims that performing preoperative urodynamics is cost-effective, 
allowing treatment to be directed toward the patients who are most likely to benefit. 
Cases that are unobstructed or equivocal can be managed by less expensive and 
less morbid therapies. 
Bosch analyzed studies of the pretreatment and posttreatment values of relevant 
urodynamic parameters.10 As he determined, the rank order of urodynamic efficacy 
shows a high level of agreement with the reported rank order of the symptomatic 
efficacy of various treatment modalities for decreasing urethral resistance. These 
analyses were performed at the grouplevel. 
In our current study of men who underwent transurethral prostate resection we 
calculated improvement or worsening of a parameter in each individual by comparing 
the preoperative value with the value 6 months after resection. Symptomatic 
improvement, decreased bother, increased general well-being and quality of life were 
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correlated with urodynamic changes to establish the relationship of the outcome of 
resection to pretreatment and posttreatment urodynamic findings. 
 
Materials and methods 
 
Men with lower urinary tract symptoms underwent basic initial evaluation (history, 
physical examination, digital rectal examination, urinalysis and renal function 
assessment) and recommended diagnostic tests (uroflowmetry and post-void 
residual urine estimation), conforming to the recommendations of the International 
Consensus Committee on BPH from 1993, as updated in 2000 by the ISC.3 Men 
were eligible for study if they were older than 45 years old, had no exclusion criteria 
specified by the ISC,3 post-void residual urine volume was estimated reliably and 
prostate size was determined by transrectal ultrasound. I-PSS4 was completed by all 
men. The symptom index was calculated by summing the 7 scores. We introduced 
an additional question into the AUA symptom index on the frequency of daytime 
voiding, which was scored as: 0: 1 to 3 times, 1: 4 to 5 times, 2: 6 to 7 times, 3: 8 to 9 
times and 4: 10 times or more. Each patient answered the quality of life question.4 
We included the 7 bother questions of the symptom problem index, of which each 
corresponds to a symptom question. The symptom problem index was calculated by 
summing the 7 scores.8 We also included BPH impact index questions, consisting of 
4 questions on patient well-being and the social implications of lower urinary tract 
symptoms.8 The BPH impact index was calculated by summing the 4 scores. 
All patients underwent filling cystometry and pressure-flow studies. Filling cystometry 
was performed with the patient supine and sitting. Pressure-flow studies were done 
twice with the patient sitting. Bladder pressure was recorded with a 5Fr catheter and 
rectal pressure was measured with a 14Fr catheter. Each was connected to an 
external pressure transducer. The bladder was filled with saline at 37 0C through a 
second 5Fr catheter at a constant rate of 50 ml. per minute. In some men an 8Fr 
double lumen catheter was used for bladder pressure measurement and bladder 
filling. Filling was stopped when the patient had a strong desire to void. The first 
pressure flow study was done with measuring and filling catheters in the bladder and 
the second study was done after removing the filling catheter. The pressure flow 
study with the lowest urethral resistance, usually during voiding with only the 
measuring catheter in the bladder, was used in further analysis. 
The Schäfer obstruction grade,11 urethral resistance factor12  and Abrams-Griffiths 
number13 were estimated from pressure flow studies. Cases with an obstruction 
grade of 0 or 1 were considered unobstructed, those with an obstruction grade of 2 
were considered to be equivocal and those with an obstruction grade of 3 or greater 
were considered obstructed. Effective capacity was defined as cystometric capacity 
minus post-void residual urine volume. Men were included in analysis if they were 
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selected for transurethral prostate resection, which was performed with a standard 
24Fr resectoscope. As necessary, a suprapubic catheter was inserted 
perioperatively. All men were invited to participate in reevaluation 6 months after 
resection, including symptom, bother and problem index questions as well as filling 
cystometry and pressure flow studies. 
We defined improvement or worsening of a urodynamic parameter in an individual as 
the ratio of the postoperative-to-preoperative value multiplied by 100%. Except for 
the Abrams-Griffiths number, Schäfer obstruction grade and contractility grade no 
urodynamic parameter could be 0 (table 1). We quantified improvement by 
considering a discrete parameter, such as the score on the symptom question, “Over 
the past month, how often have you had a weak urinary stream?” The score on that 
question was 0 to 5. The question arose whether improvement by treatment resulting 
in a decrease in a preoperative score of 5 to a postoperative score of 3 was equal to 
a decrease from 3 to 1. In our opinion the latter improvement is better. We developed 
for all discrete parameters (Schäfer obstruction grade, contractility grade and all 
scores) an improvement or worsening matrix, considering the different measures of 
improvement (see Appendix and table 6). 
The Kolmogorov-Smirnov goodness of fit test was used to analyze whether the 
distribution of a variable was normal. Statistical analyses were performed with 
distribution free tests, including Kendall and Gibbons correlation method, Wilcoxon 
signed rank test and the Mann-Whitney U test. Two-tailed significance was 
considered at 0.05. 
 
Results 
 
In 39 of the 132 study participants (29%) follow-up after 6 months was not possible 
for various reasons (table 2).Table 1 lists baseline values in the remaining 93 men 
with a mean age plus or minus standard deviation of 65 ± 8 years (range 45 to 82) as 
well as postoperative values at 6 months. Of our 93 cases 32 were unobstructed or 
equivocal (Schäfer grade 1 or 2) and 61 were obstructed (Schäfer grade equal to 3 or 
higher). In the unobstructed and equivocal cases mean prostate volume was 36 ± 10 
ml. and in the obstructed cases it was 48 ± 21 ml. 
The almost 45% increase in mean effective capacity after transurethral prostate 
resection was due to the significant mean increase in cystometric capacity from 395 ± 
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Table 1 Preoperative characteristics and postoperative values together with significant differences. 
 
Characteristic Mean Preop. ± SD (range) 
Mean Postop. ± SD 
(range) 
p value 
 
Max. free flow (ml/s) 11±4 (4-26) 23±10 (9-59) <0.001 
Detrusor pressure at max. 
flow (cm. water) 72±30 (32-200) 37±13 (17-80) <0.001 
Max. flow at pressure flow 
study (ml/s) 8±4 (1-18) 15±7 (2-37) <0.001 
Schäfer grade 3.2±1.3 (1-6) 1.0±0.9 (0-4) <0.001 
Abrams-Griffiths No. 57±33 (14-196) 7±21 (-51-76) <0.001 
Urethral resistance factor  
(cm water) 43±23 (18-161) 18±10 (5-72) <0.001 
Contractility degree 2.6±1.2 (0-5) 2.6±1.3 (0-5) Not significant. 
Cystometric capacity (ml) 395±145 (80-1000) 455±160 (170-950) <0.001 
Effective capacity (ml) 310±140 (30-660) 445±160 (150-920) <0.001 
Symptom Index 19±7 (5-34) 6±5 (0-26) <0.001 
Symptom problem index 14±8 (0-28) 3±5 (0-20) <0.001 
Quality of life 4.1±1.5 (1-6) 1.3±1.5 (0-6) <0.001 
BPH impact index 6.4±3.4 (0-13) 1.8±2.7 (0-12) <0.001 
 
 
 
 
 
 
Table 2 Reasons why 39 of 132 men were not followed at 6 months. 
 
Reason Number of patients 
No agreement with further investigations 15 
Patient condition did not allow reliable follow-up 8 
Failed catheterization during urodynamic investigation at 6 months 5 
Postoperative complications within 6 months. 4 
Patient died within 6 months postoperatively 3 
Patient. emigrated within 6 months postoperatively 4 
Total number 39 
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145 to 455 ± 160 ml. and a concomitant decrease in post-void residual urine volume 
from 85 ± 120 to 10 ± 35 ml. Table 3 lists the Kendall and Gibbons correlation 
coefficients (Rs) of the improvement of urodynamic parameters versus all scores on 
I-PSS, BPH problem index, BPH impact index and quality of life questions. Men were 
excluded from analysis if preoperative and postoperative scores were 0, leading to 
different number of men for each score. 
Improvement in obstruction grade, symptom index, symptom problem index, BPH 
impact index and quality of life were related to preoperative obstruction grade (table 
4).Baseline values of the different categories of obstruction were not equal (table 4). 
There were significant correlations of baseline parameter values and improvements 
(symptom index R=0.25, quality of life R=0.38, symptom problem index R=0.35 and 
BPH impact index R=0.31, all p<0.01). Therefore, differences in baseline values 
affected improvement (table 4). The mean preoperative score on the symptom 
question of incomplete emptying in the 59 men with and 34 without post-void  
residual urine volume was 2.56 ± 1.83 and 2.59 ± 1.73, while average postoperative 
scores were 0.56 ± 1.00 and 0.68 ± 1.23, representing 60 ± 30% and 50 ± 55% mean 
improvement, respectively.  
Table 5 lists improvements in the symptom index, symptom problem index, BPH 
impact index and quality of life in relation to preoperative and postoperative 
prevalence of urodynamically proved detrusor instability. Of the men 50 (54%) had a 
stable bladder preoperatively and the bladder remained stable 6 months after 
transurethral prostate resection in 45 (90%), while instability developed in 5 (10%). A 
total of 43 patients (46%) had an unstable bladder preoperatively, including 20 (47%) 
in whom bladder instability persisted postoperatively. Mean preoperative obstruction 
grade, mean maximum amplitude of instability, mean age, mean symptom index, 
mean symptom problem index, mean BPH impact index and mean quality of life 
score did not differ in men who maintained an unstable bladder (group 3) and those 
who achieved a stable bladder (group 1). The men in groups 1 and 2 showed 
significantly better improvement in the symptom index (p=0.02), BPH impact index 
(p=0.01) and quality of life (p=0.007) than those in whom an unstable bladder 
persisted (group 3) and in whom an unstable bladder developed postoperatively 
(group 4). The improvement in the symptom problem index was not significant 
(p=0.09). No significant differences in age was detected in the 4 groups. 
Of our cases 9 (10%) were unobstructed preoperatively and 23 (25%) were 
equivocal. These patients also benefited from prostatectomy (table 4). In these 32 
men mean effective capacity increased from 355 to 495 ml. The prevalence of
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Table 3 Improvement in urodynamic parameters according to symptoms, problems, bother and quality 
of life. 
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Table 4 Improvement in Schäfer obstruction grade, symptom index, problem index, BPH impact index 
and quality of life in relation to preoperative obstruction grade. 
 
Preop. 
Grade 
 
Number 
of 
Patients 
Av. % 
Grade 
Improve- 
ment 
Preoperative  
Symptom Index 
 
(% improvement)
Preoperative 
 Problem Index 
 
(% improvement)
Preoperative 
 BPH Impact 
Index 
(% improvement) 
Preoperative 
Quality of Life 
 
(% improvement)
1 9 15 16.1 (40) 10.3 (38) 9.2 (43) 3.3 (42) 
2 23 30 17.4 (45) 12.4 (52) 10.1 (50) 3.7 (44) 
3 23 50 17.5 (48) 13.0 (64) 9.8 (55) 4.2 (49) 
4 18 56 21.7 (60) 17.5 (70) 12.2 (61) 4.6 (61)) 
5 17 64 19.8 (63) 13.5 (58) 9.7 (58) 3.9 (55) 
6 3 83 28.0 (64) 22.3 (92) 15.3 (95) 5.3 (87) 
 
No patient had a preoperative obstruction grade of 0. 
 
Table 5 Postoperative improvement according to instability. 
 
 Group 1 Group 2 Group 3 Group 4 
Number of patients 23 45 20 5 
Mean age ± SD 66.8±6.6 63.6±8.6 67.7±7.9 65.6±7.2 
Bladder     
Preop. Unstable Stable Unstable Stable 
Postop. Stable Stable Unstable Unstable 
Symptom index     
Mean preop. ± SD 19.4±5.6 18.0±6.8 20.4±5.2 18.8±8.8 
Mean postop. ± SD 4.8±5.0 5.2±3.9 9.6±3.2 7.8±6.7 
% Improvement 61 54 37 47 
Problem index     
Mean preop. ± SD 13.1±7.4 13.6±7.2 15.1±8.2 14.6±10.9 
Mean postop. ± SD 2.4±4.4 2.4±3.4 5.4±6.0 5.0±4.7 
% Improvement 65 65 47 32 
BPH impact index     
Mean preop. ± SD 6.4±3.3 5.9±3.2 7.3±3.6 6.6±3.6 
Mean postop. ± SD 1.0±2.1 1.2±1.8 3.6±3.7 2.0±3.0 
% Improvement 67 59 39 45 
Quality of life     
Mean preop. ± SD 4.0±1.5 4.0±1.5 4.3±1.6 4.2±1.5 
Mean postop. ± SD 1.0±1.4 1.1±1.3 2.0±1.5 2.2±1.6 
% Improvement 62 55 39 34 
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instability decreased from 35% to 16% and the prevalence of post-void residual urine 
volume from 55 to 20%. The mean decrease was 2.4 to 1.4 for nocturia, 2.6 to 1.3 for 
frequency and 2.2 to 0.8 for urgency, while mean symptom problem scores on these 
symptoms decreased from 1.8 to 0.8, 2.1 to 0.5 and 2.2 to 0.8, respectively.  
 
Discussion 
 
Of our 132 study participants 39 (29%) were not followed at 6 months for various 
reasons (table 2). Of these 39 men 15 were satisfied with the results of transurethral 
prostate resection but did not agree to further investigations. In 8 patients the health 
condition did not allow investigation at 6 months since 1 had cancer, 2 had dementia, 
1 had renal insufficiency requiring dialysis, 2 had bladder stones and 2 had 
neurological complaints. In 5 men catheterization failed, including 2 with bladder neck 
stenosis, 1 who did not agree to further investigation and 2 with a maximum free flow 
rate of 15 and 25 ml. per second, respectively. In these latter 2 men catheterization 
may have failed due to the sometimes large space created in the prostatic urethra by 
transurethral resection. Another 4 patients had postoperative complications within 6 
months, of whom 1 underwent repeat transurethral prostate resection and 3 
underwent subsequent surgery for urethral stricture.   
In the 93 men evaluated the mean maximum flow rate and mean maximum detrusor 
pressure at maximum flow before and after operation were similar to those in the 
literature (table 1).14-16 The mean AUA symptom index in our group decreased from 
19 to 6 by 6 months after prostatectomy, similar to the reported decrease from 17.6 to 
7.4 by 4 weeks.4 Also, the preoperative symptom problem and BPH impact scores 
were similar to those reported by Barry et al.8 Of the 93 cases evaluated 32 were 
unobstructed or equivocal. Nevertheless, mean prostate volume in these men was 36 
ml. This finding shows that not only prostatic obstruction, but also prostatic 
enlargement was important in the treatment decision. 
Table 3 shows slight differences in the R of the urethral resistance factor (continuous 
variable) with other parameters and the R of obstruction grade (discrete variable) 
with other parameters. This difference indicates that the variation resulting from the 
difference in the definition of improvement of a continuous variable and that of 
improvement of a discrete variable had minor importance. The Abrams-Griffiths 
number is less suited for our type of improvement grading because the number can 
have a negative value. Because most parameters did not show a normal distribution, 
only distribution-free tests were used. 
Table 3 also shows that improved symptoms, decreased problems, decreased bother 
impact and improved quality of life were significantly associated with improved 
bladder outlet function. Men with high urethral resistance preoperatively benefit most 
from bladder outlet obstruction relief. Table 3 shows an R of 0.18 to 0.38 for 
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improvement in voiding symptoms, which is higher than the R of 0.10 to 0.19 for 
improvement in storage symptoms in relation to the decrease in obstruction. These 
differences were not noted for the bother score.  
Prostatectomy resulted in 45% increased effective capacity. The increase in bladder 
capacity 6 months after prostatectomy has been previously observed by Meyhoff et 
al.17 The increase in effective bladder capacity was of the same order as the reported 
decrease in effective capacity during the development of benign prostatic 
obstruction.18 Increased effective capacity significantly correlates with improvement 
in symptom frequency, urgency and voiding frequency in the daytime (table 3). 
Increased effective capacity results in decreased bother in regard to urgency, 
nocturia and trouble with normal activity. Increased effective capacity results in 
significantly better quality of life. Considering that urgency and nocturia are the most 
bothersome symptoms6 and frequency is strongly associated with well-being6, we 
conclude that the observed increase in effective capacity contributed to a significant 
decrease in bother and improvement in well-being.  
Men with no obstruction preoperatively or in equivocal condition also benefited 
moderately from prostatectomy (table 4). In table 4 the improvements are not each 
listed in ascending order, which partly may have been due to differences in the 
baseline values of the various obstruction grade categories. Because of the 
significant correlations of baseline values with improvement after transurethral 
prostate resection, the significant correlations of obstruction grade improvement with 
symptom index, symptom problem index, BPH impact index and quality of life that 
are shown in table 3 are masked in table 4. The benefit of prostatectomy in 
unobstructed and equivocal cases may be explained by the resulting mean increase 
in effective capacity from 355 to 495 ml. and decrease in the prevalence of instability 
from 35% to 16%. After prostatectomy scores for the symptoms of nocturia, 
frequency and urgency, and associated symptom problems were strongly decreased. 
It is likely that irritative effects not due to bladder outlet obstruction cause symptoms 
in benign prostatic enlargement cases.  
The decrease in post-void residual urine volume contributed significantly to the 
increase in effective capacity. Nevertheless, the feeling of incomplete emptying 
preoperatively and subjective improvement in emptying after prostate resection had 
no relationship with actual post-void residual urine volume and actual improvement in 
bladder emptying. Of preoperatively stable bladders 90% remained stable. It is 
unclear whether instability developed in the remaining 10% of bladders after 
prostatectomy or existing instability was missed preoperatively. About 50% of 
unstable bladders become stable after prostatectomy. However, which bladder 
becomes stable cannot be predicted preoperatively from symptoms, bother or 
urodynamic findings.  
The disappearance of preoperative detrusor overactivity was not related to age. Men 
with a stable bladder preoperatively were younger than those with an unstable 
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bladder, although the difference was not significant (p=0.06). Overall the group of 
men with a stable bladder after prostatectomy showed slightly higher but significant 
improvement in symptom score, BPH impact index and quality of life (table 5). Men 
with a stable bladder preoperatively are more likely to have a stable bladder after 
prostatectomy than those with an unstable bladder preoperatively. 
 
Conclusions 
 
Improved symptoms, decreased symptom problems, decreased impact of bother and 
improved quality of life are significantly associated with improved bladder outlet 
function. However, men who do not have obstruction preoperatively or are in 
equivocal condition also benefit from resection. The feeling of incomplete emptying 
preoperative and subjective improvement in emptying after prostate resection have 
no relationship with actual post-void residual urine volume and actual improvement in 
bladder emptying.  However, a notable increase in effective bladder capacity partly 
caused by improved bladder emptying after transurethral prostate resection 
contributes to a significant decrease in symptoms and bother, and to improved well-
being.   
About 50% of the unstable bladders become stable after prostatectomy. Men with a 
stable bladder after prostatectomy show greater improvement in symptoms, the BPH 
impact index and quality of life than those with an unstable bladder postoperatively. 
Most preoperatively stable bladders remain stable but which unstable bladder may 
become stable after resection cannot be predicted. Performing preoperative 
urodynamics helps to predict the degree of symptom relief, decrease in bother and  
increase in well-being resulting from transurethral prostate resection. 
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Appendix  
 
Quantification of the improvement by treatment of a discrete parameter such as the 
score on the symptom question “Over the past month, how often have you had a 
weak urinary stream?” needs some attention. The score on that question may vary 
from 0 to 5. The question arises whether improvement (Imp) by treatment resulting in 
a decrease of the preoperative score (pre) of 5 to a postoperative score (post) of 3 is 
equal to a decrease from 3 to 1. In our opinion the latter improvement is better. 
Applying the formula:  
 
   Imp = (pre-post)/(pre+post) 
 
considers these differences in improvement. However, according to this formula, 
improvement from 5 to 0 is the same as improvement from 1 to 0. This result is 
obviated by adding 1 to each score, leading to the formula: 
 
   Imp = (pre+1-post-1) / (pre+1+post+1) 
 
We wanted improvement to be 100% when the preoperative value was the maximum 
score (max), whereas the postoperative value was the minimum score (min). This 
result can be achieved by modifying the formula, that is 
 
   Imp = 100% x [(pre+1-post-1)/(pre+1+post+1)] x [(max+1+min+1)/(max+1-min-1)] 
 
In the example of the weak urinary stream it leads to an improvement or worsening 
matrix (table 6). A score of 0 means that the symptom is absent. A preoperative 
score and a postoperative score of 0 cannot be interpreted in terms of improvement 
or worsening. Similar matrixes can be developed for the Schäfer obstruction grade, 
quality of life, symptom bother scores. 
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Table 6 Improvement or worsening matrix. The horizontal axis shows the preoperative score and the 
vertical axis shows the postoperative score. 
  
         pre = 
 
post = 
0 1 2 3 4 5 
0 1 47% 70% 84% 93% 100% 
1 - 47% 0% 28% 47% 60% 70% 
2 - 70% -28% 0% 20% 35% 47% 
3 - 84% - 47% - 20% 0% 16% 28% 
4 - 93% - 60% - 35% - 16% 0% 13% 
5 -100% - 70% - 47% - 28% - 13% 0% 
 
1. A score of 0 means that the symptom is absent. A preoperative score and a postoperative score of 
0 cannot be interpreted in terms of improvement or worsening. 
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Abstract 
 
 
Objectives: To compare the benefits of TURP in urodynamically obstructed versus 
selected urodynamically unobstructed or equivocal men with severe lower urinary 
tract symptoms (LUTS) associated with benign prostatic enlargement. 
 
 
Methods: In this case series study, men with LUTS were selected if they met study 
criteria and underwent the tests recommended by the International Scientific 
Committee on Benign Prostatic Hyperplasia. They also underwent urodynamic 
investigations. Men were included when TURP was selected as the treatment 
modality. Of the 132 included subjects, 93 could be re-evaluated 6 months after 
surgery.  
 
 
Results: Of the 93 re-evaluated men, 59 were obstructed and 34 unobstructed or 
equivocal. Both groups were similar with respect to age, symptoms, bother, BPH-
impact index, and quality of life. The quantified reductions in symptoms and bother in 
the unobstructed and equivocal men were about 70% of those reductions in 
obstructed men. In the equivocal men, and even in the unobstructed men, a 
significant reduction with 40% of the urethral resistance occurred.  
 
 
Conclusions: TURP may be a good treatment alternative for unobstructed or 
equivocal men with severe LUTS associated with prostatic enlargement, who opt for 
resection or who do not respond to or do not tolerate medical therapy. 
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Introduction 
 
The number of patients with lower urinary tract symptoms (LUTS)1 suggestive of  
benign prostatic hyperplasia (BPH) will strongly increase because of an ageing 
population. In addition, the number of treatment modalities is increasing. These 
changes make patient selection at baseline more and more critical. 
The International Scientific Committee (ISC) of the International Consultation on 
BPH2 recommends the quantitative documentation of symptom prevalence using the 
International Prostate Symptom Scores (I-PSS) questionnaire and quality of life 
question developed by the Measurement Committee of the American Urological 
Association (AUA).3 This Measurement Committee also developed and validated a 
symptom problem index (SPI) with 7 bother questions each of which corresponds to 
a symptom question of I-PSS,4 and the BPH impact index (BII), consisting of 4 
questions on patient well-being and the social implications of lower urinary tract 
symptoms.4 
The relationships among urodynamic parameters, treatment outcome, symptom relief 
and patient satisfaction, are still the subject of controversy. The ISC recommends 
pressure flow studies before invasive therapies or when a precise diagnosis of 
bladder outlet obstruction is important.2 The outcome from therapy appears to be 
related to the pretreatment urodynamic findings, because patients with obstruction 
fare better than those without obstruction.5 Therefore, less expensive and less 
morbid therapies are recommended for patients who are unobstructed or equivocal. 
The use of alpha-blockers in these men has increased strongly. A concomitant 
decrease in transurethral prostatectomy has been observed. 
Men with high urethral resistance preoperatively benefit most from bladder outlet 
obstruction relief.6 Nevertheless, men who were preoperatively unobstructed or 
equivocal also benefited significantly from transurethral resection of the prostate.6 
This is especially important for unobstructed or equivocal men with severe LUTS 
associated with prostatic enlargement who opt for resection, who do not respond to 
medical therapy and/or in whom adverse effects require medication discontinuation. 
The aim of this study was to compare the quantified improvements six months after 
transurethral prostatectomy in unobstructed and equivocal men with severe LUTS 
associated with prostatic enlargement, with the outcomes of transurethral 
prostatectomy in obstructed men with prostatic enlargement. 
 
Material and methods 
 
All men, who are older than 45 years of age and visiting our outpatient department 
with lower urinary tract symptoms (LUTS) associated with benign prostatic 
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hyperplasia (BPH), undergo a basic initial evaluation and tests conforming to the 
recommendations of the International Consensus Committee on BPH from 1993 as 
updated in 2000 by the ISC.2 Their residual volume is estimated and their prostate 
size is determined by transrectal ultrasound. I-PSS, quality of life, bother, and BPH 
impact index questions are completed by all men. In our outpatient department it is 
common practice to perform filling cystometry and pressure flow studies in all of 
these men. 
On the basis of the pressure-flow measurements men are classified as unobstructed, 
equivocal or obstructed according to the provisional International Continence Society 
method for the definition of obstruction.7 In addition the urethral resistance factor 8 
(URA) is estimated. Effective capacity is defined as the cystometric capacity minus 
the post-void residual urine volume. 
Different treatment modalities for LUTS owing to prostatic enlargement are available 
in our clinic: watchful waiting, medical therapy and surgery (abdominal and 
transurethral prostate resection, electrovaporization and laser therapy). 
On the basis of the results of the investigations and the results of any previous 
treatment, the treatment alternatives are discussed by the staff of the department of 
urology with each patient. Generally surgery is advised in urodynamically obstructed 
normal risk men. In urodynamically equivocal and unobstructed men generally 
medication with alpha-blockers is usually advised. The final decision about the 
treatment modality is the result of a shared process between the patient and his 
medical attendant taking into account the benefits and the risks of treatment 
alternatives. 
From 1995 on we investigated the effects of different kinds of transurethral prostate 
surgery. All normal risk men who had no exclusion criteria specified by the ISC2 and 
who are considered for transurethral surgery are invited to participate in follow-up 
studies. After obtaining the informed consent, a re-evaluation 6 months after surgery 
was performed, including symptoms, quality of life, bother and problem index 
questions as well as filling cystometry and pressure-flow study. Between 1996 and 
2002 men were included in the present study if transurethral resection of the prostate 
(TURP) was the treatment modality. Except for prostate size (see discussion), no 
statistically significant differences between these men and the men undergoing other 
types of transurethral surgery were detected (table 1). Because some parameters are 
not normally distributed, the median value (50th percentile) and the 25th and 75th 
percentiles  are listed. 
We calculated improvement or worsening of a parameter by comparing the 
postoperative value (Vpost) to the preoperative value (Vpre). If an increase in the 
value V of the parameter was expected (for instance free flow rate) the improvement 
was defined as: Vpost-Vpre. If a reduction in the value was expected (for instance 
URA) the improvement was defined as : Vpre-Vpost. 
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The Kolmogorov-Smirnov goodness of fit test was used to analyze whether the 
distribution of a variable was normal. Statistical analyses were performed with  
 
Table 1 Baseline values in the enrolled group (n=132) versus those in the other groups undergoing 
transurethral surgery (n=109). 
 
 
Parameter 
Other men 
(n=109) 
Enrolled men 
(n=132) 
Mann-
Whitney 
U test
 
 25th 
50th 
(median) 75th 25th 
50th 
(median) 75th P-value
Age (years) 59 66 74 58 66 71 0.7 
Prostate volume (ml) 28 35 46 30 40 51 0.02 
Maximal free flow rate 
(ml/s) 8 10 14 7 10 13 0.9 
Residual volume (ml) 0 35 170 0 55 140 0.5 
Cystometric capacity 
(ml) 250 400 500 300 350 500 0.8 
Effective capacity (ml) 200 290 400 200 295 400 0.9 
Urethral resistance 
factor URA) (cm H2O) 
28.6 36.6 47.0 29.0 40.0 57.8 0.08 
I-PSS 15 20.51 24 13 19 25 0.5 
Quality of life score 3 4 5 3 4 5 0.5 
Symptom problem 
index 8 13.5
1 18 8 13.5 20 0.9 
BPH impact index 4 6 8 3 6 8 0.9 
 
1. Because of a high number of equal values some percentiles are not integers. 
 
distribution free tests, including the Fisher-Irwin test for two-by-two tables, the 
Wilcoxon signed rank test and the Mann-Whitney U test. Two-tailed significance was 
considered at 0.05. 
 
Results 
 
In 39 men of the prospectively selected 132 patients (43 equivocal or unobstructed 
and 89 obstructed) follow-up at 6 months was not possible: 15 men, were satisfied 
but did not agree to additional investigations; in 8 men, condition did not allow 
reliable follow-up; in 5, catheterization failed at follow-up urodynamic investigation; 4 
men had postoperative complications; 3 men had died; and 4 men emigrated within 6 
months after operation. Of the 39 men in whom follow-up was not possible 30 were 
   CHAPTER 3 
 64 
obstructed and 9 were equivocal or unobstructed. Of the 93 men included for 
analysis, 59 were obstructed, 28 equivocal and 6 unobstructed. The reasons why 
equivocal or unobstructed men underwent resection were: 13 men opted for 
resection, 12 men could not benefit from or did not tolerate alpha-blockers, and in 5 
men high post-void urine volumes were found. Four men underwent resection for 
different reasons.  
Except for urethral resistance factor (URA), no statistically significant differences 
were found between the baseline values of the 28 equivocal men and those of the 6 
unobstructed men. In table 2, the baseline values of the equivocal or unobstructed 
men are compared to those of the obstructed men.  
 
Table 2 Baseline values of unobstructed and equivocal men (n=34) versus obstructed men (n=59). 
 
Parameter 
Unobstructed and equivocal 
men  
(n=34)
Obstructed men  
 
(n=59)
Mann-
Whitney U 
test
 
 25th 
50th 
(median) 75th 25th 
50th 
(median) 75th P-value 
Age (years) 58 66 71 60 66 72 0.7 
Prostate volume (ml) 28 34 44 33 46 60 <0.01 
Maximal free flow rate 
(ml/s) 9.9 11.7 15.5 6 9 12 <0.01 
Residual volume (ml) 0 23 85 0 50 120 0.3 
Cystometric capacity 
(ml) 300 400 585 300 350 450 0.07 
Effective capacity (ml) 250 325 500 200 270 380 0.02 
Urethral resistance 
factor (URA) (cm H2O) 
20.6 25.2 31.5 39.1 46.0 62.1 <0.01 
I-PSS 12 18 21.25 16 20 25 0.04 
Quality of life score 2 4 5 3 5 5 0.03 
Symptom problem 
index 4.75 11 19 10 15 21 0.08 
BPH impact index 3 6,5 8.25 4 6 9 0.9 
 
 
A large similarity was found between both groups, although statistically significant 
differences were also found. The baseline values (table 2) of the 9 equivocal or 
unobstructed men who did not undergo the six-month follow-up examinations did not 
differ significantly from those of the 34 equivocal or unobstructed followed-up men 
included in the study. Except for the quality of life score, the baseline values of the 30 
obstructed men who did not undergo the six-month follow-up examinations also did 
not differ significantly from those of the 59 obstructed men. The quality of life score 
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was significantly (p=0.03) greater (quality of life was lower) in the study men (see 
discussion). 
In table 3, improvements six months after transurethral resection in the equivocal or 
unobstructed group are compared to those in the obstructed group  
 
Table 3 Improvements in unobstructed and equivocal men (n=34) versus those in the obstructed men 
(n=59). 
 
Parameter 
Unobstructed and equivocal 
men  
(n=34)
Obstructed men  
 
(n=59)
Mann-
Whitney U 
test
 
 25th 
50th 
(median) 75th 25th 
50th 
(median) 75th P-value 
URA reduction (cm H2O) 4.9 9.5 13.2 21.5 30.3 46.4 <0.001 
Maximal free flow rate 
increase (ml/s) 2.0 7.8 12.6 6.0 11.0 18.0 0.02 
Cystometric capacity 
increase (ml) -25 50 150 -50 50 150 0.7 
Effective capacity 
increase (ml) 0 130 220 50 120 200 0.6 
Reduction in symptom 
index 5 10 13.25 9 14 21 0.02 
Reduction in symptom 
bother index 2 7 14.75 6 11 18 0.04 
Reduction in quality of 
life score 1 2 4 2 3 4 0.03 
Reduction in BPH impact 
index 1.75 3.5 7 2 4 7 0.2 
 
 
Except for obstruction grade and maximal free flow rate, the changes were very 
similar in both groups. In the obstructed men the median value of URA decreased 
from 46.0 to 15.0 cm water (p<0.001), in the equivocal group from 27.9 to 16.2 
(p<0.001) and in the small group of 6 unobstructed men from 19.2 to 11.8 (p=0.03).  
No significant differences at all of improvements between the 6 unobstructed men 
and the 28 equivocal men could be detected. The different reasons why resection 
was performed in the equivocal and unobstructed men did not cause different 
postoperative benefits. 
In all 6 unobstructed men URA decreased after prostatectomy. In 4 men of the 
equivocal group, URA worsened after prostatectomy and in 2 men of the obstructed 
group. The parameters in table 3 were recalculated after exclusion of these men. The 
differences with the values in table III appear to be marginal. 
Of the 59 obstructed men, 32 (54%) had an unstable bladder preoperatively and 19 
(32%) postoperatively. Of the 34 equivocal or unobstructed men, 11 (32%) had an 
unstable bladder preoperatively and 6 (17%) postoperatively. No significant 
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difference between the decrease in prevalence of unstable bladders in both groups 
was observed.  
Of the 59 obstructed men, 27 (46%) had a residual volume higher than 50 ml 
preoperatively and 2 (3%) postoperatively. Of the 34 equivocal or unobstructed men, 
13 (38%) had a postvoid residual volume greater than 50 ml preoperatively and 3 
(9%) postoperatively. Again, no statistically significant difference between the groups 
could be detected. 
 
Comment 
 
Physicians are rather reserved about resection of the prostate in equivocal or 
unobstructed men. A problem arises when a man with considerable LUTS and 
benign prostatic enlargement but without infravesical obstruction does not want 
medication at all, does not benefit from medication or does not tolerate this 
treatment. The results of our prospective study showed that our selected equivocal or 
unobstructed men were similar to our obstructed group with respect to age, 
symptoms, bothering, BPH-index, quality of life, prevalence of post-void residual 
volume and prevalence of unstable bladder (table 2 and results). Their prostate 
volume was smaller but still significantly enlarged (table 2). Most of these men opted 
for surgery, did not benefit from medication or did not tolerate medication. These 
different reasons did not result in different post-operative benefits.  
In the obstructed group the median value of URA significantly decreased by 70%, in 
the equivocal group by 40% and even in the small unobstructed group significantly by 
40%. Thus, prostatectomy in equivocal and unobstructed men can result in a 
significant reduction in outflow resistance. 
The reductions in symptom and bother in the equivocal and unobstructed men were 
approximately 70% of those in the obstructed men (table 3). Also, the post-void 
residual urine volume and the prevalence of detrusor instability decreased after 
prostatectomy in the equivocal and unobstructed men. 
Baseline values of our enrolled men did not differ from those of the men selected for 
other transurethral surgical procedures, except for prostate size (Table 1). This 
difference can be explained by the exclusion of men for electrovaporization and laser 
prostatectomy in our clinic when prostate volume was more than 65 ml. This 
exclusion also explains the (not statistically significant) greater URA in our enrolled 
group (Table 1). In the present study 13 men (all obstructed) had a prostate volume 
greater than 65 ml. This introduced bias; however the bias was in favor of the 
obstructed group because differences between the obstructed men and the equivocal 
or unobstructed men were more pronounced. 
A large number of men (39 out of 132) could not followed-up. This may have caused 
bias. However, the baseline values of the equivocal or unobstructed men without 
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follow-up did not differ from those who had follow-up. The same applied for the 
obstructed groups. The proportion of men without follow-up was (p=0.10, not-
significant) smaller in the equivocal or unobstructed group compared to the 
obstructed group. Men who had real obstruction benefited more than those who were 
equivocal or unobstructed and therefore may have been more satisfied. Of the 15 
men who were satisfied but did not agree to additional investigations, 12 appeared to 
be obstructed preoperatively. This proportion was greater than would be expected 
from the pre-operative distribution, but the difference was not significant (p=0.25). 
Alpha-blockers are the most frequently used prescription medication.9 Witjes et al.10 
evaluated clinical and urodynamic changes in men with and without bladder outlet 
obstruction after six months of terazosin treatment. Although the inclusion and 
exclusion criteria differed slightly, the baseline values in their groups correspond to 
those in our groups. In our obstructed men, symptom reduction and increase of 
quality of life appeared to be more pronounced after prostate resection than the 
changes in their obstructed men treated with terazosin. Our urodynamic 
improvements after prostate resection even appeared to be superior to their 
urodynamic improvements after terazosin treatment. In the equivocal or unobstructed 
men, symptom reduction and increase of quality of life after terazosin treatment 
appeared to be comparable to those in our  equivocal or unobstructed men after 
prostate resection. However urodynamic improvements after prostate resection 
appeared to be superior to those after terazosin treatment. 
The number of men treated with alpha-blocker therapy is increasing. However, not all 
men can benefit enough from such medication11 and some men opt for resection or 
show adverse effects. 
Even though some bias may exist (negatively and positively) in our unobstructed or 
equivocal men who opt for resection, who did not respond to medical therapy and/or 
in whom adverse effects were associated with treatment discontinuation, prostate 
resection appeared to be a good treatment alternative. 
The presence or absence of urethral obstruction in men with lower urinary tract 
symptoms associated with prostatic enlargement should not be the decisive factor in 
treatment choice and absence of obstruction should not be an exclusion criterion for 
transurethral prostate resection. Nevertheless, decision-making remains a shared 
process between the physician and patient, taking into account the benefits and risks 
(mortality and morbidity) involved in the treatment alternatives. 
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Conclusions 
 
Equivocal or unobstructed men with severe LUTS  associated with benign prostatic 
enlargement may benefit fairly from transurethral prostatectomy compared with 
obstructed men. Therefore, the presence or absence of urethral obstruction in men 
with LUTS associated with prostate enlargement should be a less-decisive factor in 
the treatment choice. Transurethral resection may be a good treatment alternative for 
selected equivocal or unobstructed men who opt for resection, who do not respond to 
medical therapy, and/or in whom adverse effects require treatment discontinuation. 
Transurethral resection can result in a significant reduction in the urethral resistance, 
even in unobstructed men. 
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Abstract 
 
 
Purpose: We compared urodynamic and flowmetry improvements in men with lower 
urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) 
after transurethral resection of the prostate (TURP), contact laser prostatectomy and 
electrovaporization (EVAP; Vaportrode). 
 
 
Materials and Methods: A prospective randomized controlled trial was performed. 
Included were men with LUTS suggestive of BPH who met the criteria of the 
International Scientific Committee on BPH, had a prostate volume of between 20 and 
65 ml and a Schäfer’s obstruction grade ≥2. Before and six months after treatment, 
urodynamics and free flowmetry were performed. 
 
 
Results: Fifty men were randomized for TURP, 45 for laser treatment and 46 for 
EVAP. Baseline characteristics were similar in the different treatment groups. 
Detrusor contractility did not change in any of the treatment groups. The average 
maximum free flow rate increased by a factor of 2.4 after TURP, 2.5 after laser 
prostatectomy and 2.4 after EVAP. Schäfer’s obstruction grade decreased by a factor 
of 0.3 in all groups. Obstruction (Schäfer grade >2) was not noted after TURP or 
EVAP, but it was evident in 2 patients after laser prostatectomy. Effective capacity 
increased by a factor of 1.5 or more. The incidence of detrusor instability was 
decreased by half in all groups. The incidence of significant post-void residual urine 
volume decreased in all groups. 
 
 
Conclusions: There were no significant differences in the improvements of 
urodynamic and uroflowmetry parameters six months after treatment when 
comparing TURP, contact laser prostatectomy and electrovaporization in men with 
LUTS suggestive of BPH.
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Introduction 
 
Increased life expectancy causes an increase in the number of men presenting with 
lower urinary tract symptoms (LUTS), which is often associated with benign prostatic 
hyperplasia (BPH). An increasing number of these men are treated with 
pharmacotherapy, such as alpha-blockers, although a large population still requires 
surgical treatment1. For several decades transurethral prostate resection (TURP) has 
been the gold standard for surgical therapy. However, this procedure is associated 
with a mortality rate of 0.23% within 30 days of the operation2, increasing to 2.8% 
during 12 months of follow-up3. The immediate postoperative morbidity rate is 18%2 
and still 12% between 6 and 12 months postoperatively3. These rather high percents 
have led to many attempts to introduce new methods that match the benefits of 
TURP, but show a lower mortality and morbidity rate. 
In 1992 the use of laser therapy for BPH was introduced4. Several interstitial, contact 
and non-contact laser types were used and contact laser prostatectomy showed 
good results5. In 1993 another promising new treatment modality, namely 
electrovaporization (EVAP), was introduced6. These new techniques use extreme 
heat to vaporize prostatic tissue and leave behind a layer of coagulated tissue. 
Several trials comparing the outcome of different treatment methods were performed 
in the past. An extensive investigation of the urodynamic effects of various treatment 
modalities for BPH was described in the review of Bosch7. However, literature about 
randomized controlled trials comparing the urodynamic effects of new treatment 
modalities for BPH is rather scarce. We performed a randomized controlled trial in 
which we compared the urodynamic effects of contact laser therapy, EVAP and  the 
gold standard, TURP, in men with LUTS suggestive of BPH. These effects were 
studied by filling cystometry and pressure-flow studies before and six months after 
treatment, and by free uroflowmetry before and several times after treatment for up to 
12 months. 
 
Materials and Methods 
 
This prospective randomized controlled study was performed between 1996 and 
2001 at the department of urology at our institution. Included were men older than 45 
years old with LUTS suggestive of BPH. All patients underwent a history, digital 
rectal examination, transrectal ultrasonography, urodynamic evaluation, free 
uroflowmetry, post-void residual volume estimation, urinalysis and blood analysis. 
Questionnaires concerning symptom score (International prostate symptom score (I-
PSS))8, Quality of life8 and bother score (Symptom Problem Index)9, morbidity and 
sexuality were completed before and several times after surgery. In study patients 
prostate volume was between 20 ml and 65 ml and the Schäfer obstruction grade 
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was 2 or higher. Patients with any exclusion criteria of the International Consensus 
Committee on BPH were excluded from analysis10. 
Urodynamic studies consisted of filling cystometry and pressure-flow studies. 
Urodynamics were done before and 6 months after treatment. From the pressure-
flow studies, the obstruction grade (0: no obstruction, to 6: severe obstruction) and 
detrusor contractility (0: very weak, to 5: strong bladder), as proposed by Schäfer11, 
were estimated, as well as the URA (group specific urethral resistance factor)12. 
Residual urine was estimated by catheterization. Effective bladder capacity was 
defined as maximum cystometric capacity (bladder filling at strong desire) minus 
residual volume. Uroflowmetry studies were also done before treatment and they 
were repeated 1 and 6 weeks and 3, 6 and 12 months after treatment. Flowmetry 
results were only included if patients voided more than 150 ml. 
TURP was performed with a standard 24 Fr resectoscope, using glycine for irrigation. 
When necessary, a suprapubic catheter was inserted intraoperatively. Laser 
prostatectomy was performed with an SLT Nd:YAG laser (Surgical Laser 
Technologies, Oaks, Pennsylvania, USA) with an MTRL 10, 6.0 x 5.0 mm sapphire-
tipped probe. A Morgenstern scope was used to introduce the glassfiber with the 
contact probe. Isotonic salt solution was used as the irrigation fluid. EVAP was 
performed with a Vaportrode (Circon-Acmi, Stanford, Connecticut USA) element 
using glycine for irrigation. All patients intravenously received antibiotics 
perioperatively and a 20 Fr transurethral catheter was placed postoperatively. 
To calculate group size, we hypothesized that after 6 months laser prostatectomy 
resulted in 85% and EVAP in 70% of the  increase in maximum flow (Qmax,free) due 
to TURP. Power was set at 90% and 2-sided significance was considered at 5%. As 
the standard deviation (SD) 4.6 ml/s for Qmax,free was selected since this SD was 
reported13 in a similar group of men. We assumed a SD of 4.0 ml/s for the difference 
in Qmax,free. Using one-way ANOVA this resulted in group size of 32 men. This 
number is in agreement with the American Urological Association new technology 
assessment committee, which stated that more than 30 patients per group should be 
evaluated14. 
The Kolmogorov-Smirnov goodness-of-fit test was used to examine whether a 
variable was distributed normally. A number of parameters are reported with the SD 
since this convention is often followed in literature. Statistical analysis were done with 
one-way-ANOVA, the Kruskal-Wallis non-parametric test of independent variables 
and the Mann-Whitney U test.  
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Results 
 
Table 1 lists the baseline characteristics of the study patients. There were no 
statistically significant differences among the three treatment groups in any 
parameter, except effective capacity and symptom score between TURP and 
Vaportrode patients (p=0.007 and p=0.04 respectively). 
Table 2 shows maximum free flow estimated by free flowmetry. It was our intent to 
perform flowmetry before treatment and at several times after treatment up to twelve 
months. However, only at the pretreatment and six month points were sufficient 
patients evaluated to enable for statistically significant calculations (see discussion). 
There was no statistically significant difference in the increase of maximum flow 
among the groups after six months, on the Kruskal-Wallis non-parametric test of 
independent variables. Change is calculated as the ratio of posttreatment maximum 
flow after six months divided by pretreatment maximum flow. The average of these 
individually calculated changes is presented with the minimum and maximum 
change. In the TURP and laser groups there was always an increase in maximum 
free flow (minimum ratio >1.0). Three patients in the EVAP group showed a decrease 
in maximum flow (including one each from 12 to 8 ml/s, 15 to 12 ml/s and 15 to 11 
ml/s). 
The International Consultation on BPH15 recommends standard criteria for efficacy of 
BPH treatment. Efficacy is graded as excellent for ∆Qmax (change in maximum flow) 
≥10 ml/s, good if  5≤ ∆Qmax <10 ml/s, fair if 2.5≤ ∆Qmax <5 ml/s and poor if ∆Qmax 
<2.5 ml/s. Using these criteria, TURP, laser and EVAP were scored as: excellent in 
65%, 69% and 59%, good in 21%, 31% and 21%, fair in 6%, 0% and 3% and poor in 
9%, 0% and 17% of patients, respectively. A graphical representation is shown in 
figure 1. 
About 30% of all included patients per group were not reexamined by urodynamics 
six months after treatment. Table 3 lists the reasons. Table 4 shows some 
urodynamic findings in the remaining men at baseline and six months after treatment. 
Change was again expressed as the average of all individually calculated ratios of 
posttreatment outcome divided by pretreatment outcome. Statistical analysis using 
one-way-ANOVA revealed no significant differences in the changes of all urodynamic 
parameters among the three treatment groups.  
The data showed that the average detrusor pressure at maximum flow was 
decreased by half and that there was never an increase in detrusor pressure. The 
decrease in detrusor pressure was significant in all treatment groups, while 
contractility did not change significantly. The Schäfer discrete obstruction grade and 
continuous URA decreased significantly. A graphical representation is shown in 
figure 2. As mentioned in the materials and methods section, only patients 
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Table 1 Baseline characteristics of the 3 treatment groups (averages ± standard deviations). 
 
 TURP Contact Laser Vaportrode 
Number of patients included 50 45 46 
Mean age (years)  (range) 66 ± 8 (50-82) 67 ± 9 (49-82) 64 ± 10 (49-81) 
Prostate Volume (ml) 37 ± 11 37 ± 11 35 ± 11 
Maximum Free Flow (ml/s) 11 ± 4 12 ± 4 11 ± 4 
Detrusor Pressure at Qmax (cm H2O) 76 ± 27 69 ± 24 75 ± 26 
Schäfer Obstruction Grade  3 ± 1 3 ± 1 3 ± 1 
URA (cm H2O) 43 ± 20 41 ± 23 45 ± 24 
Effective Capacity (ml) 350 ± 140 300 ± 135 290 ± 145 
Detrusor Instability (prevalence) 44% 48% 33% 
Relative Residue >10% (prevalence) 46% 48% 59% 
Symptom Score 16.8 ± 6.0 18.9 ± 6.8 20.2 ± 6.6 
Bother Score 11.9 ± 6.7 12.5 ± 7. 8 14.1 ± 6.7 
Quality of Life Score 3.8 ± 1.5 3.7 ± 1.6 4.1 ± 1.4 
 
 
 
 
 
Table 2 Results of uroflowmetry (averages in ml/s ± standard deviations). 
 
 Pre week 1 week 6 month 3 Month 6 Change1 month 12 
TURP 
11 ± 4 
 
n=46 
18 ± 7 
 
n=15 
24 ± 12 
 
n=16 
25 ± 11 
 
n=15 
24 ± 7 
 
n=37 
2.4 
(1.1 – 6.4)2 
n=34 
21 ± 8 
 
n=11 
Laser 
11 ± 4 
 
n=39 
14 ± 7 
 
n=11 
20 ± 4 
 
n=8 
23 ± 11 
 
n=12 
24 ± 7 
 
n=33 
2.5 
(1.4 – 6.0)2 
n=29 
22 ± 11 
 
n=11 
Vaportrode 
11 ± 4 
 
n=41 
17 ± 10 
 
n=12 
22 ± 7 
 
n=13 
20 ± 10 
 
n=19 
23 ± 10 
 
n=33 
2.4 
(0.7 – 5.8)2 
n=29 
23 ± 8 
 
n=9 
 
1. Average of all individually calculated changes (posttreatment value/ pretreatment value). 
2. Range: this shows the minimum and maximum change. Change was calculated only in patients 
who underwent pre and posttreatment uroflowmetry. 
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Table 3 Reasons why included patients were not evaluated urodynamically after six months. 
 
 TURP Contact laser Vaportrode 
    Peroperative and postoperative 
    reasons up to one month    
Procedure during surgery changed for 
medical reasons 0 3 2 
Equipment failure during surgery resulting in 
standard therapy (TURP) - 2 1 
Postoperative complications within one 
month 2 1 0 
Surgery cancelled due to other (medical) 
problems 1 0 1 
Procedure during surgery not correctly 
performed 0 0 4 
    Postoperative reasons after one 
    month up to six months    
No agreement with re-examinations 2 4 3 
Condition of patient did not allow reliable 
follow-up 3 3 2 
Failed catheterization during urodynamics at 
six months 3 0 1 
Postoperative complications within six 
months after surgery 2 0 0 
Patient died within six months after surgery 2 0 0 
Patient emigrated within six months after 
surgery  1 0 0 
 
 
With a Schäfer grade of 2 or greater were included. The incidence of patients with a 
preoperative Schäfer grade of 2 or greater who were also examined at six months 
was 71% for TURP, 66% for laser and 81% for EVAP. In the TURP group all patients 
showed a decrease in Schäfer grade, including 94% who were unobstructed after 
TURP (Schäfer grade 0 or 1). Only two patients were equivocal (Schäfer grade 2). 
The Schäfer grade had been 5 and 4 before surgery respectively.In the laser group 
all except one patient had a decrease in Schäfer grade. In the laser group, 91% was 
unobstructed after laser therapy. The Schäfer grade increased from 4 to 5 in one 
patient, decreased from 4 to 3 in a second patient and from 3 to 2 in a third patient. In 
the Vaportrode group all except two patients had a decrease in Schäfer grade. These 
two patients showed no change with a Schäfer grade of 2 (equivocal). Of all patients 
who underwent electrovaporization 72% were unobstructed, while Vaportrode, while 
the remaining 28% became (or staid: 2 patients) equivocal. Thus, no patients were 
obstructed after Vaportrode. 
Effective capacity is the maximum cystometric volume during urodynamics minus the 
residual volume after voiding. There was a significant increase in all three groups. It 
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was highest in the Vaportrode group, although not significantly different from the 
other treatment modalities. Increase in effective capacity was the result of an 
increase in cystometric capacity and a concomitant decrease in residual volume. A 
graphical representation is shown in figure 3.  
We also calculated the percent of patients with a clinically relevant post-void residual 
volume of more than 10% of maximum cystometric capacity. In all groups, especially 
the TURP group, a large decrease in that percent was demonstrated. The prevalence 
of detrusor instability was calculated in each group. For this calculation all patients 
with measurable instability were included, as recommended by the International 
Consultation on BPH. The number of patients was decreased by half in all three 
groups after treatment.  
Table 5 shows the pre and posttreatment values for the symptom score index, 
symptom problem index (bother score) and the Quality of Life question. All changes 
were significant in all groups. There were no significant differences in changes 
among the three treatment modalities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Mean maximum free urinary flow rate at baseline (pre) and at different time intervals for up to 
12 months postoperatively for the three modalities. 
Maximum Free Flow
0
5
10
15
20
25
30
pre week 1 week 6 month 3 month 6 month 12
Fl
ow
 (m
l/s
)
TURP
Laser
Vaportrode
URODYNAMIC EFFECTS… 
79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Mean Schäfer obstruction grade at baseline and 6 months postoperatively for the three 
modalities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Effective capacity (defined as the maximum cystometric capacity minus post void residual 
urine volume) at baseline and 6 months postoperatively for the three modalities.
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Table 4 Results of the urodynamic evaluations. Results only for patients who were evaluated pre and 
posttreatment: for TURP n=34, for Contact Laser n=32 and for Vaportrode n=32. (averages ± standard 
deviations). 
 
Urodynamic parameter Pretreatment 6 months Posttreatment Change
1 Range2 
pQmax (cm H2O) 
    TURP 
    Laser 
    Vaportrode 
 
72 ± 26 
70 ± 24 
78 ± 27 
 
33 ± 10 
37 ± 12 
40 ± 13 
 
0.5 
0.6 
0.5 
 
0.2 – 1.0 
0.2 – 1.0 
0.2 – 1.0 
Contractility 
    TURP 
    Laser 
    Vaportrode 
 
2.4 ± 0.9 
2.3 ± 0.9 
2.8 ± 1.2 
 
2.6 ± 1.3 
2.5 ± 1.0 
2.8 ± 1.4 
 
1.2 
1.2 
1.0 
 
0.5 – 3.0 
0.3 – 3.0 
0.0 – 2.5 
Schäfer grade 
    TURP 
    Laser 
    Vaportrode 
 
3.3 ± 1.1 
3.3 ± 1.3 
3.5 ± 1.1 
 
0.8 ± 0.6 
1.0 ± 1.0 
1.0 ± 0.7 
 
0.3 
0.3 
0.3 
 
0.0 – 0.5 
0.0 – 1.3 
0.0 – 1.0 
URA (cm H2O) 
    TURP 
    Laser 
    Vaportrode 
 
41 ± 20 
43 ± 26 
46 ± 28 
 
14 ± 5 
17 ± 13 
16 ± 6 
 
0.4 
0.5 
0.4 
 
0.1 – 1.1 
0.1 – 1.7 
0.1 – 1.0 
Effective Capacity (ml) 
    TURP 
    Laser 
    Vaportrode 
 
340 ± 125 
300 ± 130 
305 ± 150 
 
440 ± 140 
435 ± 120 
475 ± 165 
 
1.5 
1.5 
2.1 
 
0.6 – 4.2 
0.7 – 2.8 
0.6 – 8.2 
Relative Residual Volume 
>10%3 
    TURP 
    Laser 
    Vaportrode 
 
47% 
41% 
32% 
 
3% 
16% 
13% 
  
Detrusor Instability3 
    TURP 
    Laser 
    Vaportrode 
 
47% 
44% 
31% 
 
21% 
22% 
16% 
  
 
1. Average of all individually calculated ratios (post-treatment value/ pre-treatment value).  
2. Range shows the minimum and maximum change. 
3.Prevalence. 
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Table 5 Changes in Symptom Score, Bother Score and Quality of Life (averages ± standard 
deviations). 
 
   Score Pretreatment 6 months Posttreatment Change
1 
   Symptom Score 
 TURP 
 Laser 
 Vaportrode 
16.8 ± 6.0 
18.9 ± 6.8 
20.2 ± 6.6 
 
5.3 ± 5.1 
6.6 ± 5.8 
7.2 ± 6.7 
 
0.32 
0.35 
0.36 
 
   Bother Score 
 TURP 
 Laser 
 Vaportrode 
11.9 ± 6.7 
12.5 ± 7.8 
14.1 ± 6.7 
 
2.1 ± 4.2 
2.8 ± 4.4 
3.5 ± 4.6 
 
0.18 
0.22 
0.25 
 
   Quality of Life 
 TURP 
 Laser 
 Vaportrode 
3.8 ± 1.5 
3.7 ± 1.6 
4.1 ± 1.4 
 
0.9 ± 1.2 
± 1.1 
1.6 ± 1.6 
 
0.24 
0.30 
0.39 
 
 
1. Average of all individually calculated changes (posttreatment/ pretreatment value). 
 
Discussion 
 
In three different ways heat is applied to remove the excess prostate tissue that 
causes LUTS. The gold standard, TURP, uses an electrically heated bent wire. 
Electricity flows from the active element (the electrode placed in the urethra) to the 
return electrode, which is a large surface electrode attached to the patient skin. In 
TURP there is a high current density over a small wire, resulting in tissue dissection 
and minimal coagulation16. When vessel cutting occurs, additional coagulation is 
necessary. Removed chips of prostatic tissue can be weighed and sent for 
pathological examination. 
Electrovaporization uses the same principle as TURP, but the area over which 
electricity flows is much larger, which causes vaporresection with a layer of high-
impedant-coagulated tissue a few millimeters thick. There are no chips of tissue that 
can be weighed or sent for pathological examination. Each method uses glycine, an 
electrically conductive fluid, as irrigation fluid with the potential risk of TUR syndrome. 
A review of Patel et al17 of EVAP included a meta-analysis of the first five 
prospectively randomized studies of this modality compared with loop resection. Only 
Hammadeh18 compared TURP with the same EVAP element as in our study. The 3-
year follow-up confirmed that EVAP was as effective as TURP for moderate BPH. 
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The urodynamic effect was not evaluated. The increase in Qmax (to more than 22 
ml/s) is comparable to our results and this result was maintained after 3 years. After 
that time there was even a significant difference compared with TURP patients, in 
which average Qmax was lower (18 ml/s). 
 
Laser prostatectomy can be performed in different ways. There is interstitial laser 
ablation in which a glassfiber is inserted into the prostate at fixed points. It causes 
necrosis and slow tissue sloughing for several weeks, making long catheterization 
necessary. Side fire laser prostatectomy is a non-contact laser technique in which 
laser light is deflected at a right angle at the end of the tip, causing mainly deep 
coagulation and some vaporization of prostate tissue. Contact laser prostatectomy 
uses a rounded black tip at the end of a glassfiber. Laser light energy is completely 
absorbed by the tip and transformed into heat. Direct contact of the tip with prostate 
tissue causes vaporization and coagulation, resulting in immediate tissue ablation.  
In the Oxford laser prostate trial, Keoghane et al19 studied extensively contact laser 
prostatectomy (identical device as in the present study) against TURP. They treated 
72 patients by contact laser and 76 by TURP. They presented no urodynamic 
findings. TURP results for Qmax after one year are comparable to ours (11 at 
baseline to 21 ml/s), but their laser results are worse (12 to 17 ml/s). No significant 
change was observed in change in Qmax after one year. Peri-operative blood loss 
and transfusion rate were significantly lower for the laser group.  
 
Tukhanen et al20 compared also contact laser prostatectomy (same element as in the 
present study) with TURP in prostates smaller than 40 ml. In both groups 25 patients 
were evaluated with flowmetry and urodynamics among other parameters. After 3 
and 6 months there were no significant changes between TURP and laser treatment 
for Qmax, detrusor pressure at Qmax and post-void residuals. Pre- and post-
operative values are similar to the present study.    
 
All laser techniques can be performed in saline, which should protect against the risk 
of TUR syndrome. Pathological examination is not possible.  
Table 3 lists the reasons why patients were not evaluated urodynamically six months 
after surgery. The new methods rarely suffered from technical problems making 
cross-over to TURP necessary. One contact tip broke and once the laserdevice failed 
due to software problems. Bleeding was the main reason for changing the surgical 
procedure making coagulation with a rollerball necessary. In the Vaportrode group, 
four patients were not treated according to the protocol, making evaluation 
impossible. Catheterization at the second urodynamic study never failed in the laser 
group, though this happened once in the Vaportrode group and three times in the 
TURP group. This might be caused by the sometimes large TURP space that is 
created.  
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Significance for Qmax was tested using the Kruskal-Wallis non-parametric test of 
independent variables. Repeated measurements were not used because a marked 
drop-out of results at week 1, week 6, month 3 and month 12 had occurred. An 
average of about 30% of the patients in all groups were evaluated at these intervals. 
A large variation in the increase between the different treatment groups made one-
way-ANOVA not suitable. 
Symptomatic  improvement was obvious  in all groups, but there were no significant 
differences in changes between the different modalities. Data are equal to those 
seen in the above mentioned studies18-20, although they do not provide information 
about change in bother score. A detailed evaluation of symptomatic and subjective 
changes in time is in preparation. 
 
Conclusions 
 
Urodynamic and flowmetric improvements six months after treatment show no 
significant differences when comparing TURP, contact laser prostatectomy and 
Vaportrode in men with LUTS suggestive of BPH. 
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Abstract  
 
 
Purpose: We analyze subjective changes, morbidity and mortality in men with lower 
urinary tract symptoms associated with benign prostatic hyperplasia (BPH) after 
transurethral resection of the prostate, contact laser prostatectomy and 
electrovaporization. 
 
 
Materials and Methods: A prospective, randomized controlled trial was conducted 
on men with lower urinary tract symptoms, who met the criteria of the International 
Scientific Committee on BPH, had a prostate volume between 20 and 65 ml., and 
had Schäfer’s obstruction grade 2 or greater. Objective morbidity was recorded for up 
to 12 months. Subjective morbidity was measured by a questionnaire completed by 
patients. Subjective changes were quantified using the International Prostate 
Symptom Score, Symptom Problem Index, Quality of Life question and BPH Impact 
Index. These indexes and the morbidity questionnaire were measured weekly for the 
first 6 weeks postoperatively and then at 3, 6 and 12 months. 
 
 
Results: Transurethral prostatic resection was analyzed in 50 men, laser treatment 
in 45 and electrovaporization in 46. Baseline characteristics, and changes in the 
symptom scores up to 12 months postoperatively were similar. Perioperative blood 
loss and perforation were greatest in the resection group, and retention was greatest 
in the laser group. During the first 6 postoperative weeks there was less pain and 
less haematuria after resection, and less incontinence after laser prostatectomy. 
 
 
Conclusions: Subjective changes are similar for transurethral prostatic resection, 
contact laser and electrovaporization. In the first 6 weeks after treatment there are 
only slight differences in pain, haematuria and incontinence among the therapies. 
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Introduction 
 
Transurethral resection of the prostate is the most common surgical intervention for 
men with lower urinary tract symptoms associated with benign prostatic hyperplasia 
(BPH). The last decade there has been an increasing number of men treated with 
pharmacotherapy, especially α-1 adrenergic blockers. However, not all patients can 
benefit from medication and require surgery1. Transurethral prostatic resection has 
been the gold standard for many decades but is associated with a mortality of 0% to 
0.8% within 1 month postoperatively, and 2.8% within 1 year2-5. Intraoperative 
morbidity varies from 6.9% to 14% 2-5, especially bleeding and perforation.  Morbidity 
within 30 days postoperatively varies from 9.5% to 18%, 2-5 and consists mainly of 
bleeding with or without clot retention, which can result in reoperation or transfusion. 
Late morbidity mainly consists of urethral strictures and bladder neck contractures, 
and is reported in up to11.2% of patients within 12 months2.  
In response to these complications a variety of alternative treatment modalities have 
been developed in the last decade. They all attempt to match the effects of 
transurethral prostatic resection but with lower mortality and morbidity. Contact laser 
prostatectomy and electrovaporization are 2 of these modalities which have shown 
good results in the past6, 7.  
We performed a randomized controlled trial in which we compared contact laser 
prostatectomy and electrovaporization with the gold standard transurethral prostatic 
resection. Previously we analyzed the urodynamic effects of these 3 treatment 
modalities8. There were obvious significant changes in maximum flow, cystometric 
capacity and obstruction grade, as well as other relevant changes, all of which were 
not significant, among the 3 treatment groups.  
The main reasons patients seek help for BPH are symptom bothersomeness and 
negative impact of lower urinary tract symptoms on quality of life9. The International 
Consensus Committee on BPH emphasized that therapy must be initiated according 
to the degree of symptom bothersomeness10. The Measurement Committee of the 
American Urological Association has developed and validated several questionnaires 
to quantify subjective parameters of symptoms, bothersomeness of symptoms, 
quality of life and impact of urinary problems on various domains of health11-12.  
We analyze and compare subjective changes, morbidity and mortality following 
transurethral resection of the prostate, contact laser prostatectomy and 
electrovaporization in men with lower urinary tract symptoms associated with BPH. 
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Materials and Methods 
 
This prospective, randomized controlled study was performed between 1996 and 
2001 at our medical center. The study included 141 men older than 45 years of age 
with lower urinary tract symptoms associated with BPH. History was taken in all 
patients, and digital rectal examination, transrectal ultrasonography, urodynamic 
evaluation, free flowmetry, post-void residual volume estimation, urinalysis and blood 
analysis were performed. Perioperative parameters of operative time, irrigation fluid 
volume, amount of blood loss, duration of bladder drainage and complications up to 
12 months postoperatively were recorded. 
The International Prostate Symptom Score (I-PSS)11, Quality of Life (QoL)11 , 
Symptom Problem Index (SPI or Bother Score)12 and BPH Impact Index (BII)12 were 
completed preoperatively, and 1 week, 6 weeks, 3 months, 6 months and 12 months 
postoperatively. Specific morbidity and symptomatic aspects were studied using a 
self-developed questionnaire that was completed by patients once preoperatively, 
and at weekly intervals during the first 6 weeks and 3, 6 and 12 months 
postoperatively. Questions concerned pain in the lower abdominogenital region, pain 
during voiding, haematuria, incontinence, urge and hesitancy. Patients indicated how 
many days they had 1 of these symptoms in the last week (score 0 to 7) and its 
severity (1 only minor symptoms to 5 severe symptoms). Together with the morbidity 
questionnaire, patients were asked to report the average number of voids during the 
daytime and nighttime for the last week. 
Inclusion criteria were prostate volume between 20 and 65 ml. and a Schäfer 
obstruction grade 2 or greater. Exclusion criteria were those of the International 
Consensus Committee on BPH10.  
Patients were randomized using opaque envelopes. Transurethral prostatic resection 
was performed with a standard 24Fr resectoscope using glycine for irrigation.  
Laser prostatectomy was performed using an SLT Nd:YAG laser (Surgical Laser 
Technologies, Oaks, Pennsylvania) with an MTRL 10, 6 x 5 mm sapphire tipped 
probe. A Morgenstern scope was used to introduce the glass fiber with the contact 
probe. Isotonic salt solution was used as irrigation fluid. Electrovaporization was 
performed with a Vaportrode (Circon-Acmi, Stanford, Connecticut) element using 
glycine for irrigation.  
Patients randomized for resection or electrovaporization were operated on alternately 
by experienced urologists and trainees. Patients for contact laser were mostly 
operated on by 1 experienced urologist together with a trainee. All patients received 
intravenous antibiotics intraoperatively. If necessary, a suprapubic catheter was 
inserted intraoperatively. Postoperatively a 20Fr transurethral catheter was left 
indwelling. 
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Group size was calculated with 90% power and a 5% 2-tailed significance level as 
described in detail previously8, which resulted in a group size of 32 men. This number 
agrees with the minimum number of 30 men recommended by the American 
Urological Association New Technology Assessment Committee13. 
The Kolmogorov-Smirnov goodness-of-fit test was used to examine whether a 
variable was distributed normally. A number of parameters are reported as mean with 
standard deviation (SD). Further statistical analyses were done with Fisher’s Exact 
test, Pearson chi-square test, 1-way-ANOVA, Kruskal-Wallis nonparametric test, 
Student’s t test, Mann-Whitney U test and Wilcoxon test.  
 
Results 
 
The baseline characteristics of the remaining 141 included patients are listed in table 
1. Except for the effective capacity, no statistically significant differences between the 
three treatment groups were detected. 
Table 2 shows the perioperative data. Mean operation time was within one hour and 
did not differ significantly between the three groups (p=0.09). Intra-operative visually 
estimated blood loss was significantly lower in the laser and electrovaporization 
group compared to the transurethral prostatic resection group (p<0.001). A significant 
decrease of haemoglobin concentrations (mmol/l) was only seen within the 
transurethral prostatic resection group. This decrease was significantly (p<0.001) 
more in the transurethral prostatic resection group compared to the other groups. 
The use of irrigation fluid was lowest in the electrovaporization group and this was 
significantly lower than in the laser group (p=0.01). Drainage time and hospital stay 
did not differ significantly among the groups.  
Table 3 shows the intraoperative complications. Contact laser often caused tissue 
debris, which sometimes made conversion to transurethral prostatic resection 
necessary. Transurethral prostatic resection had the highest risk of  capsule 
perforations. Table 4 shows the postoperative morbidity and mortality up to twelve 
months postoperatively.  
The prevalence of urinary tract infections, confirmed by culture, were for transurethral 
prostatic resection, contact laser and electrovaporization 10%, 9% and 5% one week 
postoperatively and 10%, 8% and 10% after six weeks respectively. 
Table 5 lists the subjective AUA scores for the different treatment groups 
preoperatively and 12 months postoperatively together with the change. Figure 1a-d 
shows graphic representations of these scores during all six intervals. In all treatment 
groups there were obvious and significant differences between the pre-operative 
scores and the 12 month postoperative scores (p<0.001). For the symptom score 
index (I-PSS) and symptom problem index (SPI) there were no significant differences 
among the different treatment groups 12 months  
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Table 1 Mean ± standard deviation of baseline characteristics of the 3 treatment groups. 
 
 TURP Contact Laser Vaportrode 
Number of patients analyzed 50 45 46 
Mean age (years)   66 ± 8 67 ± 9 64 ± 10 
Prostate Volume (ml) 37 ± 11 37 ± 11 35 ± 11 
Maximum Free Flow (ml/s) 11 ± 4 12 ± 4 11 ± 4 
Schäfer Obstruction Grade  3 ± 1 3 ± 1 3 ± 1 
Effective Capacity 1 (ml) 350 ± 140 300 ± 135 290 ± 145 
Symptom Score Index 16.8 ± 6.0 18.9 ± 6.8 20.2 ± 6.6 
Symptom Problem Index (Bother Score) 11.9 ± 6.7 12.5 ± 7.8 14.1 ± 6.7 
Quality of Life 3.8 ± 1.5 3.7 ± 1.6 4.1 ± 1.4 
BPH Impact Index 9.6 ± 4.7 9.3 ± 4.2 10.8 ± 4.1 
 
1. Effective capacity = maximum cystometric capacity – post void residual volume. 
 
 
Table 2 Mean ± standard deviation of perioperative parameters. 
 
 TURP Contact Laser Vaportrode 
Operation time (min) 58 ± 26 range: 25 - 150 
58 ± 11 
range: 30 - 80 
50 ± 16 
range: 20 - 90 
Blood loss intraoperatively 1 1.1 ± 0.3 0.6 ± 0.7 0.6 ± 0.6 
Change in Hb (mmol/l) 2 9.2 → 8.4 p < 0.001 
9.0 → 8.8 
p = 0.3 
8.8 → 8.6 
p = 0.07 
SPC intraoperatively 3 49% and 2% 9% and 6% 27% and 5% 
Irrigation fluid (l) 16 ± 7 18 ± 4 14 ± 8 
Drainage time (days) 2.1 ± 0.7 2.8 ± 3.1 1.9 ± 0.6 
Postoperative hospital stay 
(days). Mean ± SD 3.9 ± 0.9 3.8 ± 1.3 3.4 ± 0.9 
Postoperative hospital stay 
(days). Median with 2.5 and 
97.5 percentiles 
4.0 (3.0-5.9) 3.5 (2.0-6.0) 3.0 (2.0-5.0) 
1. Blood loss: 0=none, 1=moderate and 2=severe. Visual estimation intraoperatively by urologist. 
2. Hb = haemoglobin: pre → postoperative value, including significance of decrease within group.  
3. SPC = suprapubic catheter. Percentage of patients receiving an SPC intraoperatively and percent 
of patients who received an SPC already preoperatively because of micturition problems.  
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Table 3 Number of intraoperative complications (all operations included, also when patients were 
excluded for further analysis). 
 
 TURP Contact laser Vaportrode 
Capsule perforation 5 2 2 
Bleeding, making electro-coagulation necessary - 2 1 
Bleeding, making TURP necessary - 3 0 
Fausse route 1 1 1 0 
Technical failure 0 3 2 
Conversion to TURP because of tissue debris - 3 1 
Urethral injury 1 0 0 
 
1. Fausse route made during first introduction of the scope. 
 
 
 
 
 
Table 4 postoperative morbidity and mortality within 12 months (without urinary tract infections) 
 
 TURP Contact Laser Vaportrode 
Bleeding requiring transfusion 1 0 0 
Clot retention 1 2 0 
Urinary retention 0 5 0 
Re-operation (TURP) 2 1 2 
Strictures 1 meatus 2 urethral 2 urethral 1 urethral 
Other 1 myocardial infarction 1 epididymitis 1 penile deviation 
Mortality 1 cardiac failure 1 hepatic failure 0 0 
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Table 5 Mean ± standard deviation of subjective scores from AUA questionnaires of the 3 treatment 
groups  
 
 
Pretreatment 12 months Posttreatment 
Change 
as ratio  
and percent a 
Symptom Score Index 
   TURP 
   Laser 
   Vaportrode 
16.8 ± 6.0 
18.9 ± 6.8 
20.2 ± 6.6 
4.6 ± 4.8 
5.8 ± 5.7 
6.7 ± 6.4 
0.27 (-73%) 
0.31 (-69%) 
0.33 (-67%) 
Symptom Problem Index 
(Bother Score) 
  TURP 
   Laser 
   Vaportrode    
 
11.9 ± 6.7 
12.5 ± 7.8 
14.1 ± 6.7 
 
2.4 ± 4.7 
2.4 ± 3.3 
4.2 ± 5.2 
 
0.20 (-80%) 
0.19 (-81%) 
0.29 (-71%) 
Quality of Life 
  TURP 
   Laser 
   Vaportrode    
3.8 ± 1.5 
3.7 ± 1.6 
4.1 ± 1.4 
0.9 ± 1.2 
1.0 ± 0.9 
1.4 ± 1.4 
0.23 (-77%) 
0.26 (-74%) 
0.35 (-65%) 
BPH Impact Index 
  TURP 
   Laser 
   Vaportrode   
9.6 ± 4.7 
9.3 ± 4.2 
10.8 ± 4.1 
2.4 ± 3.8 
2.0 ± 2.2 
3.8 ± 4.1 
0.25 (-75%) 
0.22 (-78%) 
0.35 (-65%) 
 
1. Ratio = post value/ pre value, and percentual change = {(pre value – post value)/ pre value} * 
100%  
 
postoperatively, nor at any other time interval. For the quality of life (QoL) there was 
a significant difference (p=0.03) one week postoperatively, in favour of the group 
treated with contact laser. QoL changed one week postoperatively from 3.8 to 4.0 in 
the transurethral prostatic resection group, from 4.1 to 3.8 in the electrovaporization 
group and from 3.7 to 2.4 in the laser group. At six weeks postoperatively there was 
no significant difference among the three treatment modalities anymore, nor at any 
other time interval. For the BPH impact index (BII) there were no significant 
differences among the three treatment modalities at any interval, although there was 
a trend suggesting a larger decrease in BII for patients treated with the contact laser. 
Figure 2a shows a graphic representation of daytime frequency. There was a 
significant (p<0.02 in all groups) decrease from about 8.5 to about 6.5. There were 
no significant differences between the groups at any time interval. There was a slight 
increase of frequency during the first weeks postoperatively in all groups. After about 
six weeks the number of voids during daytime returned to the pre-operative value, 
after which it dropped further. 
SUBJECTIVE CHANGES AND MORBIDITY… 
95 
Figure 2b shows a graphical representation of nocturia. There was a significant 
(p≤0.01 in all groups) decrease from about 2.5 to 1.5. There were no significant 
differences between the groups at all time intervals. There was a slight increase 
during the first 2 weeks for all groups. At 3 months postoperatively nocturia was 
significant lower than preoperatively in all groups (p<0.001). 
Figures 3-8 show graphic representations of morbidity and symptomatic parameters. 
Figures 3a-8a show the percentage of patients having a symptom in the last week. 
Figures 3b-8b show the average severity of a symptom (score 1-only minor 
symptoms to 5-severe symptoms) multiplied by the number of days (0 to 7) a 
symptom was present during the last week calculated from the data of all patients. 
The duration-severity data were statistically analyzed. There were no significant 
differences in baseline values for all parameters between the groups. Postoperatively 
there were also no significant differences between the treatment groups at any time 
interval, except for haematuria. There is an obvious trend for a lower incidence and 
duration-severity product for haematuria in patients treated with transurethral 
prostatic resection. Only at 4 weeks postoperatively this is statistically significant 
(p=0.01). There is a not significant trend showing less pain during voiding and 
abdomino-genital pain postoperatively in the transurethral prostatic resection group. 
In the laser group there is a trend suggesting less incontinence postoperatively.  
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Figure 1a Average symptom score index preoperatively and postoperatively up to 12 months after 
transurethral resection of the prostate (TURP), contact laser prostatectomy (Laser) and 
electrovaporization (Vaportrode). 
 
 
 
 
Figure 1b Average symptom problem index preoperatively and postoperatively up to 12 months after 
transurethral resection of the prostate (TURP), contact laser prostatectomy (Laser) and 
electrovaporization (Vaportrode). 
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Figure 1c Average quality of life score preoperatively and postoperatively up to 12 months after 
transurethral resection of the prostate (TURP), contact laser prostatectomy (Laser) and 
electrovaporization (Vaportrode). 
 
 
 
 
Figure 1d Average BPH impact index preoperatively and postoperatively up to 12 months after 
transurethral resection of the prostate (TURP), contact laser prostatectomy (Laser) and 
electrovaporization (Vaportrode). 
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Figure 2a Number of daytime voids (frequency during daytime) preoperatively and postoperatively up 
to twelve months after transurethral resection of the prostate (TURP), contact laser prostatectomy 
(Laser) and electrovaporization (Vaportrode). 
 
 
 
 
Figure 2b Number of nighttime voids (nocturia) preoperatively and postoperatively up to twelve 
months after transurethral resection of the prostate (TURP), contact laser prostatectomy (Laser) and 
electrovaporization (Vaportrode). 
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Figures 3a and 3b Percentage of patients with pain during voiding in the last week (a) and average 
severity (score 1 to 5) times number of days (0 to 7) pain during voiding  was present in the last week 
(b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 4a and 4b Percentage of patients with lower abdomino-genital pain in the last week (a) and 
average severity (score 1 to 5) times number of days (0 to 7) lower abdomino-genital pain was present 
in the last week (b).
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Figures 5a and 5b Percentage of patients with haematuria in the last week (a) and average severity 
(score 1 to 5) times number of days (0 to 7) haematuria was present in the last week (b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 6a and 6b Percentage of patients with incontinence in the last week (a) and average severity 
(score 1 to 5) times number of days (0 to 7) incontinence was present in the last week (b).
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Figures 7a and 7b Percentage of patients with hesitation in the last week (a) and average severity 
(score 1 to 5) times number of days (0 to 7) hesitation was present in the last week (b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 8a and 8b Percentage of patients with urge in the last week (a) and average severity (score 1 
to 5) times number of days (0 to 7) urge was present in the last week (b). 
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Discussion 
 
A previous article about this study group demonstrated that these three treatment 
modalities score urodynamically equally six months postoperatively8. Urodynamic 
changes are however not always related to subjective changes and the latter are 
nowadays concerned to be of high importance in treatment decision9. This study 
shows that there are no significant differences among the three treatments 
concerning symptom score index (I-PSS), symptom problem index (SPI) and BPH 
impact index (BII) at all time intervals up to twelve months. In the latter there was a 
trend in favour of contact laser. Quality of life (QoL) improved (the score decreased) 
significantly faster in the laser group, although after six weeks the values were very 
similar again. This might be of some clinical importance. The changes in I-PSS are 
similar to those reported in other studies which compared contact laser with 
transurethral prostatic resection6, 14, 15 and which analyzed electrovaporization16, 17. 
Unfortunately, most studies only evaluated I-PSS and few also other AUA scores.  
Number of voids during daytime and nocturia decreased significantly for all groups 
and without significant differences between them. Nocturia is a symptom that causes 
much bothersomeness9 and frequency is strongly associated with well-being9. 
Morbidity and mortality in patients undergoing transurethral prostatic resection have 
been analyzed in several large, mostly retrospective, studies2-5. These studies 
demonstrate a decrease in mortality rate over the last decades, but an almost 
unchanged morbidity rate. Morbidity is a parameter which is not strictly defined: 
haematuria is a complication for most urologists if it requires blood transfusion, re-
operation or leads to clot retention. In the patient’s view haematuria with painful clots 
during voiding can be regarded as morbidity. Doll5 discusses shortly this problem, 
which is one of the complicating factors in comparing literature. Morbidity and 
mortality in our transurethral prostatic resection group is comparable to these large 
scale, retrospective studies. Keoghane14 compared prospectively the same contact 
laser with transurethral prostatic resection. They quantified peri-operative blood loss 
and this ranged in the laser group from 0 – 200ml (median 39ml) and in the 
transurethral prostatic resection group from 12 – 1600ml (median 200ml). Change in 
haemoglobin concentration was also statistically different in favour of laser. Four of 
their 72 laser patients were converted to transurethral prostatic resection because of 
bleeding, which agrees with our three conversions out of 58 men. Postoperatively 
none of their laser patients required blood transfusion, whereas 20% of patients 
undergoing transurethral prostatic resection were transfused. In our study we 
required only one blood transfusion in the transurethral prostatic resection group. 
Hospital stay was comparable to our results and duration of catheterization was 
shorter in their study group. Tukhanen15 compared prospectively contact laser and 
transurethral prostatic resection and demonstrated a significant difference in 
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estimated blood loss being 0-220ml in the contact laser group (mean 57ml) and 30-
520ml in the transurethral prostatic resection group (mean 175ml). Hospital stay is 
comparable to our study. They only treated prostates with a volume smaller than 40 
ml and this probably explains their reported low incidence of intra- and post-operative 
complications. 
Hammadeh16 showed significant less decrease of haemoglobin during 
electrovaporization in a randomized trial comparing electrovaporization and 
transurethral prostatic resection. No blood transfusions were required. Post-operative 
complications are comparable to ours. Matos-Ferreira17 analyzed electrovaporization 
and showed comparable results with negligible blood loss and no blood transfusions. 
Mean drainage time was 24 h and re-catheterization was necessary in 5.5%. There 
were minimal post-operative complaints and one urethral stricture, but follow-up time 
is not mentioned. 
 
Summarized, previously8 it was demonstrated that after six months there are no 
urodynamic differences between the three treatment modalities. The present study 
demonstrates that there is a comparable subjective improvement over twelve months 
postoperatively. Intra-operatively there is significantly more blood loss and there are 
more capsule perforations in the transurethral prostatic resection group. 
Postoperatively there is a comparable morbidity, although several parameters cannot 
be compared statistically. transurethral prostatic resection shows less post-operative 
pain and haematuria and contact laser shows less incontinence. Paradoxically, 
transurethral prostatic resection patients show most intra-operative blood loss, but 
lowest post-operative haematuria. Post-operative urinary retention is highest in the 
laser group. Comparing contact laser and electrovaporization there is often (also 
urodynamically) a trend in favour of contact laser. The latter seems to be a good 
alternative for transurethral prostatic resection. Contact laser might even have a 
larger therapeutic range, because it offers surgical options for patients on 
anticoagulant therapy or bleeding disorders18,19 . transurethral prostatic resection is 
often contraindicated for these patients.  There is however the opinion that large 
prostates (arbitrarily larger than 40 ml)15 are more difficult to treat. Optical results 
intra-operatively in contact laser prostatectomy are sometimes less spectacular 
compared to transurethral prostatic resection, but post-operative analysis 
demonstrates few differences. Long-term follow-up however is mandatory and is in 
progress at this moment. 
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Conclusions 
 
When comparing transurethral prostatic resection, contact laser prostatectomy and 
electrovaporization in men with lower urinary tract symptoms associated with BPH, 
there is an almost similar course in change in subjective scores, like symptom score 
index, symptom problem index, quality of life and BPH impact index up to twelve 
months postoperatively. Intra-operatively there is more blood loss and there are more 
capsule perforations in patients undergoing transurethral prostatic resection. 
Postoperatively urinary retention is highest in the laser group. Further there is less 
pain and haematuria in patients after transurethral prostatic resection during the first 
6 weeks. In the same time period there is less incontinence after contact laser. 
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Abstract  
 
 
Objectives: To compare long-term results of subjective changes, flowmetry, 
morbidity and mortality after transurethral prostate resection (TURP), contact laser 
prostatectomy (CLP) and electrovaporization in men with lower urinary tract 
symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). 
 
 
Methods: A prospective randomized controlled trial was conducted. Included were 
men with LUTS, who met the criteria of the International Scientific Committee on 
BPH, had a prostate volume between 20 and 65 ml and a Schäfer’s obstruction 
grade ≥2. Subjective changes were quantified using the International Prostate 
Symptom Score (I-PSS), Symptom Problem Index (SPI), Quality of Life (QoL) 
question and BPH Impact Index (BII). Morbidity was registered objectively and by 
patient questionnaires. Maximum flow was measured by free uroflowmetry. These 
parameters were measured at regular intervals up to one year. At the end of 2002, all 
patients were invited for a long-term follow-up including the aforementioned 
parameters. 
 
 
Results: Fifty men were randomized for TURP, 45 for laser treatment and 46 for 
electrovaporization. Seventy percent could be followed up to maximally 7 years. 
Values for I-PSS, SPI, QoL score and BII increased slightly after a mean follow-up 
time of 4.3 years. Maximum uroflow decreased similarly in all treatment groups to 
about 150% of the values preoperatively. Morbidity, reoperation rates and mortality 
were also similar. 
 
 
Conclusions: This up to seven years follow-up, demonstrates durable subjective 
and objective results for patients with LUTS associated with BPH after TURP, CLP or 
electrovaporization. There were no clinically relevant differences between these 
modalities. 
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Introduction 
 
Today’s Western world is facing an aging population with all its medical problems. 
For urologists this creates an enormous increase in men with lower urinary tract 
symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). One of the 
major challenges is to treat men who are bothered by these symptoms with a 
minimum of side effects and complications. Nowadays, most patients are treated with 
pharmacotherapeutics with less side effects, but also less efficacy than surgical 
treatment1. Therefore there is still a need for surgical intervention with transurethral 
resection of the prostate (TURP) as gold standard. However, TURP is associated 
with a rather high morbidity and mortality2,3 . In the past 10-15 years, new 
technologies led to the introduction of a variety of surgical treatment modalities. 
However, TURP is still the gold standard, which might partially be explained by a lack 
of evidence for durable long-term results of these new treatments. 
At our clinic, a randomized controlled study comparing TURP, contact laser 
prostatectomy and electrovaporization has been conducted in men with LUTS 
associated with BPH. In previous articles we published the urodynamic results six 
months postoperatively4 and subjective and symptomatic changes at various time 
intervals up to twelve months5, together with morbidity and mortality. Results were 
very similar between all treatment modalities.  
To address the importance of demonstrating durability, we studied the subjective and 
objective results of a long-term follow-up.  
 
Material and methods 
 
This prospective randomized controlled study was carried out between 1996 and 
2001 at our clinic. Included were men over 45 years of age with LUTS associated 
with BPH. All patients underwent history taking, digital rectal examination, transrectal 
ultrasonography, urodynamic evaluation, free flowmetry, post-void residual volume 
estimation, urinalysis and blood analysis.  
Patients had to be urodynamically equivocal or obstructed (Schäfer grade ≥2). Their 
prostate volume had to be between 20 and 65 ml. Patients with any of the exclusion 
criteria of the International Consensus Committee on BPH were excluded from 
analysis6.  
Symptomatic and subjective changes were measured by questionnaires validated by 
the American Urological Association (AUA). Patients completed the International 
Prostate Symptom Score Index (IPSS)7, the Symptom Problem Index (SPI)8, the 
BPH Impact Index (BII)8 and the Quality of Life question (QoL)7.  
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Next to objective complications, some specific morbidity and symptomatic aspects 
were studied using a self-developed questionnaire that was completed by patients. 
All questionnaires were completed preoperatively and postoperatively at regular 
intervals including 6 and 12 months. The self-developed questionnaire concerned 
pain in the lower abdomino-genital region, pain during voiding, haematuria, 
incontinence, urge and hesitation. Patients had to indicate for how many days they 
had one of these symptoms in the last week (score 0 to 7). If a symptom was 
present, they had to indicate its severity (score 1-only minor severity to 5-high 
severity). Together with the morbidity questionnaire, patients were asked to report 
the average number of voids during daytime and nighttime for the last week. 
Free uroflowmetry was performed at the same time intervals. Uroflowmetric results 
were only included if patients voided over 150 ml. Complications were registered 
both intraoperatively and postoperatively. 
In fall 2002, all patients who were operated on for more than 18 months ago were re-
invited to visit the outpatient department. This was primarily done by one or two 
letters and if necessary by phone in a last attempt. Patients who were previously 
excluded, were not invited. In this way, follow-up times varied individually from 1.5 to 
7 years. The same questionnaires and tests were used as during the 12 months 
follow-up. 
Details concerning TURP, laser prostatectomy and electrovaporization are described 
previously5. 
Group size was calculated with 90% power and a 5% two-tailed significance level as 
described in detail previously4. This resulted in a group size of 32 men. This number 
agrees with the minimum number of 30 men recommended by the AUA new 
technology assessment committee9.  
The Kolmogorov-Smirnov goodness-of-fit test was used to examine whether a 
variable was distributed normally All parameters are reported as mean with standard 
deviation (SD). Further statistical analyses were done with Chi-square test, one-way 
ANOVA, the Kruskal-Wallis test, Student’s t-test, Mann-Whitney U test and Wilcoxon 
signed ranks test. Significance was set at 5 percent. Statistical analyses of long-term 
data were only performed with earlier data from the same patients or between 
different treatment modalities. 
 
Results 
 
Initially, 50 men were randomized for TURP, 45 for laser and 46 for 
electrovaporization. For various reasons patients were not suited for further 
evaluation directly postoperatively or during the course of their first year 
postoperatively4,5 (see table 1). 
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After 1 year, there were still 41 TURP patients, 37 laser patients and 34 
electrovaporization patients available for further follow-up, making a total of 112 
patients. 
In fall 2002, ninety-eight patients or relatives responded finally (response rate 88%). 
Fourteen (12%) patients did not respond at all (table 1). Seventeen percent of the 
responders had been reoperated, was not willing to cooperate, died or could not be 
evaluated due to morbidity (table 1). Eighty-one responding patients (83% of the 
responders) returned all questionnaires and these could be used for long-term 
analysis (83% of the responders). Fifty-nine responding patients performed free 
uroflowmetry (60% of the responders). 
The follow-up time varied individually, because all patients were analyzed in about 
two months. Depending on individual follow-up time, patients were divided into two 
groups: follow-up time between 1-4 years and  follow-up time between 4-7 years. In 
the TURP group 15 patients were analyzed after 1-4 years and another 15 patients 
after 4-7 years with a mean follow-up of 2.7 ± 0.8 and 5.7 ± 0.8 years respectively 
and age 66.8 ± 8.2 and 70.5 ± 7.9 years respectively. In the laser group 10 and 17 
patients were analyzed after 1-4 years and 4-7 years respectively with a mean follow-
up of 2.6 ± 0.9 and 5.5 ± 0.7 years respectively and age 65.3 ± 11.0 and 72.3 ± 8.3 
years respectively. In the electrovaporization group 12 patients were analyzed after 
1-4 years and another 12 patients after 4-7 years with a mean follow-up of 2.8 ± 1.0 
and 5.4 ± 1.0 years respectively and age 64.4 ± 8.2 and 71.3 ± 11.6 years 
respectively. Preoperative baseline values of the patients analyzed after 1-4 years 
did not show any significant differences with those of the patients analyzed after 4-7 
years. There were no significant differences in age and follow-up time between the 
different treatments. 
Schäfer obstruction grades during inclusion were for TURP, laser and Vaportrode 3.5 
± 1.1, 3.4 ± 1.2 and 3.6 ± 1.1 respectively. Prostate volumes at that time were 37 ± 
11, 38 ± 9 and 35 ± 12 ml respectively. There were no significant differences 
between the different treatment groups. 
In table 2 the results of frequencies, maximum flow and AUA questionnaires are 
represented. Graphic representations of these results are shown in figures 1-3. 
Only preoperative and six and twelve months data of those patients are listed who 
were also seen at long-term follow-up. There were no significant differences between 
the different treatment groups at baseline, except for maximum flow.  
There were no significant differences for the number of voidings during daytime 
between the treatments at any time point. Nocturia also never showed significant 
differences between the treatments. However, in the laser group there was a 
significant higher nocturia (mean 1.9) in the 4-7 years group (p=0.05).  
Forty-six out of 59 patients (78%) who performed uroflowmetry were able to void 
more than 150 ml. Maximum free uroflow showed lower values in both long-term 
follow-up groups compared to earlier values. In the TURP and electrovaporization 
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Table 1 Reasons why patients dropped out from further follow-up during the course of the 
investigations. 
 
 
 TURP 
Contact 
Laser 
Vapor 
trode 
Included patients at baseline 50 45 46 
Procedure during surgery changed for medical reasons 0 3 2 
Surgery canceled due to other medical problems 1 0 1 
Equipment failure resulting in standard therapy (TURP) - 2 1 
Procedure during surgery not correctly performed 0 0 4 
Mortality within first postoperative year 2 0 0 
Morbidity making follow-up impossible within first postoperative 
year 2 0 1 
Patient emigrated within first postoperative year 1 0 0 
Reoperation (TURP) within first postoperative year 2 1 2 
Reoperation because of urethral stricture within first 
postoperative year 1 2 1 
Suitable for further evaluation after one postoperative year 41 37 34 
No response in fall 2002 4 5 5 
Number of responders in fall 2002 37 32 29 
Reoperated (TURP) 1 2 2 
Reoperated because of urethral stricture 1 0 0 
Morbidity making further follow-up impossible 2 0 0 
Not willing to cooperate 1 0 1 
Number of men died 2 3 2 
Suitable for further evaluation 30 27 24 
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Table 2 Subjective scores from AUA questionnaires, maximum uroflowmetric results and frequency 
during daytime and nighttime, of patients analyzed during follow-up. Data presented as mean with SD.  
 
 
Baseline 6 months 1 year 1-4 years 4-7 years 
Frequency during   
daytime 
   TURP 
   Laser 
   Vaportrode 
 
 
9.1 ± 4.2 
9.2 ± 4.0 
8.9 ± 2.6 
 
 
7.1 ± 1.7 
6.9 ± 2.3 
6.5 ± 2.1 
 
 
6.3 ± 1.9 
5.1 ± 1.5 
6.7 ± 3.2 
 
 
6.7 ± 2.8 
7.6 ± 2.5 
5.8 ± 2.1 
 
 
5.8 ± 3.5 
6.2 ± 2.0 
5.7 ± 1.7 
Frequency during 
nighttime 
   TURP 
   Laser 
   Vaportrode 
 
 
2.4 ± 1.5 
2.8 ± 1.4 
2.1 ± 1.5 
 
 
1.1 ± 0.8 
1.6 ± 0.9 
0.9 ± 0.8 
 
 
1.1 ± 0.6 
1.6 ± 0.8 
0.9 ± 0.6 
 
 
0.9 ± 0.9 
1.4 ± 1.1 
1.1 ± 1.2 
 
 
1.1 ± 0.6 
1.9 ± 1.1 
1.0 ± 0.9 
Maximum flow (ml/s) 
   TURP  
   Laser  
   Vaportrode 
 
 
13 ± 4  
9 ± 3 
9 ± 3  
 
 
26 ± 6  
25 ± 9 
24 ± 11  
 
 
23 ± 10  
27 ± 12  
28 ± 6 
 
 
20 ± 5  
19 ± 6  
23 ± 6 
 
 
17 ± 8 
19 ± 9 
16 ± 11 
Symptom Score Index 
   TURP 
   Laser 
   Vaportrode 
 
 
16.6 ± 5.6 
18.3 ± 8.2  
20.3 ± 6.8 
 
 
3.2 ± 2.7 
5.9 ± 5.5 
3.8 ± 2.7 
 
 
4.1 ± 4.8 
3.6 ± 3.4 
4.8 ± 4.9 
 
 
5.8 ± 7.5 
9.3 ± 5.2 
8.4 ± 8.7 
 
 
7.3 ± 7.1 
8.3 ± 6.4 
7.0 ± 5.6 
Symptom Problem Index 
   TURP 
   Laser 
   Vaportrode 
 
 
12.5 ± 6.2 
11.9 ± 7.7 
14.6 ± 7.3 
 
 
1.0 ± 1.8 
2.4 ± 4.0 
1.8 ± 2.2 
 
 
1.4 ± 2.8 
1.1 ± 1.6 
3.0 ± 4.7 
 
 
4.2 ± 6.9 
3.0 ± 3.5 
2.5 ± 5.2 
 
 
4.5 ± 7.6 
4.6 ± 5.3 
3.6 ± 3.9 
Quality of Life Score 
   TURP 
   Laser 
   Vaportrode 
 
 
3.9 ± 1.6 
3.6 ± 1.6 
4.3 ± 1.3 
 
 
0.5 ± 0.5 
0.8 ± 1.0 
1.0 ± 0.8 
 
 
0.6 ± 0.8 
0.6 ± 0.9 
1.0 ± 0.9 
 
 
1.1 ± 1.2 
2.0 ± 1.0 
1.0 ± 1.2 
 
 
1.3 ± 1.3 
1.4 ± 1.2 
1.4 ± 0.8 
BPH Impact Index 
   TURP 
   Laser 
   Vaportrode 
 
 
9.1 ± 4.7 
8.8 ± 3.8 
11.1 ± 4.0 
 
 
0.8 ± 1.2 
2.8 ± 3.2 
2.5 ± 2.3 
 
 
1.4 ± 2.1 
1.5 ± 2.0 
2.7 ± 3.0 
 
 
2.3 ± 3.4 
4.1 ± 3.1 
2.1 ± 3.3 
 
 
2.9 ± 3.8 
3.3 ± 3.1 
2.9 ± 2.3 
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F 
Figure 1a Symptom score index at baseline and during follow-up. Data are presented as mean with 
standard deviation. 
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Figure 1b Symptom problem index at baseline and during follow-up. Data are presented as mean with 
standard deviation. 
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Figure 1c Quality of life score at baseline and during follow-up. Data are presented as mean with 
standard deviation. 
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Figure 1d BPH impact index at baseline and during follow-up. Data are presented as mean with 
standard deviation. 
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Figure 2a Frequency during daytime at baseline and after follow-up. Data are presented as mean with 
standard deviation. 
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Figure 2b Frequency during nighttime at baseline and after follow-up. Data are presented as mean 
with standard deviation. 
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Figure 3 Maximum free uroflow rate at baseline and after follow-up. Data are presented as mean with 
standard deviation. 
 
 
group, results after 1-4 years follow-up were significantly higher compared to their 
preoperative values. In the laser group, results after 4-7 years were significantly 
higher than preoperatively. However, there are no significant differences between the 
different methods for prostatectomies at any time interval. 
International Prostate Symptom Score index (IPSS), Symptom Problem index (SPI), 
the Quality of Life score (QoL) and BPH Impact Index (BII) show slight, but not 
significant, increases during long-term follow-up  
There are no significant differences between the treatment groups. All values, at both 
follow-up times, are significantly lower than pre-operative values, except for laser 
patients after 1-4 year follow-up (p between 0.07 and 0.10). 
The incidences of pain during voiding, lower abdomino-genital pain, hesitation or 
haematuria were in all groups during long-term follow-up between 0-5%. There was a 
small increase in urgency, with an incidence of 15 to 22%, although the ‘severity x 
duration’ product was low, about 2.3 in all treatment modalities. The incidences of 
incontinence were 8%, 39% and 15% in the TURP, laser and electrovaporization 
group respectively. The high incidence in the laser group was accompanied by a 
‘severity x duration’ product of 3.7 (maximum 35), indicating only incidental small 
urine loss. This number is comparable with those in the TURP and 
electrovaporization groups: 2.5 and 3.3 respectively. 
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In the period after the first postoperative year, 1 TURP patient underwent a second 
TURP, and 2 patients each underwent TURP in the laser and electrovaporization 
groups. Including the reoperations in the first postoperative year (table 1), 
reoperation rates after a mean follow-up of 4.3 years for TURP, laser and 
electrovaporization were 6%, 7% and 9% respectively. There was one urethral 
stricture in the TURP group after one year and this was not seen in the other groups. 
Seven patients (7%) died more than 1 year postoperatively according to relatives 
who responded (table 1). Including mortality in the first postoperative year, mortality 
rates after a mean follow-up of 4.3 years were for TURP, laser and 
electrovaporization 8%, 7% and 4% respectively. These deaths were not related to 
their prostatic surgery or related to BPH complications. 
Two patients were excluded because of morbidity (2%): both for prostatic carcinoma. 
Two were not willing to cooperate (2%): both patients were not satisfied with the 
results.  
Comment 
 
At 1 year postoperatively we were able to further evaluate 112 of the initially 141 
included patients. Table 1 lists the reasons why the remaining 29 patients could not 
be evaluated. Of these 112 patients finally 14 did not respond. This means that 14 
patients were lost–to-follow-up of the initially 141 included patients. The response 
rate of 88% enabled an adequate follow-up. However, patients were only analyzed 
once after their one year follow-up. This results in a large variation in individual 
follow-up time varying from 1.5 to 7.0 years. Secondly, the low number of patients 
creates a low power, so that significant differences might not always be detected. In 
each treatment group there were 24-30 patients scattered over the long time interval, 
with 2-6 patients per follow-up year. Therefore, patients were divided over two follow-
up time intervals of 3 years each: a follow-up time of 1-4 years and a follow-up time 
of 4-7 years. In this way, data can be presented and interpreted more 
comprehensibly. Statistical analyses were only performed on data from patients who 
were seen at baseline and at long-term follow-up. Although the two groups consist of 
different patients (with similar baseline values), we still think this division is 
meaningful, because there is a large time difference between the two groups. 
The results of this follow-up demonstrate a high durability for symptomatic and 
subjective relief. The various AUA validated questionnaires show only a small rise 
with no statistical significant differences between the treatment modalities. This rise 
might partially be explained by normal aging during which symptoms and bothering 
increase. IPSS index in the Olmsted County study increased with 0.44 units per year 
for men in the sixties10. An equivalent study in the Netherlands also showed a 
significant increase in IPSS with age11.  
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Frequencies during daytime and nighttime were for all groups during long-term 
follow-up very similar compared to the values 1 year Postoperatively. We have no 
good explanation for the significant higher mean nocturia (1.9) in laser patients after 
4-7 years. 
The number of patients evaluated by uroflowmetry is limited, because not all patients 
were able to visit the outpatient department due to the high age of a number of 
patients. Maximum uroflow showed lower values after long-term follow-up: about 20 
ml/sec. after 1-4 years  and between 16 and 19 ml/sec. after 4-7 years follow-up. 
These decreases can not be fully explained by normal aging as was observed in the 
Olmsted County Study12,13. Cross sectional data from this study showed mean 
maximum flows of about 15.5 ml/sec. and about 14 ml/sec. for age groups of 65-69 
years and 70-74 years respectively. Annualized percent decrease in the 60-69 years 
and 70-79 years age groups were 2.3% and 6.5% respectively. 
Follow-up results from AUA questionnaires and maximum uroflow are compared to 
data from men without a history of prostatic disease. Comparison to these data is 
difficult, because a surgical intervention might interfere with normal aging processes 
of bladder and prostate. 
The specific morbidity and symptom questionnaires demonstrated few differences 
between the treatment groups and most parameters were scored only incidentally. 
Urgency and incontinence showed higher values. The 39% incidence of incontinence 
in the laser group is much higher than in the other groups, although the ‘severity x 
duration’ products are low and very similar in all groups.  
Several other studies have analyzed long-term results of laser and 
electrovaporization. Keoghane et al published 3 and 5-year data from the Oxford 
laser prostatectomy trial14,15, comparing laser with TURP. Initially 152 patients were 
randomized. After follow-up times of 3 and 5 years, eighty-seven (57%) and fifty-
seven (38%) patients were available for further analysis. IPSS after 3 and 5 years are 
comparable to results of the present study. Maximum uroflow was slightly lower with 
14.0 ml/sec. after 5 years for both TURP and laser. Reoperation rates were higher: 
18% for laser and 14.5% for TURP. In a non-randomized study, Floratos16 analyzed 
results of laser after a median follow-up time of 3.9 years. IPSS and Quality of life 
showed stable results, similar to the present study, but maximum uroflow 
progressively worsened to a median of 11.1 ml/sec after about 4 years. Retreatment 
rate was 14%. 
Long-term electrovaporization results were published by Hammadeh et al17. They 
demonstrated durable results comparing TURP with Vaportrode after 3 years follow-
up. IPSS and Quality of Life results after 3 years were very similar to results after one 
year. The same was demonstrated for maximum flows, which were 18.0 ml/sec. and 
22.2 ml/sec. for TURP and electrovaporization  respectively after 3 years. 
Reoperation rate after 3 years was 13% for electrovaporization. There were no 
significant differences between the treatments.  
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We found no clinically relevant differences between the treatment groups during 
long-term follow-up. Today in our clinic, TURP is still often used as a treatment 
modality. However, contact laser prostatectomy is used on a regular basis for high 
risk patients, because of the low blood loss during surgery. A selected group of men 
is more and more treated with laser prostatectomy in a day care setting. 
 
Conclusions 
 
This up to seven years follow-up, demonstrates in general durable subjective and 
objective results for patients with LUTS associated with BPH after TURP, contact 
laser or electrovaporization. IPSS, SPI, QoL and BII increase slightly and maximum 
uroflow decreases to about 150% of the preoperative values. There are no clinically 
relevant differences between the different treatment groups during long-term follow-
up. 
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Abstract 
 
 
Purpose: To compare costs of transurethral resection of the prostate (TURP), 
contact laser prostatectomy (CLP) and electrovaporization in men with lower urinary 
tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). 
 
 
Materials and Methods: A randomized controlled trial was conducted. Included were 
men with LUTS, who met the criteria of the International Scientific Committee on 
BPH. Subjective changes were quantified using questionnaires validated by the 
American Urologic Association (AUA). Maximum free urinary flow rate was estimated. 
Morbidity and mortality were registered. These parameters were measured at regular 
intervals up to one year and once during long-term follow-up. A cost analysis 
together with a sensitivity analysis was performed based on a follow-up of 12 
months.  
 
 
Results: Fifty men were randomized for TURP, 45 for laser treatment and 46 for 
electrovaporization. Subjective and objective changes were very similar during the 12 
months follow-up. Costs were highest for CLP and lowest for electrovaporization. 
However, hospital stay decreased during trial more for CLP and electrovaporization 
than for TURP. Recalculations demonstrated almost equal costs for CLP and TURP 
and lowest costs for electrovaporization. 
 
 
Conclusions: Electrovaporization has lower costs than CLP and TURP in patients 
with LUTS associated with BPH. CLP and TURP show very similar costs. 
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Introduction 
 
From a physician’s point of view one would like to offer a patient an optimal 
treatment; that is the combination of a maximum relief of symptoms and bothering 
with a minimum of morbidity. However, to suggest that medical decision making can 
be divorced from consideration of costs, denigrates the complexity of patient care. 
Choices must be made between alternative treatments and these decisions must be 
based on both costs and outcomes1. 
These choices are becoming more and more important in treatment of men with 
lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia 
(BPH). Resources are limited and there is an increase in patients presenting with 
LUTS together with an increase in treatment modalities. 
Since the early 1990s, a plethora of new minimally invasive therapies has been 
introduced to treat men with LUTS associated with BPH. Most studies have been 
conducted to analyze the clinical outcome results of these surgical therapies. Only a 
few performed a cost-effectiveness analysis or other types of economic analyses. 
Until 1996, there were only fourteen  papers identified that performed some type of 
economic analysis2. Only eight of these satisfied more than half of the criteria given 
by Drummond et al regarding the assessment of economic evaluations3. Today, 
economic analysis is recommended by the committee on the economics of BPH of 
the international consultation on BPH4. Several data are available about medical 
therapy, TURP, contact and non-contact laser therapy and some other minimally 
invasive therapies5-12. 
At our clinic, a randomized controlled study comparing transurethral resection of the 
prostate (TURP), contact laser prostatectomy (CLP) and electrovaporization 
(Vaportrode) has been done in men with LUTS associated with BPH. Previously, we 
published the urodynamic changes six months postoperatively13 and subjective and 
symptomatic changes at various time intervals up to a maximum of seven years 
postoperatively, together with morbidity and mortality14,15. Improvements, morbidity 
and mortality of the three treatment modalities were very similar. In order to compare 
these treatments economically, a cost analysis has been performed, including a 
sensitivity analysis. 
 
Material and methods 
 
A prospective randomized controlled study was carried out between 1996 and 2001 
at our clinic. Detailed descriptions of inclusion and exclusion criteria, together with 
details about used materials, operation techniques and measurement techniques are 
published previously13-15. Included were men over 45 years of age with LUTS 
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associated with BPH. Patients were randomized between TURP, contact laser 
prostatectomy and electrovaporization (Vaportrode). Symptomatic and subjective 
results were analyzed using questionnaires16,17 validated by the American Urological 
Association (AUA). Patients completed the International Prostate Symptom Score 
Index (IPSS), the Symptom Problem Index (SPI), the BPH Impact Index (BII) and the 
Quality of Life (QoL) question. Uroflowmetry was performed to estimate maximum 
flow. Morbidity and mortality were registered. These questionnaires and tests were 
used preoperatively and postoperatively at regular intervals including 6 months and 1 
year. In a long-term follow-up, the same parameters were studied once in each 
patient at an individually varying time interval with a mean of  4.3 years15.  
Primary outcomes were IPSS, SPI, BII, QoL score and maximum flow. There were no 
clinical relevant differences for these outcomes between the three treatment 
modalities up to one year13 and during long-term follow-up15. Morbidity and mortality 
were also very similar14. Significant changes were seen in operative parameters, like 
a shorter duration in hospital stay for electrovaporization and less blood loss in laser 
treatment14.  
An analysis is made of costs included in the different treatment modalities. Statistical 
evaluation of these costs is not performed, because several assumptions are made 
to calculate these costs. The margins of these assumptions are sometimes unclear, 
which makes statistical evaluation complicated, unreliable and therefore does not 
provide useful information. The cost analysis is from a health care perspective. 
Collection and valuation of resource use data  
a) Personal time in operating theater: costs per treatment were calculated using 
annual salaries adjusted for real time spent on direct patient care. One urologist and 
one urology trainee were counted for the full operating time, one anesthesist was 
counted for his time with the patient, two surgeon assistants and one anesthesist 
assistant were counted for the full time a patient was in the operating theater. 
Overhead costs for the operating theater are 41% and are presented separately. 
b) Use of surgical equipment for TURP, laser and electrovaporization: capital 
equipment is valued using 2003 market prices. Life-spans for electro-generators and 
laser-generator were assumed to be 7 years. Opportunity costs of 5% per annum 
were assumed. Costs for service and maintenance are added. Electro-generators 
and laser-generators are also used for several other types of urological surgery, e.g. 
transurethral electroresection or laser coagulation of bladder carcinoma, laser 
coagulation of condylomata acuminata or incisions of the bladder neck. In this way, a 
percentage of the specific use for prostate surgery (allocation rate) was calculated for 
both generator types. Initial calculations were based on allocation rates of 51%, 29% 
and 60% for TURP, laser and electrovaporization respectively. Consumables for 
TURP (resection loops), laser (fibers and tips) and electrovaporization (vaporization 
wheels) are valued at 2003 market prices. Laser fibers were used on average 2.5 
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times, resection loops 25 times and vaporization wheels 5 times each. Costs for 
sterilization and maintenance were added. 
c) Perioperative hospital stay and use of resources: all patients received 
intraoperatively antibiotics intravenously and postoperatively analgesics. Blood 
analysis regarding haemoglobin and electrolytes was performed several times during 
hospital stay. Costs for hospital stay including overhead costs were calculated per 
day using data from the finance department.  
e) Inpatient rehospitalization: all surgery related complications were registered. Costs 
were calculated in the same way as mentioned before. 
Sensitivity analysis 
Valuation of resource use data is partially based on assumptions. Small changes in 
these assumptions can sometimes cause large differences in costs. Accuracy for 
several assumptions is hard to make and calculations incorporate often indirect 
estimations of costs. Dayprices for hospital stay vary over short time and overhead 
costs can only be estimated by subtraction of total costs by certain specified costs. 
An important factor in total costs per treatment is hospital stay. This changed during 
the years the trial was one. Therefore, a recalculation with different values is 
performed. A mean long-term follow-up of 4.3 years demonstrated a change in 
reoperation rates (re-TURP) compared to those after 12 months15. Recalculations 
have been made with these long-term rates. Life span of equipment might change, 
because technological advances are made rapidly. Recalculations have been made 
with a 4 year life spans for all equipment. Another complicating factor is the 
percentual allocation of machinery to prostatectomies. These rates are mentioned 
before and represent the time that the electro-generator or laser-generator was used 
for prostatectomies during the course of the study in our center. Especially the laser 
rate might change because new developments might change allocation. 
Recalculations have been made with 40% and 80% rates for laser.  
Costs are presented in Euros (€). Statistical analyses were performed with ANOVA 
and Student’s t-test. Data are presented as means with standard deviation (SD). 
 
Results 
 
Table 1 shows the preoperative major outcome results and those after 12 months, 
together with the absolute and percentual change in these results. Statistical analysis 
did not show any significant differences at baseline or after 12 months between the 
treatment groups for these parameters, nor were there significant differences in the 
changes of these parameters in 12 months between the different treatment groups14. 
Resource use data for staff operation time was 58±26 min, 58±11 min and 50±16 min 
for TURP, laser and electrovaporization respectively. Nurse operation time was  
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Table 1 Results at baseline and after 12 months follow-up including change for the different treatment 
groups. Data presented as mean ± SD. 
 
 
Baseline 12 months Posttreatment 
Absolute change 
(percent change) 
Symptom Score Index 
   TURP 
   Laser 
   Electrovaporization 
 
16.8 ± 6.0 
18.9 ± 6.8 
20.2 ± 6.6 
 
4.6 ± 4.8 
5.8 ± 5.7 
6.7 ± 6.4 
 
-12.2  (-73%) 
-13.1  (-69%) 
-13.5  (-67%) 
Symptom Problem Index  
   TURP 
   Laser 
   Electrovaporization 
 
11.9 ± 6.7 
12.5 ± 7.8 
14.1 ± 6.7 
 
2.4 ± 4.7 
2.4 ± 3.3 
4.2 ± 5.2 
 
-9.5  (-80%) 
-10.1 (-81%) 
-9.9  (-71%) 
Quality of Life score 
   TURP 
   Laser 
   Electrovaporization 
 
3.8 ± 1.5 
3.7 ± 1.6 
4.1 ± 1.4 
 
0.9 ± 1.2 
1.0 ± 0.9 
1.4 ± 1.4 
 
-2.9  (-76%) 
-2.7  (-74%) 
-2.7  (-65%) 
BPH Impact Index 
   TURP 
   Laser 
   Electrovaporization 
 
9.6 ± 4.7 
9.3 ± 4.2 
10.8 ± 4.1 
 
2.4 ± 3.8 
2.0 ± 2.2 
3.8 ± 4.1 
 
-7.2  (-75%) 
-7.3  (-78%) 
-7.0  (-65%) 
Maximum flow (ml/sec.) 
   TURP 
   Laser 
   Electrovaporization 
 
11.4 ± 3.7 
11.5 ± 4.1 
10.8 ± 4.2 
 
21.4 ± 8.4 
22.0 ± 11.2 
22.7 ± 8.3 
 
+10.0 (+88%) 
+10.5 (+91%) 
+11.9 (+110%) 
 
 
93±38 min, 86±26 min and 85±32 min for TURP, laser and electrovaporization 
respectively. Hospital stay was 3.9±0.9 days, 3.8±1.3 days and 3.4±0.9 days for 
TURP, laser and electrovaporization respectively. The reoperation rate (re-TURP) 
was 4.0%, 2.2% and 4.3% within 12 months for TURP, laser and electrovaporization 
respectively.  
Calculated costs per patient are listed in the upper part of table 2. Costs of operating 
room equipment were almost similar between TURP and electrovaporization, but 
more expensive for laser equipment. This resulted in laser being the most expensive 
treatment (€ 1714), followed by TURP (€ 1552) and electrovaporization (€ 1354) 
being the cheapest.  
The results of a sensitivity analysis are represented in the lower part of table 1. 
Significant decreases in hospital stay were observed more in laser and 
electrovaporization patients than in TURP patients during the trial. Hospital stay for 
laser and electrovaporization patients were 3.8 and 3.4 days respectively, and 3.9 
days for TURP patients. For all treatment modalities there was a reduction in this  
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Table 2 Costs in Euros (€) per patient after 12 months follow-up for the three different treatments. A 
sensitivity analysis is included showing the costs after recalculations with different assumptions.  
 
 TURP Contact Laser Electro- vaporization 
Operation time: staff  € 232 € 232 € 206 
Operation time: nurses  € 171 € 158 € 156 
Consumables € 19 € 194 € 30 
Overhead operating theater € 173 € 235 € 160 
Theater costs   € 595   € 809   € 550 
Post-operative hospital stay € 695 € 679 € 615 
Consumables € 129 € 130 € 118 
Re-operations including re-
hospitalization € 133 € 95 € 71 
Post-operative costs   € 957   € 904   € 804 
Total costs   € 1552   € 1714   € 1354 
Total costs 
with different assumptions    
Hospital stay last 2 years € 1494 € 1526 € 1260 
Re-TURP rates  
6.0%, 6.7% and 8.7%1 € 1519 € 1589 € 1311 
Life span equipment 4 years1 € 1502 € 1550 € 1270 
Allocation laser 40%1 € 1494 € 1545 € 1260 
Allocation laser 80%1 € 1494 € 1611 € 1260 
 
Recalculations based on hospital stay of the last two years of the trial. 
 
number of hospital days when comparing with the last two trial years. Values of 
hospital stay during the last 2 years of the trial were 3.6 days, 2.9 days and 2.8 days 
for TURP, laser and electrovaporization patients respectively. Costs for laser become 
more equal to costs for TURP, while electrovaporization is still the cheapest. All other 
recalculations are made with values for hospital stay during the last 2 years. Rates 
for re-TURP were previously demonstrated during long-term follow-up15. All extra 
recalculations have only small effects on total costs: electrovaporization is always 
cheapest and laser costs are almost similar to TURP costs. 
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Discussion 
 
Previous publications about this trial showed that the three treatment modalities 
showed similar symptomatic, subjective and objective results after 12 months. Even 
after a mean follow-up of 4.3 years subjective and objective results were very similar. 
Analysis of morbidity  also demonstrated only small differences between the three 
treatment modalities13-15. As mentioned in the introduction, resources are scarce in 
today’s world and outcome results should be compared to their costs, before making 
treatment decisions. The economic analysis of our trial demonstrates relevant 
differences between the costs of TURP, contact laser and electrovaporization. The 
initially calculated costs are best for electrovaporization and better for TURP 
compared to contact laser. An important observation was made regarding hospital 
stay: there were significant decreases for all treatment modalities during the time the 
trial was on, but these were larger for laser and electrovaporization patients. A too 
careful regimen regarding hospital stay might have been used in the first years, 
because one had to become confident with the postoperative results of these new 
techniques. Hospital stay data of the last two years together with reoperation rates 
observed during long-term follow-up demonstrate that electrovaporization has still the 
lowest costs, and laser and TURP results are very similar. Other recalculations are 
all based on these hospital stay values, because these are assumed to be most 
realistic for the future. Maybe hospital stay can even be reduced more in a selected 
group of patients. Several patients have been operated with good results using 
contact laser in daycares setting or they were discharged within 24 h. Mueller9 
presented a study of 50 consecutively operated patients with contact laser. Ninety-six 
percent was discharged within 24 h without catheter. Other recalculations with a 
shorter life time for (laser) equipment, re-TURP rates based on long-term results or 
different allocation rates hardly changed the total costs. 
Postoperative follow-up includes reoperations and rehospitalizations, but not 
outpatient follow-up. The latter might be an important factor, but this can hardly be 
demonstrated in this trial. Patients were seen according to the trial protocol on a 
regular base. In this way it is difficult to differentiate between visits that were made 
because of our protocol or because there was a medical need for an extra visit. 
However, large differences are not expected, because of two reasons. Analysis of 
the total number of outpatient visits postoperatively did not show significant 
differences between the treatment groups. Secondly, analysis of morbidity with 
weekly patient questionnaires during six weeks postoperatively and after 3, 6 and 12 
months did not demonstrate clinically relevant differences among the three treatment 
modalities. 
This evaluation does not report all data involved in an economic analysis as 
recommended by the committee on the economics of BPH from the international 
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consultation on BPH4. These cost data should also include patient costs and costs of 
lost productivity from the workplace. In a study regarding non-contact laser treatment, 
patient costs were only of minor importance to the total costs5. Costs of lost 
productivity might have a relevant influence, but is more difficult to quantify. In the 
present study, about 70% was 60 years of age or more. A substantial number of 
patients contributed to lost productivity, though we did not quantify these costs. 
There are no other publications about economic analyses regarding 
electrovaporization. Keoghane et al have published an economic analysis about the 
use of contact laser prostatectomy in the Oxford laser trial, which compares contact 
laser with TURP7,8. Comparisons with other analyses are difficult, because 
assumptions are different and not always known, prices are valued to other years 
and there are differences in currency. Theater consumables in the Oxford laser trial 
(1997 prices) were ₤67 for TURP and ₤311 for contact laser. The percentual 
difference is much larger than in the present study, which might reflect diminishing 
costs for laser consumables. Total costs (including costs for the operating theater, 
hospital stay, community, capital services and re-operations) were ₤971.4 for TURP 
and ₤1252.2 for contact laser treatment. These are 29% higher costs for laser, which 
is a much larger difference than the 10% higher costs for laser (table 1) in the 
present study. Mueller9 published average costs of contact laser that were very 
similar to costs for TURP. Equipment costs were highest for laser, but 96% was 
discharged within 24 h. There are however, no detailed calculations of these costs. 
Recently, Noble et al5 published a similar economic evaluation comparing TURP, 
side fire (non-contact) laser ablation and conservative management. They concluded 
that for symptomatic improvement non-contact laser treatment was the most costly 
modality with lower cost-effectiveness ratios than TURP. 
 
Conclusions 
 
Evaluation after 12 months and even after long-term follow-up demonstrates very 
similar subjective and objective results between men with LUTS associated with BPH 
after TURP, contact laser prostatectomy or electrovaporization. Costs for laser 
equipment are higher than for TURP and electrovaporization. Shorter hospital stay 
for laser and electrovaporization make total costs for laser similar to costs for TURP 
and make total costs for electrovaporization lowest.  
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Abstract  
 
 
Introduction: Bleeding disorders or the use of anticoagulant medication are 
contraindications for transurethral prostate resection (TURP) in men with lower 
urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). 
Laser prostatectomy has proven to be adequate surgical therapy with less blood loss 
than TURP. 
 
 
Materials and methods: A prospective, controlled study was done in patients at 
high-risk (HR) with LUTS suggestive of BPH. They were treated with contact laser 
prostatectomy (CLP) or the combination of CLP with visual laser ablation 
prostatectomy (VLAP). High-risk was defined as having bleeding disorders or using 
anticoagulants. As a control, men at normal-risk (NR) with LUTS suggestive of BPH 
were treated with CLP. Patients completed validated questionnaires and underwent 
urodynamics at baseline and six months postoperatively.  
 
 
Results: A total of 75 patients were included, namely 19 in the HR-CLP group, 11 in 
the HR-CLP-VLAP group and 45 in the NR-CLP group. Obstruction relief and 
symptomatic and subjective improvement were equal in all three groups. Effective 
capacity (maximum cystometric capacity minus post-void residual volume) also 
improved significantly in all groups except the HR-CLP group. Maximum uroflow 
improved in all groups but not significantly in the HR-CLP group. 
intra and postoperatively complications were slightly higher in HR patients. However, 
blood transfusion was never necessary and there was no mortality. 
 
 
Conclusions: CLP and especially CLP-VLAP perform nearly as well in high-risk 
patients compared with CLP in those at normal-risk. These procedures are safe for 
patients at high-risk with LUTS suggestive of BPH. 
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Introduction 
 
Men presenting with lower urinary tract symptoms (LUTS) suggestive of benign 
prostatic hyperplasia (BPH) are treated in several ways depending on the severity of 
their symptoms, bother and their preference. For several decades, transurethral 
resection of the prostate (TURP) has been the gold standard when surgical treatment 
was necessary. Nevertheless, this surgical procedure is associated with an intra-
operative morbidity, especially bleeding and perforation, varying from 6.9 to14%1-4. 
Morbidity within 30 days Postoperatively varies from 9.5% to 18%1-4 and consists 
mainly of bleeding. This makes TURP in men on anticoagulant therapy or with 
bleeding disorders contraindicated. Temporarily stopping anticoagulant drugs, e.g. in 
patients with pulmonary embolism, chronic atrial fibrillation, cardiovascular incidents 
or prosthetic heart valves increases the risk of thrombo-embolic processes. If there is 
an important indication for surgical intervention, the most commonly used procedure 
is stopping anticoagulants several days preoperatively and using heparin 
intravenously per-operatively5. The much shorter half-life of heparin makes it possible 
to stop it only for a few hours peri-operatively. Postoperatively, oral anticoagulant 
therapy can be resumed. This procedure only partially reduces the risk for thrombo-
embolic processes. In addition, there is already an increased risk of 6.8%-10% for 
deep venous thrombosis in normal patients undergoing TURP6. 
In the past, some authors concluded that it is possible to perform TURP while 
continuing oral anticoagulant therapy7, without temporarily stopping intravenous 
heparin8 or with heparin subcutaneously9,10. These studies, however, were only 
performed in very small populations and few clinicians follow these regimens. 
The introduction of laser prostatectomy in various modalities offered a new 
perspective for these patients. All laser types have the ability to coagulate and 
minimize bleeding. Previously, we demonstrated that contact laser prostatectomy 
(CLP) performs urodynamically, symptomatically and subjectively equal to the gold 
standard TURP11,12. Regarding intra-operative and post-operative complications, 
there was significantly less blood loss in men treated with CLP. 
Several other authors reported good results for all types of laser therapy in patients 
on anticoagulant therapy or with bleeding disorders, however, the literature is scarce 
and is often only case reports13-17. 
We analyzed the results of CLP and a combination of CLP with visual laser ablation 
prostatectomy (VLAP). Patients were men with LUTS suggestive of BPH that also 
had various bleeding disorders, or were using oral anticoagulants or thrombocyte 
aggregation inhibitors.  
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Materials and methods 
 
A prospective, controlled study was conducted between 1994 and 2002 at our clinic. 
High-risk (HR) patients were defined as patients using anticoagulants 
(acenocoumarol or fenprocoumon, both coumarine derivatives), using thrombocyte 
aggregation inhibitors (carbasalate calcium) or having various bleeding disorders. 
These patients were selected in, or referred to our outpatient department. HR 
patients with LUTS suggestive of BPH were included if withdrawal of anticoagulants 
created unacceptable risks according to their cardiologist. Conservative treatment 
had to fail or they had to be in urinary retention. Patients on coumarine derivatives 
with an INR (international normalized ratio) <1.2 directly preoperatively were 
excluded.  
Patients had to be urodynamically equivocal or obstructed (Schäfer grade ≥2) and 
their prostate volume had to be between 20 and 65 ml. Patients with any of the 
exclusion criteria (except bleeding disorders or anticoagulants) of the International 
Consensus Committee on BPH were excluded from analysis18, e.g. prostate cancer 
or urolithiasis. If patients fulfilled the inclusion and exclusion criteria and signed 
informed consent, they were treated with hybrid therapy (a combination of CLP and 
VLAP) or CLP. Hybrid therapy was performed from 1994 to 1996 and CLP from 1996 
to 2002. 
All patients had thorough histories taken and underwent digital rectal examination, 
transrectal ultrasonography, urodynamics, free uroflowmetry, post-void residual urine 
volume estimation, urinalysis and blood analysis including haemoglobin and 
coagulation parameters. Symptomatic and subjective parameters were measured by 
questionnaires validated by the American Urological Association (AUA). Patients 
completed the International Prostate Symptom Score Index (IPSS)19, the Symptom 
Problem Index (SPI or bother score index)20, the BPH Impact Index (BII)20 and the 
Quality of Life question (QoL)19. These questionnaires were completed before 
surgery and 6 months Postoperatively. Urodynamics consisted of filling cystometry, 
pressure-flow studies and free uroflowmetry. These were performed preoperatively 
and six months Postoperatively. Post-void urine volume was estimated by 
catheterization. Effective bladder capacity was defined as the maximum cystometric 
capacity minus the post-void residual volume. Uroflowmetric results were only 
included if patients voided over 150 ml. Complications were registered both intra-
operatively and Postoperatively for up to twelve months. 
CLP was performed with an SLT Nd:YAG laser with an MTRL 10, 6x5 mm, sapphire 
tipped probe (Surgical Laser Technologies, Oaks, Pennsylvania). It uses laser light to 
heat a rounded black tip. Upon contact with prostatic tissue this causes direct tissue 
ablation by vaporization and leaves behind a coagulated layer. VLAP was performed 
with a Nd:YAG laser with a right angle fibre delivery system (Urolase CR Bard Inc., 
LASER IN HIGH RISK PATIENTS… 
139 
Covington, Georgia). This type of free beam laser deflects laser light at a right angle 
to necrotize, vaporize and coagulate prostatic tissue. A gold-plated alloy dish 
reflector tip fixed to the distal end ensured 90º deflection of laser light into the 
prostatic tissue. Laser treatment was applied to four positions in the lateral lobes for 
prostate volumes below 40 ml and to eight positions for larger prostates. At each site, 
laser light was applied for 90 seconds at a setting of 40 watts. CLP was used after 
VLAP to vaporize and coagulate the bladder neck and, if present, the median 
prostatic lobe.  
All patients were operated while using intravenous antibiotics and the surgeries were 
always performed by the same urologist. A three-way catheter was left in place, 
Postoperatively. 
Parallel to the present study, a partially overlapping randomized controlled trial11,12 
was conducted comparing TURP, electrovaporization and CLP in men with LUTS 
suggestive of BPH. Inclusion and exclusion criteria were similar except for the 
bleeding status of the patients. These normal-risk (NR) patients treated with CLP 
were used as a control.  
Statistical analyses were performed with ANOVA, Kruskal-Wallis, Chi-square test, 
Student-t test, Mann-Whitney U test and Wilcoxon signed-ranks test. The 
Kolmogorov-Smirnov test was used to analyze the normal distribution of parameters. 
Significance was set at p=0.05. Data are presented as means ± standard deviations, 
unless otherwise mentioned. 
 
Results 
 
Between 1994 and 2002, thirty high-risk (HR) patients were treated by laser 
prostatectomy: 11 by hybrid therapy (VLAP-CLP) and 19 by CLP. From 1996 to 
2002, forty-five normal-risk (NR) patients were treated with CLP11,12.  
Table 1 lists the high-risk characteristics for the two HR groups. In the HR-CLP 
group, 11 patients used coumarine derivatives, 3 patients used thrombocyte 
aggregation inhibitors and 5 patients suffered from bleeding disorders. From the 
latter subgroup; 2 had haemophilia, 1 a uraemic thrombopathy, 1 a myelodysplastic 
syndrome and 1 a coagulation disorder of unknown origin. In the HR-Hybrid group, 8 
patients used coumarine derivatives and 3 suffered from bleeding disorders of 
unknown origin.  
Table 2 lists the baseline characteristics of the HR patients and the NR-CLP patients. 
There were no significant differences at baseline between the groups. 
In table 3 the baseline values are presented together with the 6 months post-
operative results. These values are also graphically represented in figures 1 to 4.  
Within the different groups there were always significant changes, with the following 
exceptions: maximum flow and effective capacity in the HR-CLP group; bother index,  
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Table 1 High-risk characteristics. In 1a only the main reason for using anti-coagulant therapy is 
presented. 
 HR-CLP n=19 
HR-Hybrid 
n=11 
   1a: Anti-coagulants or thrombocyte aggregation 
   inhibitors   
Prosthetic heart valve(s) 2 2 
Vascular prosthesis 1 0 
Chronic atrial fibrillation 3 (5)1 1 (3)1 
Aneurysma cordis 1 1 
Myocardial infarction 2 1 
Pacemaker 1 0 
Deep venous thrombosis  0 1 
Pulmonary embolism 1 1 
Cerebro-vascular accident  3 1 
1b: Bleeding disorders   
Haemophilia 2 0 
Other bleeding disorders 3 3 
1. The number between brackets shows the total number of men with atrial fibrillation. This number 
includes men with atrial fibrillation in whom their was another main reason to start anticoagulant 
therapy. 
 
Table 2 General, urodynamic and symptomatic characteristics of high-risk (HR) patients and normal-
risk (NR) controls preoperatively. Data presented as means ± standard deviation.  
 HR-Hybrid HR-CLP NR-CLP p level between1 
Number of patients 11 19 45 - 
Age (years) 72 ± 5 70 ± 7 67 ± 9 0.2 
Prostate volume (ml) 37 ± 14 35 ± 17 37 ± 11 0.9  
Obstruction grade 
(Schäfer) 3.1 ± 1.4 3.3 ± 1.0 3.2 ± 1.2 0.9
  
Maximum flow (ml/sec) 11.8 ± 3.1 12.5 ± 1.8 11.5 ± 4.1 0.7  
Effective capacity (ml) 272 ± 209 369 ± 167 302 ± 133 0.3  
Symptom Score Index 21.1 ± 5.0 18.9 ± 6.5 18.9 ± 6.8 0.5  
Symptom Problem Index 11.9  ± 5.6 11.7 ± 7.3 12.5 ± 7.8 0.4  
BPH Impact Index 12.8 ± 4.3 10.3 ± 3.5 9.5 ± 4.0 0.07  
Quality of Life 3.9 ± 2.1 4.0 ± 1.3 3.7  ± 1.6 0.8  
1. ANOVA and chi-square test used. 
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Table 3 Urodynamic, symptomatic and subjective changes postoperatively of high-risk (HR) patients 
and normal-risk (NR) controls. Data presented as means ± standard deviation. 
 
1. Ratio = postvalue/ prevalue, and percent change = {(prevalue – postvalue)/ prevalue} * 100% 
p level  
  
Pretreatment 6 months Posttreatment 
Change as 
ratio and 
percent 1 within between 
Schäfer obstruction 
grade 
  HR-Hybrid 
  HR-CLP 
  NR-CLP 
 
 
3.1 ± 1.4 
3.3 ± 1.0 
3.2 ± 1.2 
 
 
1.2 ± 1.2 
1.1 ± 0.4 
1.0 ± 1.0 
 
 
0.39 (-61%) 
0.33 (-67%) 
0.31 (-69%) 
 
 
<0.01 
<0.01 
<0.001 
0.7 
Maximum Flow 
(ml/s) 
  HR-Hybrid 
  HR-CLP 
  NR-CLP 
 
 
11.8 ± 3.1 
12.5 ± 1.8 
11.5 ± 4.1 
 
 
22.6 ± 9.9 
17.8 ± 5.5 
23.8 ± 7.2 
 
 
1.92 (+92%) 
1.42 (+42%) 
2.07 (+107%)
 
 
0.01 
0.08 
<0.001 
 
0.01 
(0.01 between 
HR-CLP and 
NR-CLP) 
Effective capacity 
(ml) 
  HR-Hybrid 
  HR-CLP 
  NR-CLP 
 
 
272 ± 209 
369 ± 167 
302 ± 133 
 
 
417 ± 209 
357 ± 173 
437 ± 120 
 
 
1.53 (+53%) 
0.97 (-3%) 
1.45 (+45%) 
 
 
0.02 
0.7 
<0.001 
0.08 
Symptom Score 
Index 
  HR-Hybrid 
  HR-CLP 
  NR-CLP 
 
 
21.1 ± 5.0 
18.9 ± 6.5 
18.9 ± 6.8 
 
 
8.0 ± 7.8 
7.6 ± 4.5 
6.6 ± 5.8 
 
 
0.38 (-62%) 
0.40 (-60%) 
0.35 (-65%) 
 
0.04 
0.01 
<0.001 
0.7 
Bother Score Index 
  HR-Hybrid 
  HR-CLP 
  NR-CLP 
 
 
11.9 ± 5.6 
11.7 ± 7.3 
12.5 ± 7.8 
 
 
3.8 ± 5.6 
3.6 ± 4.3 
2.8 ± 4.4 
 
 
0.32 (-68%) 
0.31 (-69%) 
0.22 (-78%) 
 
 
0.09 
0.04 
<0.001 
0.3 
BPH Impact Index 
  HR-Hybrid 
  HR-CLP 
  NR-CLP 
 
 
12.8 ± 4.3 
10.3 ± 3.5 
9.5 ± 4.0 
 
 
5.3 ± 6.8 
2.5 ± 2.1 
3.2 ± 3.5 
 
 
0.41 (-59%) 
0.24 (-76%) 
0.34 (-66%) 
 
 
0.1 
0.01 
<0.001 
0.09 
Quality of Life 
  HR-Hybrid 
  HR-CLP 
  NR-CLP 
 
 
3.9 ± 2.1 
4.0 ± 1.3 
3.7 ± 1.6 
 
 
2.2 ± 2.3 
1.6 ± 1.4 
1.1 ± 1.1 
 
 
0.56 (-44%) 
0.40 (-60%) 
0.30 (-70%) 
 
 
0.3 
0.03 
<0.001 
0.5 
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Table 4 Perioperative parameters. Data presented as means ± standard deviation. 
 
 HR-Hybrid HR-CLP NR-CLP p level betweenc
Operation time (min) 50 ± 15 58 ± 16 58 ± 11 0.6 
Blood loss 
intraoperatively a 0.7 ± 0.8 0.5 ± 0.7 0.6 ± 0.7 0.8 
Change in Hb (mmol/l) b 
8.9 ± 1.2 → 
8.5 ± 0.9 
p = <0.01 
8.5 ± 0.7 → 
8.0 ± 1.0 
p = 0.03 
9.0 ± 0.9 → 
8.8 ± 0.8 
p = 0.3 
0.06 
Irrigation fluid (l) 16 ± 6 16 ± 5 18 ± 4 0.2 
Drainage time (days) 7.3 ± 6.6 median: 6 
2.6 ± 1.3 
median: 2 
2.8 ± 3.1 
median: 2 <0.01 
Postoperative hospital 
stay (days).  7.0 ± 1.1 6.1 ± 2.3 3.8 ± 1.3 <0.001 
INR direct 
preoperatively 2.2 ± 1.2 2.1 ± 0.9 - 0.7 
Energy (kJ) 51 ± 17 58 ± 24 48 ± 17 0.2 
1. Blood loss: 0=none, 1=moderate and 2=severe. Visual estimation intra-operatively by urologist. 
2. Hb = haemoglobin: pre → post-operative value, including significance of decrease within group 
(Student-t test). 
3. Operation time, change in Hb, irrigation and hospital stay with ANOVA; blood loss, drainage time 
and energy with Kruskal-Wallis test. INR with Student’s t test. 
 
BPH impact index and Quality of Life in the HR-Hybrid group. All changes were 
significant in the NR controls. Statistical analysis of the relative changes between the 
groups did not show any significant differences, except for maximum free flow. 
Further analysis demonstrated a significant difference (p=0.01) between NR-CLP and 
HR-CLP patients. Urodynamically there was always desobstruction in both HR 
groups. Postoperatively in the HR-CLP group, all patients had Schäfer grade 1 
except one patient with grade 2. In the HR-Hybrid group there was one patient  with 
Schäfer grade 3 Postoperatively (grade 4 at baseline); the remaining patients had 
Schäfer grade <2. Forty-one out of 45 NR-CLP patients had Schäfer grade <2 
Postoperatively11. 
Peri-operative data are presented in table 4. Mean operation time was less than one 
hour in all groups and no significant differences were observed. There were also no 
significant differences in use of irrigation fluid or laser energy . INR was estimated in 
patients on coumarine derivatives and did not differ significantly between the HR 
groups. Visually estimated blood loss intra-operatively also showed no significant 
differences between the groups. Within the HR groups there was a small, but 
significant, decrease in haemoglobin. No significant change was observed in the NR 
controls. Analysis of this haemoglobin change between the three groups did not 
show a significant difference, although there was a trend in favour of the NR controls  
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Table 5 Number of intraoperative complications. 
 
 HR-Hybrid HR-CLP NR-CLP  
Capsule perforation 0 0 2 
Bleeding, making electrocoagulation necessary 1 3 b 2 
Bleeding, making TURP necessary 0 0 3 
False passage 0 0 1 1 
Technical failure 0 0 3 
Use of TURP because of tissue debris 3-5 4 2 3 
 
1. False passage made during first introduction of the scope 
2. One patient required TURP for tissue debris and electrocoagulation for bleeding, which were 
counted seperately. 
 
 
 
 
 
 
 
 
Table 6 Postoperative morbidity and mortality within 12 months (without urinary tract infections). 
 
 HR-Hybrid n=11 
HR-CLP 
n=19 
NR-CLP 
n=45 
Bleeding requiring transfusion 0 0 0 
Clot retention 1 3 2 
Urinary retention 1 1 5 
Reoperation (TURP) 0 1 1 
Reoperation (electrocoagulation) 1 0 0 
Urethral strictures 0 1 2 
Bleeding requiring rehospitalization 
and irrigation 1 2 
1 0 
Other 0 0 1 epididymitis 
Mortality 0 0 0 
 
1. In one patient INR was >5 and vitamin K was used to correct coagulation status next to irrigation. 
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Figure 1 Graphic representation of the Schäfer obstruction grade in the three different groups at 
baseline and six months postoperatively. Data presented as means ± standard deviations. 
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Figure 2 Graphic representation of the maximum free flow (in ml/sec.) in the three different groups at 
baseline and six months postoperatively. Data presented as means ± standard deviations. 
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Figure 3 Graphic representation of the effective capacity in the three different groups at baseline and 
six months postoperatively. Effective capacity is defined as the maximum cystometric capacity minus 
the post-void residual volume. Data presented as means ± standard deviations. 
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Figure 4 Graphic representation of subjective and symptomatic parameters in the three different 
groups at baseline and six months postoperatively. SS: symptom score index, BS: bother score index 
or symptom problem index, BII: BPH impact index, and QL: Quality of Life. Data presented as means  
± standard deviations.   
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(p=0.06). No significant difference for drainage time was demonstrated between the 
CLP groups, but there was an obvious and significant difference between these 
groups and the HR-Hybrid group. Hospital stay was significantly longer in the HR 
groups compared to the control patients. 
Table 5 presents the intra-operative complications. In all groups, electroresection 
was sometimes performed because of tissue debris. Electro-coagulation was most 
used in the HR-CLP group. Comparison to the HR-Hybrid group is impossible 
because of small numbers. Post-operative complications are described in table 6.  
More complications were observed in the HR patients. Blood transfusions were not 
necessary in any of the groups, nor was there any mortality. 
 
Discussion 
 
In the early nineties, many new treatment modalities were developed to overcome 
the relatively high morbidity and mortality rates of TURP1-4, including the introduction 
of several laser treatments. Their good coagulative characteristics make them 
theoretically ideal to perform prostatectomies in high-risk patients. A randomized 
controlled trial at our department demonstrated that CLP matched the symptomatic, 
subjective and urodynamic improvements of TURP but with less blood loss11,12. Intra-
operative and post-operative complications were also comparable.  
The use of electroresection to remove tissue debris was only used in the first years of 
this study in very specific situations that were not foreseen, and only to remove a few 
small tissue particles. The clinical significance is very doubtful and we abandoned 
this practice in later years. 
Several studies on HR patients with different laser types have been conducted in the 
past. Polepalle17 conducted an interstitial laser therapy pilot study in an ambulatory 
setting on 8 men with LUTS while continuing warfarin anticoagulant therapy.  No 
patients required hospitalization, blood transfusion or irrigation. Maximum uroflow 
and symptom score improved fairly. Bolton16 presented a VLAP study with ten 
symptomatic BPH patients and continuing warfarin peri-operatively. There were no 
significant peri-operative complications, with one patient needing irrigation because 
of clot retention. Maximum uroflow improved from 9 to15 ml/sec, post-void residual 
volume decreased from 485 to 105 ml and symptom score decreased from 21 to 7. 
Kingston15 also reported a VLAP study in 20 men with continuous warfarin therapy 
and 2 men with coagulation disorders (idiopathic thrombocytopenia and leukaemia). 
Mean prostate volume was with 56 ml larger than in the present study. After six 
months, symptom score improved from 21 to 7, maximum uroflow from 9.8 ml/sec to 
12.0 ml/sec and post-void-residual urine from 80 ml to 48 ml.  Three patients required 
post-operative blood transfusions and one of these patients sustained a 
cerebrovascular accident because of reversal of anticoagulant therapy and TURP. 
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One patient developed epididymo-orchitis and one required rehospitalization 
because of haematuria.  
Until now, two studies with CLP in HR patients have been conducted. Keoghane13 
presented three cases of men continuing warfarin therapy with mixed results. One 
patient was readmitted Postoperatively because of minor secondary haemorrhage, 
one patient recovered with good results and one patient (prostate volume 112 ml) 
suffered from haemorrhage directly Postoperatively, requiring 5 units of blood. 
Mueller14 reported six cases of men treated with CLP who continued warfarin peri-
operatively. In all men, catheter removal and hospital discharge occurred on day one. 
None developed any significant bleeding peri-operatively and all had excellent relief 
of their obstructive symptoms.  
To the best of our knowledge, the present study is the first to perform urodynamics in 
all patients and to make use of a control group. The latter makes it possible to see if 
HR patients are operated less efficiently because of fear of bleeding. The first 11 HR 
patients were treated with CLP-VLAP (Hybrid), but from 1996 HR patients were 
treated with CLP only. The main reasons for this change were that CLP is easier to 
perform and gives similar results to hybrid therapy. Because of this, CLP was used in 
a second trial with normal risk patients, increasing our experience significantly. 
All groups were statistically compared, although patients in the present study were 
not randomized. However, inclusion and exclusion criteria are equal and baseline 
values are also very similar, except for their bleeding status. 
A good desobstruction was achieved in all groups. Nevertheless, there was only a 
minor increase in maximum flow in the HR-CLP group (p=0.08). This can be partially 
explained by a decrease in contractility within this group (2.6 to 2.0: p=0.4). There 
was a slight increase in contractility in the HR-Hybrid group (2.9 to 3.3: p=0.3). The 
same explanation may be apply to the effective capacity: a large increase in the HR-
Hybrid group and the control group, but almost no change in the HR-CLP group. 
However, because of a large variation within the groups there was no significant 
difference in the change between the groups. There were no significant differences in 
the symptomatic and subjective improvements between the groups. Within the 
groups, all improvements were significant except for the HR-Hybrid group. In this 
group, only the symptom score index improved significantly (p=0.04). Change in 
haemoglobin did not differ significantly between the groups, though there was a trend 
in favour of the control group (p=0.06). Haemoglobin decrease was not significant in 
the control group and was small (0.4 mmol/l), but significant, within the HR groups. 
The clinical relevance of these changes is small, demonstrating intra-operative 
safety. Drainage times were comparable between the two CLP groups and were 
significantly shorter than in the HR-Hybrid group. This difference can be explained by 
directly obtained desobstruction in CLP caused by vaporization. VLAP causes more 
tissue necrosis and requires a longer catheterization period. Hospital stay did not 
differ significantly between the HR groups. HR-CLP patients were hospitalized for 
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longer observation periods as a precautionary measure. Retrospectively, this 
regimen may have been too careful since only 3 out of 19 patients had clot retention 
and these were always in men with gross haematuria after catheter removal. Intra-
operative and post-operative complications were not compared statistically because 
of small numbers. There may be slightly more intra-operative bleedings and post-
operative clot retentions in the HR-CLP group. Although some other studies reported 
blood transfusions, these were never necessary in the present study.  
Conclusions 
 
The use of CLP and the combination CLP with VLAP in high-risk patients with LUTS 
suggestive of BPH can safely be performed. Compared to CLP in normal risk 
patients, there are only small differences in symptomatic and subjective 
improvements. Urodynamic desobstruction was equal in all groups, although HR-
CLP patients showed a smaller increase in maximum flow and an unchanged 
effective capacity. Intra-operative and post-operative complications were almost 
equal between all groups. Blood transfusion was never necessary nor was there any 
mortality. 
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GENERAL DISCUSSION 
 
Chapter 1 gives an introduction to several aspects that are related to the prostate. It 
describes the anatomy and physiology of the prostate and the etiology of benign 
prostatic pathology with its natural history. The term LUTS (lower urinary tract 
symptoms) is described together with the possibilities to quantify these symptoms 
and their bothersomeness. This term refers to the location of several urinary 
problems, instead of the old term ‘prostatism’, which refers to an incorrect etiology. It 
is clearly stated that many factors can cause LUTS. The exact share of the different 
(benign) pathological states is thus far not completely solved. Benign pathological 
states can be categorized into a histological diagnosis, a mechanical diagnosis or a 
volumetric diagnosis, respectively BPH (Benign Prostatic Hyperplasia), BPO (Benign 
Prostatic Obstruction) and BPE (Benign Prostatic Enlargement).  
 
The term BPH is used in the title of this thesis, merely because it is such a generally 
accepted term. The adjective ‘clinical’ is necessary to indicate that LUTS are 
involved. All patients that were included in the studies of the following chapters are 
described as having ‘LUTS associated with BPH’ or ‘LUTS suggestive of BPH’.  One 
can argue the accuracy of these descriptions, because most patients have never 
been histologically diagnosed. However, these descriptions are often used in 
literature because of the lack of accurate terminology. 
 
Chapters 2 and 3 deal with urodynamics in the context of performing the gold 
standard, TURP. In chapter 2, men with LUTS associated with BPH who were 
treated by TURP were studied.  Ninetythree patients could be evaluated after 6 
months of the 132 men that were included. Of these 93 men, 32 men were 
preoperatively unobstructed (Schäfer grade 1 or 2) and the remaining 61 were 
obstructed (Schäfer grade ≥3). Symptomatic improvements were significantly related 
with a decrease in bladder outlet obstruction. Nevertheless, also the unobstructed 
patients benefited from TURP. Looking at all patients, there was a 45% increase in 
effective capacity, which contributed to a significant improvement in I-PSS, SPI, QoL 
and BII. Of the patients with a preoperative stable bladder, 90% remained stable 
postoperatively. In those with a preoperative unstable bladder, 50% became stable 
postoperatively. However, which bladder becomes stable could not be predicted 
preoperatively from subjective or objective parameters. 
 
The finding in chapter 2 that patients who were not obstructed or were equivocal 
showed a significant and clinical relevant increase in both subjective and objective 
findings, was the reason to analyze this topic more intensively in chapter 3. It 
appeared that the quantified reduction of symptoms and bother in the unobstructed 
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and equivocal men were about 70% of those reductions in obstructed men. In the 
equivocal men and even in the unobstructed men a significant reduction with 40% of 
the urethral resistance occurred. It is demonstrated that for unobstructed or equivocal 
men with considerable LUTS and BPE, who opt for resection, who do not respond to 
medical therapy and/or in whom adverse effects are associated with treatment 
discontinuation, prostate resection appeared to be a good treatment alternative. The 
presence or absence of urethral obstruction should not be the decisive factor in 
treatment choice, and absence of obstruction should not be an exclusion criterion for 
transurethral prostate resection. 
 
The expanding armamentarium of minimally invasive surgical modalities over the last 
decade, has not dethroned TURP as being the gold standard. This raises some 
questions. How is it possible that all these new technologies cannot surpass or even 
match a modality that is half a century old? And when exactly is a new treatment 
more successful than an older one? The answers are probably hard to find. Each 
(surgical) treatment strategy should be evaluated in a context of objective and 
subjective treatment results, complications and side-effects. And possibly more 
aspects are of importance in the acceptance of a new modality: are the surgical 
characteristics interestingly to perform, what is the cost-effectiveness ratio, are long-
term results available, have there been multicenter, randomized, controlled trials and 
what is the influence of the manufacturers? Many characteristics are important and it 
takes a lot of time and effort of many scientists and clinicians to correctly introduce a 
new modality. The scientific standards are high nowadays and demand that each 
new surgical modality is compared to the gold standard (TURP) in a randomized 
setting.  
In reality, the process of introducing a new modality is influenced by many factors, 
like individual (scientific) ambition and financial fundings. In this way, the process 
does not always comply with the stringent methodological rules. A long time period 
can elapse from the first pilot studies presenting the feasibility of a technique to long-
term results from large randomized controlled studies. Sometimes this process is not 
even completed, because another new technique deserves more attention. It can be 
of more interest to publish about another new technique than to perform all the work 
involved in long-term follow-up of patients treated with an already known modality. A 
regrettable event from a scientifically point of view. 
The history of the introduction of TURP presents a perfect example of a process that 
did not follow the solid methodological rules of medical science. New developments 
improved the quality of endoscopic surgery and slowly made TURP the most popular 
surgical modality. Unfortunately, its success caused a historical, scientific gap, that 
will never be filled. It became normal to perform a TURP instead of an open 
prostatectomy, without waiting for a decent comparison between these two surgical 
modalities. Besides one small randomized study, there has been no comparison 
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between open prostatectomy and TURP. Nowadays, it is considered unethical to 
perform a randomized trial comparing these two techniques. TURP became the gold 
standard over several decades, and it is still considered to be so at this moment. 
Many of today’s urologists have been educated with TURP as gold standard and it 
will cost a lot of effort to change this regimen. It is to be hoped, that all new 
techniques that demonstrated to be feasible alternatives, obtain their deserved 
objective, scientific attention. Ultimately, it is in the interest of the patient’s quality of 
life that new medical technologies are developed, tested and introduced. 
 
In our clinic, a randomized, controlled trial was performed from 1996 to 2002 
comparing two minimally invasive surgical modalities to the gold standard TURP. 
These new modalities were contact laser prostatectomy and electrovaporization, both 
introduced in urology about ten years ago. The number of randomized controlled 
trials however is limited and several aspects, like costs, have almost never been 
studied. Included were men over 45 years of age with LUTS associated with BPH. All 
patients underwent history taking, digital rectal examination, transrectal 
ultrasonography, urodynamic evaluation, free flowmetry, post-void residual volume 
estimation, urinalysis and blood analysis. Patients had to be urodynamically 
equivocal or obstructed (Schäfer grade ≥2). Their prostate volume had to be between 
20 and 65 ml. Patients with any of the exclusion criteria of the International 
Consensus Committee on BPH were excluded from analysis. The results of this 
randomized controlled trial are presented in chapters 4 to 7. 
 
Chapter 4 compares the urodynamic results of TURP, contact laser prostatectomy 
(CLP) and electrovaporization. The baseline characteristics of the three groups are 
very similar. The number of included patients complies with the calculated group 
sizes. A total of 50, 45 and 46 men were randomized for TURP, CLP and 
electrovaporization respectively. Six months postoperatively we were able to 
evaluate 70% of the initially examined patients. There were no statistically significant 
differences in the changes between the different modalities for all urodynamic 
parameters. Detrusor pressure at maximum urinary flow decreased by half. There 
was no significant change in bladder contractility. The Schäfer discrete obstruction 
grade and the continuous urethral resistance factor decreased significantly. After 
TURP, 94% was unobstructed (Schäfer grade 0 or 1), after CLP 91% of the patients 
were unobstructed and after electrovaporization 72% were unobstructed while the 
remaining 28% became equivocal (Schäfer grade 2). Effective capacity was defined 
as the maximum cystometric capacity minus the residual volume after voiding. The 
average increase in all groups was at least 50%. This increase was the result of an 
increase in maximum cystometric capacity and a concomitant decrease in postvoid 
residual volume. The prevalence of detrusor instabilities halved in all groups. A 
clinical relevant postvoid residual urine volume was defined as a volume of more 
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than 10% of the maximum cystometric capacity. In all groups there was a decrease 
of at least 60%. Maximum urinary flow rate (Qmax) was measured at several 
intervals, but only at baseline and after 6 months we were able to analyze enough 
patients to evaluate these changes statistically. There were no significant changes in 
the increases in Qmax between the different groups. Qmax increased in all groups 
from about 10 ml/s to about 24 ml/s after 6 months. There were almost no technical 
problems with the new techniques that made it necessary to cross-over to TURP. 
Results in the CLP group and electrovaporization group are comparable to other 
studies that have been performed with these modalities. 
 
TURP has been the gold standard for many decades, but is associated with a 
relatively high morbidity. This challenged many to develop techniques with a lower 
mortality and morbidity, but with still a good improvement in symptomatic and 
subjective parameters. Chapter 5 compares symptomatic and subjective changes 
using AUA questionnaires and compares perioperative parameters, morbidity and 
mortality of the three different surgical modalities. 
Mean operation time was within one hour in all groups and did not differ significantly 
in all groups. Haemoglobin did not change significantly within the CLP and 
electrovaporization groups, though there was a significant change (p<0.001) within 
the TURP patients. Drainage time and hospitalization were very similar and no 
significant differences were demonstrated. Intraoperative complications showed 
some differences between the groups. Capsule perforation was highest in the TURP 
group (10%), bleeding requiring electrocoagulation or conversion was most often 
necessary in CLP (4% and 8% respectively) and technical failures never happened in 
the TURP group, but 3 and 2 times in the CLP and electrovaporization groups 
respectively. Urinary retention was highest in the CLP group. Two men died in the 
TURP group after 4.5 and 6 months and no men died within 12 months in the other 
groups. There were no significant differences in the changes of the AUA validated 
questionnaires over 12 months Postoperatively. The average decreases in these 
scores were for I-PSS from about 18 to about 6, for SPI from about 12 to about 3, for 
BII from about 10 to about 3 and for the QoL score from about 3.8 to 1.1. Frequency 
during daytime and during nighttime decreased significantly in all groups, but again 
no statistically significant differences could be detected. Some specific morbidity and 
symptomatic parameters were measured using self-developed questionnaires. These 
demonstrated a higher urinary incontinence in the TURP group. Paradoxically, a 
higher postoperative haematuria was shown in the CLP group.  
 
Chapters 4 and 5 demonstrate only small differences between the three treatment 
modalities in urodynamic findings after 6 months and in symptomatic and subjective 
changes up to twelve months. As mentioned before, it is important to compare results 
on a long-term basis. Such study was performed and is described in chapter 6. All 
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patients that were included during the course of the study, were reinvited to the 
outpatient department in fall 2002. Only patients who were operated on for more than 
18 months ago were included.  In this way, follow-up times varied individually from 
1.5 to 7 years. The same questionnaires and tests were used as during the 12 
months follow-up: I-PSS, SPI, QoL question, BII and the selfdeveloped 
questionnaires about specific morbidity and symptoms including number of voids 
during daytime and nighttime. If patients were able to visit the outpatient department, 
they were asked to perform uroflowmetry. After 1 year, there were still 41 TURP 
patients, 37 laser patients and 34 electrovaporization patients available for further 
follow-up, making a total of 112 patients. In fall 2002, ninety-eight patients or relatives 
responded finally (response rate 88%). Fourteen patients did not respond (12%). 
Eighty-one responding patients returned all questionnaires and these could be used 
for long-term analysis (83% of the responders). Another 6 had been re-operated 
(6%), 2 were excluded because of morbidity (2%), 2 were not willing to cooperate 
(2%) and 7 patients died (7%) according to relatives. Fifty-nine responding patients 
performed free uroflowmetry (60% of the responders).  
The response rate of 88% enabled an adequate follow-up. However, patients were 
only analyzed once after their one year follow-up, resulting in a large variation in 
individual follow-up time. Secondly, the low number of patients creates a low power, 
so that significant differences might not always be detected. In each treatment group 
there were 24 to 30 patients scattered over the long time interval, with 2 to 6 patients 
per follow-up year. Therefore, patients were divided over two follow-up time intervals 
of 3 years each: a follow-up time of 1-4 years and a follow-up time of 4-7 years. In 
this way, data can be presented and interpreted more comprehensively. Statistical 
analyses were only performed on data from patients who were seen at baseline and 
at long-term follow-up.  
The results of this follow-up demonstrate a high durability for symptomatic and 
subjective relief. The various AUA validated questionnaires show only a small rise 
with no statistical significant differences between the treatment modalities. This rise 
might partially be explained by normal aging in which symptoms and bothering 
increase. Frequencies during daytime and nighttime were for all groups during long-
term follow-up very similar compared to the values 1 year postoperatively. We have 
no good explanation for the significant higher mean nocturia (1.9) in laser patients 
after 4-7 years. Maximum uroflow showed lower values after long-term follow-up: 
about 20 ml/s after 1-4 years between 16 and 19 ml/s after 4-7 years follow-up. 
These decreases can not be fully explained by normal aging as was observed in 
other studies. The specific morbidity and symptom questionnaires demonstrated few 
differences between the treatment groups and most parameters were scored only 
incidentally.  
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The committee on the economics of BPH from the International Consultation on BPH 
from 2000 recommended that future studies on treatment strategies should 
incorporate an economic analysis. Until today, relatively few studies have analyzed 
economic parameters in BPH treatment studies. Chapter 7 compares the costs of the 
three surgical treatments in our randomized trial. Previous chapters concluded only 
minor differences in these outcome results, even after long-term follow-up. Obvious 
differences were seen in the equipment costs, with laser being the most expensive. 
Electrovaporization has the lowest costs and laser costs are slightly higher than 
TURP costs (about 10% higher). Hospital stay decreased over the course of the trial 
most in laser and electrovaporization patients. A sensitivity analysis was performed 
and recalculated costs became almost equal for laser compared to TURP. Total 
costs for electrovaporization were still lower than the other modalities. 
 
In chapter 5, it was shown that their were no statistically significant changes in 
haemoglobin levels in the CLP group. This is caused by the combination of direct 
tissue ablation by vaporization and coagulation of the remaining tissue. TURP leaves 
an almost native layer of tissue behind that causes more blood loss. This makes 
TURP contra-indicated for men using anticoagulants or with bleeding disorders. Only 
small studies have been performed thus far with the use of laser in this high-risk 
group. Chapter 8 compares the results of a group of high-risk (HR) men treated with 
CLP or the combination of CLP with VLAP (hybrid therapy). High-risk patients were 
defined as men using anticoagulants (acenocoumarol or fenprocoumon), platelet 
aggregation inhibitors or with various bleeding disorders. Hybrid therapy was used in 
the first years and replaced by CLP, because the latter was easier to use and 
demonstrated equal results. A group of normal risk patients from our randomized, 
controlled trial was used as a control group. In the HR groups there were obvious 
symptomatic and subjective improvements 6 months postoperatively measured by 
the AUA validated questionnaires: I-PSS, SPI, QoL question and BII. However, these 
changes were not always statistically significant. Urodynamics after 6 months 
showed a good desobstruction in all groups. However, there was only a minor 
increase in maximum flow in the HR-CLP group. Partially, this can be explained by a 
decrease in contractility within this group. Haemoglobin decrease was not significant 
in the control group and small (0.4 mmol/l) but significant within the HR groups. 
However, the clinical relevance of these changes is small, demonstrating 
intraoperative safety. Drainage times were almost equal between the two CLP 
groups and were significantly shorter than in the HR-hybrid group. This difference 
can be explained by direct obtained desobstruction in CLP caused by vaporization. 
VLAP causes more tissue necrosis and requires longer catheterization. However, 
hospital stay did not differ significantly between the HR groups. HR-CLP patients 
were kept some extra days in hospital to watch them carefully. Retrospectively, this 
regimen might have been too careful, because only 3 out of the 19 patients had a clot 
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retention and this were always men with gross haematuria after catheter removal. 
Possibly, there are slightly more intraoperative bleedings and postoperative clot 
retentions in the HR-CLP group. Although some other studies reported blood 
transfusions, these were never necessary in the present study.  
 
CONCLUSIONS 
 
Improvements after transurethral prostate resection are significantly associated with 
decreased bladder outlet obstruction. However, also increase in effective capacity, 
absence of prevalence of instabilities and residual volumes contribute to a significant 
decrease in symptoms and bother. Therefore also men who were preoperatively 
unobstructed or equivocal may benefit significantly from TURP. The presence or 
absence of urethral obstruction in men with LUTS associated with prostatic 
enlargement (BPE) should be a less decisive factor in treatment choice. The absence 
of obstruction should never be an exclusion criterion for TURP. 
Our randomized, controlled trial comparing TURP, contact laser prostatectomy and 
electrovaporization demonstrates in general only small differences between these 
different modalities. Urodynamically there are no statistically significant differences 6 
months Postoperatively. Uroflowmetric results are very similar and increase with a 
factor of 2.4 after 6 months. AUA validated questionnaires demonstrate no 
statistically significant differences over the course of 12 months between the three 
groups. Improvement of I-PSS, SPI, QoL question and BII are very similar. 
Intraoperative and postoperative morbidity show some differences between the three 
modalities: capsule perforations are more seen in TURP, bleeding intraoperatively 
more in CLP, although significant changes in haemoglobin are only seen in TURP. 
Long-term follow-up demonstrates durable results for symptomatic and subjective 
parameters using the same questionnaires as used before. Maximum uroflowmetry 
results decreases to about 150% of the baseline values. A cost analysis of these 
modalities showed that electrovaporization had the lowest costs, followed by TURP 
and CLP, which costs are almost similar.  
CLP and the combination of CLP with VLAP demonstrate to be safe methods in 
treating high-risk patients using anticoagulants or with bleeding disorders. There are 
statistically significant and clinical relevant improvements in most subjective and 
urodynamic parameters, also when compared to a group of normal-risk men who 
were treated with CLP. 
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FUTURE PERSPECTIVES 
 
At this moment, TURP is still the most practiced surgical modality for men with BPH 
and moderate to severe LUTS worldwide. And it will stay the gold standard for BPH 
surgery probably for many more years for reasons that were mentioned before. 
Many, mostly academic, centers are nowadays involved in developing and testing 
new minimally invasive methods to treat these patients. Today’s residents in urology 
will become more familiar with surgery that is different from TURP. This will make 
them more accessible to new techniques, contrary to many urologists who have 
learnt only TURP and performed this throughout their professional career.  
At our center contact laser prostatectomy is used on a regular base for patients using 
anticoagulants or with bleeding disorders. More and more selected normal risk 
patients are also treated with contact laser on a short stay base with only one 
overnight stay or even in a daycare setting. These practices will probably become 
more practiced in the future and the logistical and financial hospital structures should 
adapt to this new situation. Other centers use different minimally invasive options like 
TUMT, which is often performed in an outpatient based structure. Slowly, several of 
these new modalities will probably be adapted by several non-university hospitals.  
In the near future, the patient with LUTS associated with BPH might be able to 
choose from many treatment options, varying from pharmacotherapy to several 
minimally invasive (surgical) modalities including TURP. New developments but also 
the arduous evaluation processes of recently introduced methods should 
continuously be stimulated. This in order to offer the constantly increasing number of  
men with LUTS always the optimal treatment.
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Deze samenvatting beoogt het geven van een beknopt overzicht van de inhoud van 
dit proefschrift in een voor niet-medici begrijpelijk Nederlands. Het blijkt echter toch 
altijd weer moeilijk voor hen de inhoud begrijpelijk en duidelijk samen te vatten. Laat 
het in ieder geval beschouwd worden als een oprechte poging daartoe. Ik vind het de 
moeite waard om uit te leggen wat urologie is en de resultaten van dit proefschrift 
toegankelijk te maken. 
 
De urologie is een specialisme binnen de geneeskunde dat zich bezig houdt met 
ziekten aan de organen van de urinewegen. Van ‘boven-naar-beneden’ zijn dit de 
nieren, de urineleiders, de blaas en de plasbuis. Bij mannen komen daar nog de 
prostaat en de uitwendige geslachtsorganen bij. Deze organen vormen een vrij 
duidelijk afgebakend deel van het lichaam waar het nodige mee mis kan gaan. Er 
kunnen ontstekingen optreden, steenvorming kan plaatsvinden, er bestaan allerlei 
aangeboren afwijkingen en er kunnen tumoren ontstaan.  
Met name in de prostaat ontstaan vaak tumoren. Dit kastanje vormige orgaan, ook 
wel de voorstanderklier genoemd bevindt zich direct onder de blaas. De exacte 
functie van dit orgaantje is niet geheel duidelijk. Het produceert prostaatvocht, wat 
belangrijk is bij onderdelen van het transport van zaadcellen. Er is meer bekend over 
wat er allemaal mis kan gaan met de prostaat, dan wat nu precies verder de functie 
van dit orgaan is.  
Met het stijgen van de leeftijd verandert er bij de meeste mannen nogal wat in de 
prostaat. Cellen gaan zich delen en dit leidt tot een goedaardige of een 
kwaadaardige tumor. Het woord tumor betekent feitelijk alleen dat er iets in omvang 
toeneemt en dit hoeft niet noodzakelijk kwaadaardig te zijn. Een kwaadaardige tumor 
betekent dat er sprake van kanker is. In dit proefschrift gaat het niet om 
prostaatkanker, maar juist om goedaardige prostaatvergrotingen. Dit laatste wordt 
ook wel BPH genoemd (Benigne Prostaat Hyperplasie), zoals in de titel van dit 
proefschrift is te lezen. Bij een aanzienlijk deel van de mannen boven de 30 jaar gaat 
de prostaat groeien; bij de een langzaam, bij de ander snel. Dat kan betekenen dat 
de plasbuis, die midden door deze klier loopt, dichtgedrukt wordt.  
Als dat gebeurt, wordt het voor de blaas moeilijker om tijdens het plassen alle urine 
via de plasbuis naar buiten te krijgen. Als reactie gaat de spierwand van de blaas  
verdikken, maar toch wordt de plasstraal vaak minder krachtig. Daarnaast zijn er nog 
vele andere verschijnselen of symptomen die kunnen optreden, zoals het vaker 
moeten plassen (zowel overdag als ’s nachts), sterke aandrang om te moeten 
plassen of het zogenaamde ‘nadruppelen’. Vervelende klachten die vaak, maar niet 
altijd, samengaan met een goedaardige vergroting van de prostaat. Vele andere 
afwijkingen aan de urinewegen kunnen soortgelijke klachten geven. Deze klachten 
kunnen ook optreden bij mannen met prostaatkanker, maar het is niet zo, dat 
mannen met plasklachten hier meer kans op hebben dan mannen zonder 
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plasklachten. Prostaatkanker en goedaardige vergroting van de prostaat (BPH) zijn 
twee aparte ziekten, hoewel ze wel samen bij één man kunnen voorkomen. 
Mannen die hinder hebben van hun plasklachten of zich hier zorgen over maken, 
komen bij de huisarts of de uroloog terecht. Het vragen naar de precieze klachten en 
het verrichten van aanvullend onderzoek is nodig om de juiste diagnose te stellen. 
Dit aanvullende onderzoek bestaat uit het verrichten van een rectaal onderzoek 
(toucher) waarbij de prostaat gevoeld kan worden. Verder wordt er meestal 
bloedonderzoek gedaan, wordt de straalkracht tijdens het plassen gemeten, wordt 
een echo gemaakt van de prostaat en worden er enkele vragenlijsten gebruikt om 
een goed inzicht te krijgen in de hoeveelheid symptomen en de mate waarin deze 
symptomen klachten geven. In sommige gevallen wordt tevens een urodynamisch 
onderzoek verricht. Hierbij worden, met gebruik van speciale drukmetertjes die in de 
blaas worden gebracht, de blaas en plasbuis helemaal doorgemeten. Zo kan 
bijvoorbeeld worden gemeten in welke mate de prostaat het plassen belemmert. 
Als duidelijk is dat de plasklachten worden veroorzaakt door BPH, bestaan er diverse 
behandelmogelijkheden. De keuze hangt af van de mate waarin er klachten bestaan 
en uit de voorkeur van patiënt en arts voor bepaalde middelen. Soms is het genoeg 
om uit leggen waar de klachten vandaan komen en de patiënt gerust te stellen dat er 
geen kanker is. Er zijn tegenwoordige diverse medicijnen die de klachten kunnen 
verminderen en er kan geopereerd worden. In dit proefschrift gaat het om 
verschillende operaties die mogelijk zijn. 
Tot ongeveer 1960 werd er geopereerd via een snede in de onderbuik. Daarna werd 
een nieuwe techniek steeds populairder. Het was technisch mogelijk geworden om 
met behulp van speciale lichtbronnen en verfijnde optische lenzen toegang te krijgen 
tot de prostaat via de plasbuis. Dit wordt transurethrale (=door de plasbuis) scopie 
(=kijken) genoemd. Door deze natuurlijke toegangsroute te gebruiken is het niet 
meer nodig om een snede te maken en dus een litteken achter te laten. Een 
elektrisch lisje aan het einde van een smalle buis (=scoop) maakt het mogelijk om 
stukjes prostaatweefsel weg te snijden. Deze techniek wordt TURP genoemd 
(=Trans Urethrale Resectie van de Prostaat) en is de gouden standaard voor 
chirurgie bij BPH. 
Met deze techniek zijn goede resultaten te behalen, maar er komen vaak 
bijwerkingen voor zoals bloedverlies. Dit leidt tot ziekte en zelfs sterfte tijdens en na 
de operatie. Sinds het begin van de jaren negentig, nu ruim tien jaar geleden, zijn er 
vele nieuwe technieken uitgeprobeerd. Het doel is om dezelfde goede resultaten van 
TURP te behalen, maar dan met minder bijwerkingen. In dit proefschrift wordt de 
gouden standaard TURP vergeleken met twee van deze nieuwe technieken: een 
laser en een elektrisch cilindertje. Bij de laser wordt er laserlicht via glasvezels door 
de scoop geleid die in de plasbuis wordt gebracht. Aan het einde zit een saffieren 
bolletje met een zwart oppervlak dat door het laserlicht extreem heet wordt. In 
contact met de prostaat verdampt het prostaatweefsel en blijft er een dichtgeschroeid 
…CHAPTER 10 
164  
laagje achter. Dit  type laser wordt de contact laser genoemd. De techniek met het 
elektrisch cilindertje wordt electrovaporizatie genoemd en lijkt veel op de contact 
laser. Elektriciteit verhit een cilindertje aan het uiteinde van de scoop. Dit cilindertje, 
met kleine tandjes, wordt dan tegen de prostaatkwabben aan gerold, waardoor het 
weefsel eveneens verdampt en dichtschroeit. 
 
Het eerste hoofdstuk, de inleiding, behandelt voor een groot deel wat hierboven 
uitgebreid aan de orde is gekomen.  
 
In het tweede hoofdstuk wordt gekeken naar het urodynamisch onderzoek. Bij dit 
onderzoek worden blaas, prostaat en plasbuis ‘doorgemeten’ om inzicht te krijgen in 
het functioneren hiervan. Dit inderzoek werd uitgevoerd bij patiënten die een TURP 
ondergingen. Zowel voor de ingreep als zes maanden later werd dit gedaan in 
combinatie met het invullen van diverse vragenlijsten over plasklachten. De 
resultaten van de vragenlijsten werden vergeleken met de resultaten van het 
urodynamisch onderzoek. Op deze wijze werd inzicht verkregen in de onderlinge 
relatie. Dit inzicht maakt het mogelijk om op basis van het urodynamisch onderzoek 
tot op zekere hoogte te kunnen voorspellen wat de gevolgen van een 
prostaatoperatie zullen zijn.  
 
In het derde hoofdstuk wordt dieper ingegaan op een bijzondere groep mannen met 
plasklachten. Zij hadden weliswaar een vergrote prostaat, maar deze drukte de 
plasbuis vrijwel niet of heel weinig in. Deze mannen werden geopereerd middels een 
TURP en vergeleken met mannen die een vergrote prostaat hadden met wel een 
duidelijk vernauwde plasbuis. De mannen uit de laatste groep bleken, zoals te 
verwachten, de meeste baat te hebben bij de ingreep. Opvallend was echter, dat de 
meeste mannen uit de groep met een ‘openstaande’, vergrote prostaat eveneens vrij 
goede verbeteringen lieten zien. Vaak waren de verschillen tussen deze twee 
groepen slechts gering. Dit maakt duidelijk dat de oorzaak van plasklachten niet 
simpelweg ligt in een prostaat die de plasbuis dichtdrukt en dat de behandeling van 
TURP mogelijk niet alleen berust op het verbeteren van de doorgankelijkheid van de 
prostaat 
 
In het vierde tot en met het zevende hoofdstuk wordt de TURP op verschillende 
manieren vergeleken met de contact laser en de electrovaporizatie. Dit is een studie 
die op de afdeling urologie van Universitair Medisch Centrum Utrecht (UMC Utrecht) 
is uitgevoerd tussen 1996 en 2002. Hieraan deden patiënten mee met plasklachten 
samengaand met goedaardige prostaatvergroting. Indien zij toestemden om in 
studieverband geopereerd te worden, bepaalde het lot welke van de drie technieken 
tijdens de operatie gebruikt zou worden.  
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In het vierde hoofdstuk wordt aangetoond dat er tijdens het urodynamisch onderzoek 
geen verschillen zijn gevonden tussen de drie chirurgische methoden. Zowel voor de 
operatie als 6 maanden na de operatie werd dit onderzoek verricht, waarbij met fijne 
meetinstrumenten de blaas, prostaat en plasbuis werden ‘doorgemeten’. Er bleken 
goede verbeteringen te zijn in de straalkracht en de weerstand over de prostaat was 
fors verminderd.  
 
In het vijfde hoofdstuk wordt gekeken naar de bijwerkingen tijdens en na de operatie. 
Er bleek over het algemeen duidelijk minder bloedverlies op te treden bij de twee 
nieuwe technieken in vergelijking met TURP. Toch trad er af en toe een bloeding op 
die het nodig maakte om terug te vallen op de bekende oude manier, de TURP. In 
het jaar dat op de operatie volgde, bleken er geen duidelijke verschillen 
waarneembaar te zijn tussen de drie groepen.  
 
In het zesde hoofdstuk  wordt gekeken naar enkele lange termijn resultaten. Een 
techniek kan op korte termijn fraaie resultaten tonen, maar het is belangrijk om te 
laten zien of deze resultaten ook duurzaam zijn. Alle patiënten die meer dan 
anderhalf jaar tevoren geopereerd waren, werden gevraagd vragenlijsten in te vullen 
en zo mogelijk naar de polikliniek te komen. In totaal verkregen we van 88% van de 
patiënten resultaten. Patiënten waren anderhalf tot zeven jaar geleden geopereerd. 
De gemiddelde tijd tussen operatie en dit vervolgonderzoek was 4,3 jaren. Zoals te 
verwachten waren de symptomen en klachten weer enigszins toegenomen en was 
de straalkracht afgenomen. Er waren echter slechts geringe verschillen tussen de 
drie groepen en de resultaten waren nog altijd beduidend beter dan voor de operatie. 
Hiermee werd de duurzaamheid van de verschillende technieken aangetoond. Een 
beperking is, dat we alle patiënten slechts eenmaal op de lange termijn gezien 
hebben en dat voor iedere patiënt de tijd tussen de operatie en het lange termijn 
vervolgonderzoek verschillend was.  
 
In het zevende hoofdstuk wordt gekeken naar kosten die samengaan met de 
verschillende operaties. De kosten voor de gezondheidszorg stijgen enorm en dit 
maakt het noodzakelijk om kosten van een behandeling af te wegen tegen de 
resultaten die er mee te boeken zijn. Om de kosten van een ingreep te berekenen 
werd gekeken naar een aantal kostenaspecten: kosten van apparatuur tijdens de 
operatie, het aantal dagen dat patiënten in het ziekenhuis moesten blijven en kosten 
van extra behandelingen die nodig waren als de ingreep niet goed was gegaan. 
Deze kosten werden vergeleken met de resultaten van de vragenlijsten en 
straalkrachtmetingen na 1 jaar. De kosten voor laser waren het hoogst, maar deze 
patiënten konden, net zoals de electrovaporizatie patiënten, sneller uit het ziekenhuis 
ontslagen worden dan de TURP patiënten. Aangezien de resultaten na 1 jaar 
vergelijkbaar waren, leidde dit tot de beste kosten-baten verhouding voor de 
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electrovaporizatie, gevolgd door de TURP en laser. De laatste twee verschilden 
weinig.  
 
In het achtste hoofdstuk, tevens het laatste wetenschappelijke artikel, wordt een 
speciale risicogroep van mannen met plasklachten en BPH geopereerd met lasers. 
Deze mannen gebruiken bloedverdunners of hebben bloedingsziekten, zodat ze 
geen gewone TURP mogen hebben. Er werd geopereerd met de contact laser of een 
combinatie hiervan met een zijwaards schijnende laser. De resultaten werden 
vergeleken met de mannen uit de voorgaande hoofdstukken die geen verhoogd 
bloedingsrisico hebben. Deze studie laat zien, dat er veilig geopereerd kan worden 
met deze lasers. De resultaten zijn weliswaar iets minder goed dan bij de normale 
patiënten, maar er worden duidelijke verbeteringen geboekt.
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Het tot stand komen van dit proefschrift was een karwei dat onmogelijk was geweest 
zonder de hulp van vele mensen. Direct of indirect wisten zij mij keer op keer weer te 
steunen, op weg te helpen, bij te sturen of te motiveren. De afgelopen jaren heb ik 
naast mijn klinische werkzaamheden, heel wat dagen en avonduren doorgebracht 
met het verwerken van data, het overdenken van resultaten, het bespreken hiervan 
met mijn begeleiders en het schrijven en herschrijven van artikelen. In dit stukje, 
waarin ongetwijfeld mensen vergeten zullen worden, wil ik al diegenen danken die dit 
proefschrift mede mogelijk gemaakt hebben. 
 
Mijn grootste dank gaat uit naar mijn co-promotor dr. G.E.P.M. van Venrooij. Beste 
Ger, jij bent zonder enige twijfel de grote drijvende kracht geweest achter deze 
promotie. Niet alleen heb je bij een grote hoeveelheid patienten (urodynamische) 
data verzameld (waarmee je de enige bent die alle studiepatienten gezien en 
gesproken heeft), jij was ook degenen die elke keer weer al mijn stukken uitgebreid 
bestudeerde, tot in detail met me doornam en altijd tijd wist te maken.  
Grote dank gaat natuurlijk ook uit naar prof. dr. T.A. Boon, mijn promotor. Beste 
professor, u bent degene geweest die mij de kans heeft gegeven om de BPHIL 
studie af te ronden en de enorme hoeveelheid data te mogen gebruiken om op te 
promoveren. Dank voor de vrijheid die ik kreeg om naast het werk op de afdeling tijd 
te kunnen besteden aan de wetenschap en dank voor de leerzame tijd op het UMCU. 
Onmisbaar was mijn voorgangster Mardy Eckhardt die alweer ruim 2 jaar geleden 
promoveerde op diagnostiek bij klinische BPH. Jij hebt destijds al een enorme 
hoeveelheid werk verricht voor de BPHIL studie waar ik dankbaar gebruik van heb 
kunnen maken.  
En gezellig was het ook altijd met Els; niemand zo gezellig om mee aan bureau te 
zitten! 
Mijn steun en toeverlaat bij crashende laptops en andere technische vraagstukken 
waren steeds de “laserboys”: Arjan, Herk-Jan, Matthijs, Ruud en in het bijzonder 
Christiaan. 
Natuurlijk dank aan alle arts-assistenten van de afdeling: Ben, dr. Bob (Roshani), 
Jaap, Jacob, Laetitia, Mircea en Risto.  
Dank aan de overige stafleden Tycho Lock en Jeroen van Moorselaar. Veel dank ook 
aan de alweer een tijd elders werkzame Karel Gisolf, die mij snel wist duidelijk te 
maken dat urologie het boeiendste en leukste vakgebied is.  
Alle poli verpleegkundigen, urodynamica verpleegkundigen (Angelique, Ria en 
Femmy) en secretaresses dank ik voor hun hulp bij het zien van de studiepatienten. 
En altijd dolle pret was het met de verpleging van (destijds) C4 oost! 
Altijd blij ben ik geweest met mijn paranimfen met wie ik beiden al zo veel heb 
meegemaakt: Moyo Kruyt en Martin Meijers. 
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Mijn moeder en mijn zus Yvonne zijn meer dank waard dan hier kort te beschrijven 
is. 
En dan Floor. Hoewel je alleen de laatste strubbelingen van het vervaardigen van dit 
proefschrift hebt meegemaakt, ben ik bijzonder blij met je, omdat je ervoor gezorgd 
hebt dat ik mij deze tijd altijd zal hernneren als de periode waarin ik jou ben 
tegengekomen! 
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De schrijver van dit proefschrift werd geboren op 19 november 1972 in Nijmegen. In 
1991 slaagde hij voor het eindexamen Atheneum B op de scholengemeenschap St. 
Ursula in Horn (Limburg). In 1992 eindigde hij zijn studie scheikundige technologie 
aan de TU in Eindhoven om met geneeskunde aan te vangen aan de universiteit van 
Diepenbeek in Belgie. In 1993 kon hij deze studie vervolgen aan de universiteit van 
Utrecht. In 1997 werkte hij enkele maanden op het Barcroft laboratorium in de White 
Mountains in Californie (VS). Onder supervisie van prof. dr. J.B. West deed hij 
onderzoek op het gebied van de hoogtefysiologie. Zijn medische graad verkreeg hij 
in april 2000. Hierop aansluitend begon hij met onderzoek bij de vakgroep urologie 
van het Universitair Medisch Centrum Utrecht (UMCU) onder leiding van prof. dr. 
T.A. Boon. In januari 2001 werd aangevangen met de werkzaamheden die tot deze 
promotie hebben geleid. Tegelijkertijd werd gestart met het verrichten van klinische 
werkzaamheden op dezelfde afdeling. In februari 2003 werd in het kader van de 
opleiding urologie begonnen met de vooropleiding chirurgie in het Rijnstate 
ziekenhuis te Arnhem onder leiding van dr. J.H.G. Klinkenbijl. Zijn verdere opleiding 
tot uroloog zal volbracht worden in Tilburg en Utrecht. 
